Page last updated: 2024-11-12

piroxicam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID54676228
CHEMBL ID527
CHEMBL ID1518938
CHEBI ID8249
SCHEMBL ID21350
SCHEMBL ID13462
SCHEMBL ID3703617
MeSH IDM0016899

Synonyms (279)

Synonym
BIDD:PXR0154
MLS001148207
HMS3267I03
AB00052074-22
AB00052074-21
2h-1,2-benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-n-2-pyridinyl-, 1,1-dioxide
smr000035997
DIVK1C_000369
KBIO1_000369
NCI60_022912
felden
feldene
feldene fast
feldene gel
baxo
cp-16171
4-hydroxy-2-methyl-n-pyridin-2-yl-2h-1,2-benzothiazine-3-carboxamide 1,1-dioxide
piroftal
4-hydroxy-2-methyl-n-(2-pyridyl)-2h-1,2-benzothiazine-3-carboxamide-1,1-dioxide
cp 16171
4-hydroxy-2-methyl-n-(2-pyridyl)-2h-1,2-benzothiazin-3-caboxyamid-1,1-dioxid [german]
roxicam
nsc 666076
chf 1251
c15h13n3o4s
brn 0627692
ccris 3719
einecs 252-974-3
4-hydroxy-2-methyl-n-2-pyridyl-2h-1,2-benzothiazine-3-carboxamide 1,1-dioxide
piroxicamum [inn-latin]
nsc-666076
EU-0100900
piroxicam, >=98% (tlc)
feldene (tn)
D00127
piroxicam (jp17/usp/inn)
SPECTRUM_001115
LOPAC0_000900
BPBIO1_000245
PRESTWICK_573
BIO1_000363
NCGC00015823-02
BIO2_000835
NCGC00021244-03
BIO1_000852
NCGC00015823-01
BIO1_001341
tocris-0960
BIO2_000355
cas-36322-90-4
lopac-p-5654
PRESTWICK3_000211
IDI1_000369
BSPBIO_001030
BSPBIO_002460
PRESTWICK2_000211
IDI1_002110
SPECTRUM5_001445
BCBCMAP01_000176
36322-90-4
C01608
piroxicam ,
(4-hydroxy-2-methyl-1,1-dioxobenzo[e]1,2-thiazin-3-yl)-n-(2-pyridyl)carboxamide
nsc666076
4-hydroxy-2-methyl-1,1-dioxo-n-(2-pyridyl)-1$l^{6},2-benzothiazine-3-carboxamide
piroxicam, meets usp testing specifications
DB00554
pyroxycam
NCGC00021244-06
NCGC00021244-07
NCGC00021244-09
4-hydroxy-2-methyl-n-(pyridin-2-yl)-2h-1,2-benzothiazine-3-carboxamide 1,1-dioxide
MLS000069644 ,
MLS000038002
KBIO3_001680
KBIO2_006731
KBIO2_004163
KBIO2_002938
KBIO2_005506
KBIO2_001595
KBIO3_000720
KBIOGR_000370
KBIO3_000719
KBIOSS_000370
KBIOGR_001315
KBIO2_000370
KBIOSS_001595
SPECTRUM3_000780
SPECTRUM2_001287
SPBIO_001293
SPBIO_002142
PRESTWICK0_000211
NINDS_000369
SPECTRUM4_000968
PRESTWICK1_000211
SPECTRUM1500491
OPREA1_714707
BSPBIO_000221
NCGC00021244-05
NCGC00015823-03
NCGC00015823-04
MLS001304054
NCGC00021244-08
piroxicamum
CHEBI:8249 ,
4-hydroxy-2-methyl-n-(2-pyridyl)-2h-1,2-benzothiazin-3-caboxyamid-1,1-dioxid
NCGC00015823-09
HMS2092A05
HMS2089B06
4-hydroxy-2-methyl-3-(pyrid-2-yl-carbamoyl)-2h-1,2-benzothiazine 1,1-dioxide
HMS1990D11
P 5654 ,
NCGC00015823-14
CHEMBL527
cp-16,171
AKOS000714958
HMS1792D11
HMS1362D11
HMS501C11
HMS1568L03
HMS1920H22
A19556
4-hydroxy-2-methyl-n-2-pyridinyl-2h-1,2-benzothiazine-3-carboxamide 1,1-dioxide
NCGC00188982-01
HMS3262D22
HMS2095L03
EN300-70724
3-{hydroxy[(pyridin-2-yl)amino]methylidene}-2-methyl-3,4-dihydro-2h-1lambda6,2-benzothiazine-1,1,4-trione
(4-hydroxy-2-methyl-1,1-dioxobenzo[e]1,2-thiazin-3-yl)-n-(2-pyridyl)carboxamid e
tox21_200151
NCGC00257705-01
P1905
4-hydroxy-2-methyl-n-(2-pyridyl)-2h-1,2-benzothiazine-3-carboxamide 1,1-dioxide
4-hydroxy-2-methyl-3-(2-pyridylcarbamoyl)-2h-1,2-benzothiazine 1,1-dioxide
nsc-757284
nsc757284
pharmakon1600-01500491
dtxsid5021170 ,
dtxcid401170
tox21_110231
MLS004774122
bdbm85245
cas_36322-90-4
nsc_4856
HMS2231G03
CCG-36403
NCGC00015823-07
NCGC00015823-13
NCGC00015823-05
NCGC00015823-06
NCGC00015823-08
NCGC00015823-11
NCGC00015823-15
NCGC00015823-12
NCGC00015823-10
piroxicam [usan:usp:inn:ban:jan]
13t4o6vmam ,
unii-13t4o6vmam
rosiden
pirkam
flogobene
zunden
reudene
bruxicam
riacen
ak1015
piroflex
piroxicam usp
caliment
solocalm
erazon
larapam
artroxicam
sasulen
roxiden
geldene
improntal
roxam
FT-0673949
piroxicam (feldene)
BCP0726000299
FT-0630590
NCGC00015823-18
LP00900
piroxicam [usp-rs]
piroxicam [usan]
piroxicam [orange book]
piroxicam [inn]
piroxicam [vandf]
piroxicam [mart.]
piroxicam [who-dd]
piroxicam anhydrous
piroxicam [ep monograph]
piroxicam [mi]
piroxicam [jan]
piroxicam [usp monograph]
AM84917
4-hydroxy-2-methyl-n-(pyridin-2-yl)-2h-benzo[e][1,2]thiazine-3-carboxamide 1,1-dioxide
S1713
HMS3369B07
gtpl7273
4-hydroxy-2-methyl-1,1-dioxo-n-pyridin-2-yl-1lambda6,2-benzothiazine-3-carboxamide
HY-B0253
SCHEMBL21350
SCHEMBL13462
SCHEMBL3703617
NCGC00015823-17
tox21_110231_1
KS-5322
NCGC00261585-01
tox21_500900
n-(2-pyridyl)-4-hydroxy-2-methyl-2h-1,2-benzothiazine-3-carboxamide 1,1-dioxide
4-hydroxy-2-methyl-n-2-pyridinyl-2h-1,2-benzothiazine-3-carboxamide1,1-dioxide
F0001-2399
1044566-76-8
(z)-3-(hydroxy(pyridin-2-ylamino)methylene)-2-methyl-2h-benzo[e][1,2]thiazin-4(3h)-one 1,1-dioxide
W-106626
piroxicam, british pharmacopoeia (bp) reference standard
3,4-dihydro-2-methyl-4-oxo-n-2-pyridyl-2h-1,2-benzothiazine-3-carboxamide 1,1-dioxide
CHEMBL1518938
AC-24190
HMS3403D11
HMS3429L03
AB00052074_23
AB00052074_24
OPERA_ID_442
mfcd00057317
AKOS025312555
4-hydroxy-2-methyl-1,1-dioxo-n-(pyridin-2-yl)-2h-1$l^{6},2-benzothiazine-3-carboxamide
AKOS026749939
piroxicam, united states pharmacopeia (usp) reference standard
HMS3655C04
piroxicam for system suitability
piroxicam, european pharmacopoeia (ep) reference standard
piroxicam, pharmaceutical secondary standard; certified reference material
piroxicam 1.0 mg/ml in methanol
SR-01000000199-3
SR-01000000199-12
SR-01000000199-5
sr-01000000199
SR-01000000199-9
SBI-0050875.P004
HMS3712L03
SW219862-1
piroxicam d3 (n-methyl d3)
Q408676
piroxicam: form alpha2
piroxicam: form alpha1
4-hydroxy-2-methyl-n-(2-pyridyl)-2h-1,2-benzothiazine -3-carboxamide-1,1-dioxide malonic acid
piroxicam:malonic acid
piroxicam-(methyl-d3)
4-hydroxy-2-methyl-n-2-pyridinyl-2h-1,2-benzothiazine-3-carboxamide-1,1-dioxide
2h-1,2-benzothiazine-3-carboxamide,4-hydroxy-2-methyl-n-2-pyridinyl-, 1,1-dioxide
Z1137167677
HMS3678H15
piroxicam,(s)
3-{hydroxy[(pyridin-2-yl)amino]methylidene}-2-methyl-3,4-dihydro-2h-1$l^{6},2-benzothiazine-1,1,4-trione
BCP02919
HMS3414H17
SDCCGSBI-0050875.P005
NCGC00015823-29
HMS3884C08
D70554
GLXC-26155
NCGC00015823-20
4-hydroxy-2-methyl-n-(pyridin-2-yl)-2h-benzo[e][1,2]thiazine-3-carboxamide1,1-dioxide
GLXC-26156
(3z)-3-{hydroxy[(pyridin-2-yl)amino]methylidene}-2-methyl-3,4-dihydro-2h-1lambda6,2-benzothiazine-1,1,4-trione
3-(hydroxy[(pyridin-2-yl)amino]methylidene)-2-methyl-3,4-dihydro-2h-1lambda(6),2-benzothiazine-1,1,4-trione
m02aa07
piroxicam (usan:usp:inn:ban:jan)
piroxicamum (inn-latin)
piroxicam (usp monograph)
piroxicam (ep monograph)
4-hydroxy-2-methyl-n-2-pyridinyl-2h-1,2-benzothiazine-3-carboximide-1,1-dioxide
s01bc06
piroxicam (mart.)
piroxicam (usp-rs)
m01ac01

Research Excerpts

Toxicity

Both piroxicam and placebo gels were well tolerated. Mild adverse effects, mainly gastrointestinal, considered possibly related to treatment were recorded in 4 patients treated with nimesulide.

ExcerptReferenceRelevance
" There was no significant difference between treatment groups in the number of patient withdrawals due to adverse reactions or in the number of patients reporting side effects."( Safety and efficacy of etodolac compared with piroxicam in patients with degenerative joint disease of the knee.
Bulstra, S; Dick, WC; Feenstra, RM; Schardijn, GH,
)
0.13
" Both piroxicam and placebo gels were well tolerated, with 7 piroxicam and 15 placebo patients reporting primarily skin-related adverse effects."( Piroxicam 0.5% topical gel compared to placebo in the treatment of acute soft tissue injuries: a double-blind study comparing efficacy and safety.
Russell, AL, 1991
)
0.28
"9%) patients experienced adverse drug reactions, the commonest being gastrointestinal (11."( A study of the safety of tenoxicam in general practice.
Caughey, D; Waterworth, RF, 1989
)
0.28
" The toleration profile of piroxicam is typical of an inhibitor of prostaglandins, with a relatively low reported incidence of adverse events necessitating discontinuation of therapy."( Toleration and safety of piroxicam.
Heynen, G, 1987
)
0.27
" Documentation is derived from clinical trials, post-marketing surveillance, special studies, and spontaneous reports of adverse drug reactions from foreign countries."( Worldwide safety experience with diclofenac.
Catalano, MA, 1986
)
0.27
" The purpose of the present study was to look for an association of plasma drug concentration with the variables of: age, sex, adverse events and efficacy."( Piroxicam and naproxen plasma concentrations in patients with osteoarthritis: relation to age, sex, efficacy and adverse events.
Giercksky, KE; Herland, OB; Holme, I; Hundal, O; Husby, G; Rugstad, HE, 1986
)
0.27
"In the Norwegian comparative trials of piroxicam and naproxen in osteoarthritis, conducted by Husby and co-workers and Rugstad et al, relationships between plasma drug concentrations and the following were examined: efficacy in patients with osteoarthritis; all adverse reactions; and serious adverse events, which included gastrointestinal ulceration or bleeding and congestive heart failure."( The Norway study: plasma concentrations, efficacy, and adverse events.
Rugstad, HE, 1986
)
0.27
" Finally, the worldwide database of more than 77,000 patients monitored in postmarketing surveillance studies is examined to assess gastrointestinal side effects and the relation of age and sex to these adverse events."( Clinical benefits and comparative safety of piroxicam. Analysis of worldwide clinical trials data.
Meisel, AD, 1986
)
0.27
" Of additional interest is the relationship between piroxicam pharmacokinetics (particularly steady-state plasma levels) and adverse effects."( Piroxicam pharmacokinetics: recent clinical results relating kinetics and plasma levels to age, sex, and adverse effects.
Hobbs, DC, 1986
)
0.27
" The most common type of adverse reaction to all medications (isoxicam, aspirin, and indomethacin) was gastrointestinal: 22."( Evaluation of the safety of isoxicam.
Burch, FX, 1985
)
0.27
" The gastrointestinal system is the major site of adverse effects."( Pharmacology, clinical efficacy, and adverse effects of piroxicam, a new nonsteroidal anti-inflammatory agent.
Dahl, SL; Ward, JR,
)
0.13
"The Food and Drug Administration has collected spontaneous reports on adverse events (AE) from manufacturers and individuals."( Comparing reporting rates of adverse events between drugs with adjustment for year of marketing and secular trends in total reporting.
Tsong, Y, 1995
)
0.29
" Adverse reactions, mostly regarding the G-I tract, were significantly more frequent in the tenoxicam group than in the etodolac group: 23."( Double-blind comparison of the efficacy and safety of etodolac SR 600 mg u.i.d. and of tenoxicam 20 mg u.i.d. in elderly patients with osteoarthritis of the hip and of the knee.
Bogliolo, A; Perpignano, G; Puccetti, L, 1994
)
0.29
" Of 273 elderly patients treated with at least 600 mg daily, only 12% withdrew because of adverse events, a rate similar to that in the younger age-group."( Safety profile of etodolac in the elderly population.
Bacon, PA, 1994
)
0.29
" An attempt to prevent its toxic effects has been made using piroxicam, a non-steroidal anti-inflammatory drug (NSAID)."( Effect of piroxicam on the nephrotoxicity induced by ochratoxin A in rats.
Baudrimont, I; Betbeder, AM; Creppy, EE; Guilcher, J; Murn, M, 1995
)
0.29
" Safety was measured in 3 ways: (1) physician global rating scale, (2) number of patients with adverse events, and (3) dropouts due to adverse events."( A study to determine the efficacy and safety of tenoxicam versus piroxicam, diclofenac and indomethacin in patients with osteoarthritis: a meta-analysis.
Bersinic, S; Cuddy, LJ; Riedemann, PJ; Torrance, GW; Tugwell, PX, 1993
)
0.29
" There were no significant differences between treatments in the number of adverse events."( Comparison of the efficacy, safety, and pharmacokinetic profiles of extended-release ketoprofen and piroxicam in patients with rheumatoid arthritis.
Caldwell, JR,
)
0.13
" The incidence of > or = 1 adverse event considered by the investigator to be related or probably related to therapy was similar in all groups."( Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis.
DeLapp, RE; Eversmeyer, W; Jensen, CP; Poland, M, 1993
)
0.29
" The type and frequency of adverse events were comparable for the two drugs."( A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip.
Bluhmki, E; Distel, M; Lindén, B, 1996
)
0.29
" Forty-two adverse events possibly or probably related to treatment were observed in the aceclofenac group and 37 in the tenoxicam group."( Aceclofenac is as safe and effective as tenoxicam in the treatment of ankylosing spondylitis: a 3 month multicenter comparative trial. Spanish Study Group on Aceclofenac in Ankylosing Spondylitis.
de Buergo, M; Montull Fruitós, E; Rico Lenza, H; Villa Alcázar, LF, 1996
)
0.29
" Piroxicam and meloxicam suppositories were equally well tolerated, with no serious adverse events recorded in either treatment group."( A comparison of the local tolerability, safety and efficacy of meloxicam and piroxicam suppositories in patients with osteoarthritis: a single-blind, randomized, multicentre study.
Angelini, M; Carrabba, M; Cigarini, P; Galanti, A; Marini, MG; Paresce, E, 1995
)
0.29
" No significant differences occurred in the incidence of any specific adverse event."( Comparison of the efficacy and safety of etodolac and piroxicam in patients with rheumatoid arthritis. Etodolac Study 326 Rheumatoid Arthritis Investigators Group.
Lightfoot, R, 1997
)
0.3
" The incidence of adverse events was significantly lower in the meloxicam group (22."( Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis.
Alegre, C; Baumelou, E; Bégaud, B; Dequeker, J; Hawkey, C; Isomäki, H; Kahan, A; Littlejohn, G; Mau, J; Papazoglou, S; Steinbrück, K, 1998
)
0.3
" Tolerability was evaluated by incidence of adverse events whilst safety was evaluated by measurement of haematological and biochemical profile pre and post therapy."( Comparative double blind study of the efficacy and safety of tenoxicam vs. piroxicam in osteoarthritis of knee and hip joints.
Adelowo, OO; Chukwuani, CM; Grange, JJ; Ojeasebhulo, EE; Onabowale, BO,
)
0.13
" These COX-2 and ODC inhibitor drugs were not overtly toxic at the doses used when administered to mice after weaning."( Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.
Cole, CE; Hawk, ET; Jacoby, RF; Kelloff, G; Lubet, RA; Newton, MA; Tutsch, K, 2000
)
0.31
" Mild adverse effects, mainly gastrointestinal, considered possibly related to treatment were recorded in 4 patients treated with nimesulide and in 12 patients treated with piroxicam."( Comparative efficacy and safety of nimesulide versus piroxicam in osteoarthritis with special reference to chondroprotection.
Gulati, P; Gupta, V; Rastogi, S; Rohtagi, D; Sharma, S, 1999
)
0.3
" The better GI tolerability of meloxicam was also suggested by fewer adverse GI events and no withdrawals due to adverse events compared with piroxicam."( Endoscopic comparison of the gastroduodenal safety and the effects on arachidonic acid products between meloxicam and piroxicam in the treatment of osteoarthritis.
Chang, DM; Hsieh, TC; Hsu, CT; Kuo, SY; Young, TH, 2001
)
0.31
" No adverse events were complained."( [Long term study on the efficacy and safety of lornoxicam in rheumatoid arthritis].
Focherini, MC; Frizziero, L; Reta, M; Rocchi, P; Valentini, M, 2002
)
0.31
"Retrospective analysis of adverse event databases."( Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration.
Hartnell, NR; Wilson, JP, 2004
)
0.32
"Reports of adverse events submitted to the FDAs Spontaneous Reporting System and the Adverse Event Reporting System from January 1969-December 2000 for these drugs were analyzed according to the number of adverse events reported for each drug per year from the time the drug was approved until December 2000."( Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration.
Hartnell, NR; Wilson, JP, 2004
)
0.32
" Various other factors affected spontaneous reporting of adverse events, as peaks in the number of reports were seen numerous times for each drug after the initial 5-year marketing period."( Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration.
Hartnell, NR; Wilson, JP, 2004
)
0.32
" Unlike general toxicity data, their prenatal toxic effects were not extensively studied before."( Comparison of developmental toxicity of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats--DFU and piroxicam study.
Burdan, F, 2005
)
0.33
"Both selective and non-selective COX-2 inhibitors were toxic for rats fetuses when administered in the highest dose."( Comparison of developmental toxicity of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats--DFU and piroxicam study.
Burdan, F, 2005
)
0.33
" It appears that once daily, short-term use of piroxicam alone and in combination with cimetidine in cats is relatively safe based on the parameters evaluated in this study."( Multiple dose pharmacokinetics and acute safety of piroxicam and cimetidine in the cat.
Chun, R; Corse, M; Garrett, L; Heeb, HL; Hunter, RP; Koch, DE; Moore, L; Pellerin, MA; Radlinsky, M, 2005
)
0.33
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" As determined by Toxilight-cytotoxicity assay, the drug was only toxic to the cancer cells at 100 microM."( Cytostatic and cytotoxic effects of cyclooxygenase inhibitors and their synergy with docosahexaenoic acid on the growth of human skin melanoma A-375 cells.
Chiu, LC; Ooi, VE; Tong, KF, 2005
)
0.33
" Facial swelling was evaluated with a measuring tape and adverse effects and patient satisfaction were recorded."( Efficacy and safety of combined piroxicam, dexamethasone, orphenadrine, and cyanocobalamin treatment in mandibular molar surgery.
Barroso, AB; Bezerra, MM; Bezerra, RC; Frota-Bezerra, FA; Guzzo, GC; Lima, V; Moraes, ME; Moraes, MO; Moraes, RA; Santana, GS; Vasconcellos, MC; Viana, FA, 2006
)
0.33
" The incidence of adverse events was similar in both groups but more patients from the piroxicam group dropped out of the study due to these events."( The efficacy, safety and carry-over effect of diacerein in the treatment of painful knee osteoarthritis: a randomised, double-blind, NSAID-controlled study.
Aksaranugraha, S; Asavatanabodee, P; Louthrenoo, W; Nilganuwong, S; Saengnipanthkul, S, 2007
)
0.34
"This study assessed the efficacy and adverse effects of preoperatively administered lornoxicam versus tramadol in adults, for post-tonsillectomy pain."( Effects of preoperative lornoxicam versus tramadol on postoperative pain and adverse effects in adult tonsillectomy patients.
Akçabay, M; Arslan, M; Işik, B; Ozsoylar, O, 2009
)
0.35
" Adverse effects in the postoperative 6h period were noted."( Effects of preoperative lornoxicam versus tramadol on postoperative pain and adverse effects in adult tonsillectomy patients.
Akçabay, M; Arslan, M; Işik, B; Ozsoylar, O, 2009
)
0.35
" Incidence and severity of adverse events were comparable for the three treatments; overall tolerability was rated as very good/good by 93% of the patients."( Efficacy and safety of lornoxicam compared with placebo and diclofenac in acute sciatica/lumbo-sciatica: an analysis from a randomised, double-blind, multicentre, parallel-group study.
Geertsen, MS; Herrmann, WA, 2009
)
0.35
") occurring after the start of rabeprazole treatment were handled as adverse events."( Efficacy and safety of rabeprazole in non-steroidal anti-inflammatory drug-induced ulcer in Japan.
Mizokami, Y, 2009
)
0.35
" This retrospective study aimed to evaluate adverse effects in cats receiving long-term daily piroxicam."( Evaluation of adverse events in cats receiving long-term piroxicam therapy for various neoplasms.
Bulman-Fleming, JC; Rosenberg, MP; Turner, TR, 2010
)
0.36
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
"Following day-case surgery, patients were provided with appropriate analgesic medication, and adverse events (AEs; defined as all recorded events with symptoms) were recorded by the investigator during the in-hospital stay and by the patient for the next 3 days using entries recorded morning and evening in a patient diary."( Safety of lornoxicam in the treatment of postoperative pain: a post-marketing study of analgesic regimens containing lornoxicam compared with standard analgesic treatment in 3752 day-case surgery patients.
Hejl, C; Krøner, K; Likar, R; Rawal, N; Simin-Geertsen, M, 2010
)
0.36
" All toxic effects of gemcitabine in dogs were recorded."( Toxic effects and antitumor response of gemcitabine in combination with piroxicam treatment in dogs with transitional cell carcinoma of the urinary bladder.
Jeglum, AK; Lindner, D; Marconato, L; Nelson, V; Suslak-Brown, L; Zini, E, 2011
)
0.37
" However, this combination of chemotherapy did provide a new treatment alternative with fewer adverse effects."( Toxic effects and antitumor response of gemcitabine in combination with piroxicam treatment in dogs with transitional cell carcinoma of the urinary bladder.
Jeglum, AK; Lindner, D; Marconato, L; Nelson, V; Suslak-Brown, L; Zini, E, 2011
)
0.37
" As concurrent use may be warranted for a given individual and the adverse event (AE) profile for each can be overlapping (gastrointestinal), a phase I trial was performed in tumour-bearing (non-mast cell) dogs to establish the safety of the combination using a standard 3+3 cohort design."( Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study.
Chon, E; Kubicek, LN; McCartan, L; Vail, DM, 2012
)
0.38
"Although NSAIDs are very effective drugs, their use is associated with a broad spectrum of adverse reactions in the liver, kidney, cardiovascular (CV) system, skin and gut."( Piroxicam-β-cyclodextrin: a GI safer piroxicam.
Scarpignato, C, 2013
)
0.39
"Intravitreal lornoxicam causes dose-related toxic effect to the retina at a concentration of 1,500 μg."( Evaluation of vitreous clearance and potential retinal toxicity of intravitreal lornoxicam (xefo).
Charisis, S; Diakonis, VF; Naoumidi, I; Plainis, S; Tsika, C; Tsilimbaris, MK; Tsourdou, A; Tzatzarakis, MN, 2013
)
0.39
"Intra-operative and postoperative bleeding score, platelet aggregometry before and 30 min after study drug administration, the verbal rating pain scale, time to first postoperative analgesic request, total analgesic consumption during 1st 24 h postoperative and adverse effects were evaluated."( Safety and efficacy of pre-incisional peritonsillar lornoxicam in paediatric post-tonsillectomy pain: a prospective double-blind, placebo-controlled, split-body clinical study.
Abdel-Azeem, HG; Abdel-Ghaffar, HS; Roushdy, MM, 2015
)
0.42
"The lack of significant complications suggests that pre-incisional peritonsillar lornoxicam followed by intravenous paracetamol rescue analgesia may be safe for tonsillectomy in children."( Safety and efficacy of pre-incisional peritonsillar lornoxicam in paediatric post-tonsillectomy pain: a prospective double-blind, placebo-controlled, split-body clinical study.
Abdel-Azeem, HG; Abdel-Ghaffar, HS; Roushdy, MM, 2015
)
0.42
" Adverse effects were recorded in both groups."( Efficacy and safety of lornoxicam vs ibuprofen in primary dysmenorrhea: a randomized, double-blind, double dummy, active-controlled, cross over study.
Acharya, H; Nakum, K; Patel, JC; Patel, PB; Tripathi, CB, 2015
)
0.42
" The incidence of adverse effect was also similar in both groups."( Efficacy and safety of lornoxicam vs ibuprofen in primary dysmenorrhea: a randomized, double-blind, double dummy, active-controlled, cross over study.
Acharya, H; Nakum, K; Patel, JC; Patel, PB; Tripathi, CB, 2015
)
0.42
" The following were evaluated: onset and duration of anesthetic action on soft tissues, intraoperative bleeding, hemodynamic parameters, postoperative analgesia, and mouth opening and wound healing during the 7th postoperative day, along with the incidence, type, and severity of adverse reactions."( Efficacy and Safety of 2% and 4% Articaine for Lower Third Molar Surgery.
Brozoski, DT; Calvo, AM; Colombini-Ishikiriama, BL; Dionísio, TJ; Faria, FA; Gonçalves, PZ; Lauris, JR; Sant'ana, E; Santos, CF; Senes, AM, 2015
)
0.42
"Nonsteroidal anti-inflammatory drugs (NSAIDs), which are globally prescribed, exhibit mainly anti-inflammatory and analgesic effects but also can cause adverse effects including gastrointestinal erosions, ulceration, bleeding, and perforation."( (1)H-Nuclear magnetic resonance-based metabolic profiling of nonsteroidal anti-inflammatory drug-induced adverse effects in rats.
Choi, KH; Chung, MW; Lee, HJ; Park, JH; Um, SY, 2016
)
0.43
" The purpose of this study was to retrospectively identify factors predisposing cancer-bearing dogs to adverse events (AEs) following piroxicam therapy."( Risk factors for treatment-related adverse events in cancer-bearing dogs receiving piroxicam.
Childress, MO; Eichstadt, LR; Moore, GE, 2017
)
0.46
" Reports of gastrointestinal adverse effects with traditional NSAIDs and cardiovascular adverse effects associated with selective cyclooxygenase-2 (COX-2) inhibitors have prompted the hunt for a better NSAID with no or minimal adverse effects."( Comparison of Clinical Effectiveness and Safety of Newer Nonsteroidal Anti-inflammatory Drugs in Patients of Osteoarthritis of Knee Joint: A Randomized, Prospective, Open-label Parallel-group Study.
Garg, Y; Gore, R; Kumar, A; Singh, J; Sohal, HS,
)
0.13
"Piroxicam has toxic effects on the liver as indicated by biochemical, histological and immunohistochemical results."( Histological study of the protective role of ginger on piroxicam-induced liver toxicity in mice.
Badawi, MS, 2019
)
0.51
" It has been observed that NSAIDs have adverse gastrointestinal tract effects such as irritation and ulceration during anti-inflammatory therapy."( Nanovesicle Formulation Enhances Anti-inflammatory Property and Safe Use of Piroxicam.
Adikwu, M; Attama, A; Builders, P; Ezeh, R; Mbah, C; Nzekwe, I; Ofoefule, S; Ogbonna, J; Ugwu, G, 2021
)
0.62
"This study aimed to explore the potentials of a transdermal nanovesicular formulation for safe and enhanced delivery of piroxicam (PRX), a poorly water-soluble NSAID."( Nanovesicle Formulation Enhances Anti-inflammatory Property and Safe Use of Piroxicam.
Adikwu, M; Attama, A; Builders, P; Ezeh, R; Mbah, C; Nzekwe, I; Ofoefule, S; Ogbonna, J; Ugwu, G, 2021
)
0.62
" This may be further developed as a safe alternative to the oral form."( Nanovesicle Formulation Enhances Anti-inflammatory Property and Safe Use of Piroxicam.
Adikwu, M; Attama, A; Builders, P; Ezeh, R; Mbah, C; Nzekwe, I; Ofoefule, S; Ogbonna, J; Ugwu, G, 2021
)
0.62
"To assess the impact of prophylactic omeprazole and famotidine on the incidence and severity of gastrointestinal (GI) adverse events (AEs) in dogs with cancer treated with single agent piroxicam."( A prospective, randomized, placebo-controlled, double-blinded clinical trial comparing the incidence and severity of gastrointestinal adverse events in dogs with cancer treated with piroxicam alone or in combination with omeprazole or famotidine.
Fulkerson, CM; Moore, GE; Shaevitz, MH, 2021
)
0.62

Pharmacokinetics

Piroxicam-beta-cyclodextrin was equivalent to or tended to show less gastrointestinal mucosal toxicity than standard piroXicam, as assessed by endoscopy and faecal blood loss. The half-life and systemic clearance of piroxICam to be unaffected by age.

ExcerptReferenceRelevance
" After a single 10mg dose the value of Tmax was higher than that reported for piroxicam (10mg)."( Pharmacokinetic profile of droxicam.
Martínez, L; Sánchez, J, 1991
)
0.28
" After a single dose, tenoxicam had a half-life (t1/2) of 33 h, an apparent clearance (CL."( The effect of haemodialysis on the pharmacokinetics of tenoxicam in patients with end-stage renal disease.
al-Ghamdi, MS; al-Mohanna, FA; al-Mustafa, ZH; al-Saeed, IS, 1992
)
0.28
"We compared the endoscopic effects and pharmacokinetic profiles of an experimental buccal formulation of piroxicam to oral capsules in an attempt to determine whether nonsteroidal antiinflammatory drug-induced gastropathy is due to a local or systemic effect."( A pharmacokinetic and endoscopic comparison of an oral and an experimental buccal piroxicam formulation.
Brater, DC; Figueroa, N; Greene, P; Mueller, BA; Rex, DK, 1992
)
0.28
" Pharmacokinetic analysis was carried out fitting exponential equation to experimental data."( Pharmacokinetics of piroxicam in rats.
Fernandez-Troconiz, JI; Fos, D; Lopez-Bustamante, LG, 1991
)
0.28
" It had an elimination half-life of 40."( Pharmacokinetics and pharmacodynamics of piroxicam in dogs.
Galbraith, EA; McKellar, QA, 1991
)
0.28
" In the first study there were no statistically significant differences between the pharmacokinetic variables for ranitidine in the presence or absence of piroxicam."( A lack of pharmacokinetic interaction between ranitidine and piroxicam.
Dixon, JS; Lacey, LF; Langley, SJ; Page, MC; Pickup, ME, 1990
)
0.28
"Clinical phase I pharmacokinetic studies with lornoxicam were performed with the 4 mg dose of lornoxicam."( Pharmacokinetics of lornoxicam in man.
Hitzenberger, G; Radhofer-Welte, S; Rosenow, D; Takacs, F, 1990
)
0.28
" It has a relatively short elimination half-life (about 4 hours), and no significant differences in pharmacokinetic data have been found between young and elderly volunteers."( Clinical pharmacokinetic studies with lornoxicam.
Johnston, A; Turner, P, 1990
)
0.28
" Serum theophylline concentration versus time curves were plotted and pharmacokinetic parameters determined for each subject."( Lack of effect of piroxicam on theophylline clearance in healthy volunteers.
Barlow, JC; Maponga, C; Schentag, JJ, 1990
)
0.28
" Non-compartmental pharmacokinetic parameters were calculated by area/moment analysis."( Effects of dose and sex on the pharmacokinetics of piroxicam in the rat.
Boudinot, FD; Roskos, LK, 1990
)
0.28
" Virtually all of the pharmacokinetic parameters computed for the two groups were similar."( Influence of liver cirrhosis upon the pharmacokinetics of tenoxicam.
Crevoisier, C; Heizmann, P; Meyer, J; Zaugg, PY, 1989
)
0.28
"The influence of cimetidine on piroxicam plasma levels and pharmacokinetic parameters was studied in both rats and healthy volunteers."( Influence of cimetidine on the pharmacokinetics of piroxicam in rat and man.
Foda, AM; Said, SA, 1989
)
0.28
" The pharmacokinetic parameters of Piroxicam from micronized substance are practically consonant to similar parameters of the preparation Felden cps."( [The effect of particle size on the pharmacokinetics of piroxicam].
Elis, J; Jirincová, J; Macek, J; Tománková, H; Vácha, J, 1989
)
0.28
" The mean elimination half-life of isoxicam in five patients was 42."( Pharmacokinetics of isoxicam in hepatic disease.
Cuisinaud, G; Ferry, N; Ouzan, D; Sassard, J; Trepo, C, 1986
)
0.27
" Chlortenoxicam was found to have a relatively short mean elimination half-life of about 4 hours, with considerable inter-subject variability, but there was no significant difference between young and elderly subjects."( Chlortenoxicam pharmacokinetics in young and elderly human volunteers.
Ankier, SI; Brimelow, AE; Crome, P; Ferber, HP; Johnston, A; Turner, P; Warrington, SJ, 1988
)
0.27
" The extraction ratio in the liver is small resulting in a long elimination half-life with a mean of 72 hours."( Overview on the pharmacokinetics of tenoxicam.
Guentert, TW; Heintz, RC; Joly, R, 1987
)
0.27
" It is therefore confirmed that piroxicam beta-cyclodextrin has the same pharmacokinetic behaviour at the steady-state in elderly subjects, as the active principle in a non-complexed form."( Pharmacokinetic study on piroxicam at the steady-state in elderly subjects and younger adults after administration of piroxicam beta-cyclodextrin.
Acerbi, D; Bonati, C; Boscarino, G; Bufalino, L; Cesari, F; D'Ambrosio, E; Mansanti, P; Scali, G, 1988
)
0.27
" Distribution and clearance of isoxicam were probably not affected as its half-life was not changed, its plasma peak concentration increased, and the time to reach this peak decreased."( The effect of administration of phenytoin on the pharmacokinetics of isoxicam.
Caillé, G; Du Souich, P; Lacasse, Y; Larivière, L; Vézina, M,
)
0.13
" A wide variation in pharmacokinetic parameters was seen between individuals but there was no suggestion that renal function influenced pharmacokinetics."( Pharmacokinetics and effects of isoxicam on renal function in patients with renal insufficiency.
Boutagy, J; Brooks, PM; Forrest, M; McCredie, M; Munro, I; Pei-Ling, L; Podgorski, M; Prowse, M, 1986
)
0.27
" There were no significant differences in the half-life which averaged 30."( A comparison of isoxicam pharmacokinetics in young and elderly subjects.
Blake, D; Darragh, AS; Frank, GJ; George, CF; Hosie, J; Renwick, AG; van Marle, W, 1986
)
0.27
"1 The pharmacokinetic characteristics and bioavailability of isoxicam were investigated in healthy male volunteers following various routes of administration."( Pharmacokinetics of isoxicam following intravenous, intramuscular, oral and rectal administration in healthy volunteers.
Kölle, EU; Vollmer, KO, 1986
)
0.27
"Only recently have the pharmacokinetic characteristics of nonsteroidal anti-inflammatory drugs (NSAIDs) been recognized as decisive factors in understanding the effects and side effects of these drugs."( Clinical relevance of nonsteroidal anti-inflammatory drug pharmacokinetics.
Brune, K, 1987
)
0.27
"2 h) or time to peak concentration (9."( Pharmacokinetic disposition of isoxicam in hepatic cirrhosis.
East, DS; Esquivel, M; Heathcote, J; Ogilvie, RI; Shaw, DH, 1987
)
0.27
" The mean areas under the plasma concentration-time curve (138 +/- 53 micrograms/ml X h) and terminal half-lives in patients with impaired renal function did not differ from values previously reported in normal volunteers, nor did the peak concentration of tenoxicam."( Pharmacokinetics of tenoxicam in patients with impaired renal function.
Descoeudres, C; Frey, FJ; Guentert, TW; Heizmann, P; Horber, FF; Weidekamm, E, 1986
)
0.27
" A pharmacokinetic test to compare the plasma levels of piroxicam obtained in rat and dog was then made after oral administration of droxicam and piroxicam."( Pharmacokinetics of droxicam in rat and dog.
Esteve, A; Martínez, L; Roser, R; Sagarra, R, 1986
)
0.27
" A full pharmacokinetic analysis was performed."( A pharmacokinetic comparison of tenoxicam in plasma and synovial fluid.
Allen, JG; Bird, HA; Dixon, JS; Wright, V, 1985
)
0.27
"Even the most widely used non-steroidal anti-inflammatory drugs (NSAID's) show considerable variations in their pharmacokinetic behaviour in volunteers and moreso in patients."( Pharmacokinetic factors as causes of variability in response to non-steroidal anti-inflammatory drugs.
Brune, K, 1985
)
0.27
" No effect was evident on the extent of absorption or other pharmacokinetic parameters."( The effects of food and of antacid on the single oral dose pharmacokinetics of tenoxicam.
Dixon, JS; Francis, RJ; Harris, PA; Lowe, JR,
)
0.13
" A full pharmacokinetic analysis was performed."( A pharmacokinetic comparison of tenoxicam in plasma and synovial fluid.
Allen, JG; Bird, HA; Dixon, JS; Wright, V, 1985
)
0.27
" A pharmacokinetic profile was performed after a single 20 mg oral dose."( Single and multiple oral dose pharmacokinetics of tenoxicam in the elderly.
Allen, JG; Bird, HA; Dixon, JS; Francis, RJ; Hill, J; Le Gallez, P; Wright, V, 1985
)
0.27
" The pharmacokinetic profiles of the isoxicam plasma concentration/time data obtained over 96 h following the doses of isoxicam before and during propranolol administration were compared."( The effect of administration of propranolol on the pharmacokinetics of isoxicam.
Besner, JG; Caillé, G; Lacasse, Y; Larivière, L; Vézina, M,
)
0.13
"A single-dose pharmacokinetic study to determine the effect of age on the disposition of isoxicam and piroxicam was carried out on a group of old and a group of young subjects."( Pharmacokinetic projections for isoxicam and piroxicam in old and young subjects.
Campbell, AJ; Edwards, IR; Ferry, DG, 1985
)
0.27
" Pharmacokinetic parameters in 18 patients with evidence of mild or moderate renal impairment at study entry were not different from those in patients without impairment."( Single-dose and steady-state pharmacokinetics of piroxicam in elderly vs young adults.
Casey, E; Darragh, A; Gordon, AJ; Hobbs, D; O'Byrne, H, 1985
)
0.27
" The results indicate that the mean half-life of isoxicam is approximately 24 hours and is independent of dosage."( Pharmacokinetics of isoxicam in the elderly.
Buchanan, WW; Grace, EM, 1985
)
0.27
" The median half-life of elimination from the body was found to be 72 hours (range 42 to 100 hours)."( Pharmacokinetics of tenoxicam in healthy human volunteers.
Brandt, R; Dubach, UC; Enrico, JF; Guentert, TW; Heintz, RC; Jeunet, FS, 1984
)
0.27
" Due to the central role of the liver in the overall elimination of the majority of these compounds, hepatic disease will most likely lead to a significant alteration in their pharmacokinetic behaviour."( Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs.
Blackburn, JL; Loewen, GR; Verbeeck, RK,
)
0.13
" Pharmacokinetic analysis of the data showed the half-life and systemic clearance of piroxicam to be unaffected by age."( Pharmacokinetic observations on piroxicam in young adult, middle-aged and elderly patients.
Bradbrook, ID; Corless, D; Rogers, HJ; Woolf, AD, 1983
)
0.27
" In short term pharmacodynamic studies in healthy volunteers, piroxicam-beta-cyclodextrin was equivalent to or tended to show less gastrointestinal mucosal toxicity than standard piroxicam, as assessed by endoscopy and faecal blood loss."( Piroxicam-beta-cyclodextrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in rheumatic diseases and pain states.
Balfour, JA; Lee, CR, 1994
)
0.29
"There was no significant difference in the pharmacokinetic parameters of tolbutamide (500 mg) determined before and after 14 days treatment with tenoxicam (20 mg/day) in 7 healthy volunteers (6 male, 1 female)."( The effect of tenoxicam on tolbutamide pharmacokinetics and glucose concentrations in healthy volunteers.
Day, RO; Geisslinger, G; Paull, P; Williams, KM, 1995
)
0.29
"The pharmacokinetic profile of total and free methotrexate (MTX) and the effect of piroxicam on MTX pharmacokinetics was studied in 20 rheumatoid arthritis patients receiving a stable dosage of MTX (10 mg/week)."( Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients.
Acquaviva, P; Bernard, JC; Bologna, C; Bressolle, F; Combe, B; Edno, L; Lafforgue, P; Sany, J, 1995
)
0.29
" Pharmacokinetic studies comparing piroxicam beta-cyclodextrin with plain piroxicam have been carried out in both patients and healthy subjects."( Supermolecular inclusion of piroxicam with beta-cyclodextrin: pharmacokinetic properties in man.
Acerbi, D; Merz, PG; Rietbrock, N; Rietbrock, S; Woodcock, BG, 1993
)
0.29
" No statistically significant differences in the pharmacokinetic parameters were noted between the first and last dose of extended-release ketoprofen; that is, there was no accumulation of ketoprofen."( Comparison of the efficacy, safety, and pharmacokinetic profiles of extended-release ketoprofen and piroxicam in patients with rheumatoid arthritis.
Caldwell, JR,
)
0.13
" A mean elimination half-life of 67 hours (49 to 81 hours) has been estimated."( Clinical pharmacokinetics of tenoxicam.
Nilsen, OG, 1994
)
0.29
" Cmax was increased significantly when tenoxicam was given with probenecid (2."( Neither cimetidine nor probenecid affect the pharmacokinetics of tenoxicam in normal volunteers.
Day, RO; Geisslinger, G; Paull, P; Williams, KM, 1994
)
0.29
" The elimination half-life varies between 30 and 70 hours."( Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.
Brunetto, AV; Mattila, MJ; Olkkola, KT, 1994
)
0.29
"The influence of decreased albumin concentration on the pharmacokinetic behaviour of Piroxicam was studied in vivo in rats that had undergone plasmapheresis."( Effect of induced hypoalbuminemia on distribution, total clearance and unbound clearance of piroxicam in vivo in the rat.
Fos, D; Lopez-Bustamante, LG; Troconiz, JI,
)
0.13
" It is completely absorbed after oral and intramuscular administration and slowly eliminated, the long half-life in tissues consenting once-daily administration."( Pharmacokinetics of tenoxicam at different dosage regimes.
Demartini, G; Dugnani, S; Fraschini, F; Scaglione, F; Triscari, FA, 1993
)
0.29
" Piroxicam concentrations were determined by HPLC analysis, and pharmacokinetic parameters were characterized by area-moment analysis."( Effects of age on the pharmacokinetics of piroxicam in rats.
Boudinot, FD; Boudinot, SG; Funderburg, ED, 1993
)
0.29
" A two-compartment population pharmacokinetic model that includes the effect of fu on the kinetic parameters was proposed to describe tenoxicam plasma concentration profiles."( Tenoxicam pharmacokinetics in rats: a population model.
Fos, D; Lopez-Bustamante, LG; Troconiz, IF, 1995
)
0.29
" To derive a model relating drug targeting index (DTI) to the pharmacokinetic parameters of the target and systemic sites, and to compare predictions with observations."( Regional drug delivery II: relationship between drug targeting index and pharmacokinetic parameters for three non-steroidal anti-inflammatory drugs using the rat air pouch model of inflammation.
Brennan, BS; Gifford, LA; Houston, JB; Martin, SW; McLachlan, A; Rowland, M; Stevens, AJ, 1995
)
0.29
" The pharmacokinetic parameter values (mean +/- RSD) of piroxicam after administration of droxicam alone were: AUC0-->infinity = 125."( A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics.
Maya, MT; Morais, JA; Pais, JP; Ruas Da Silva, J,
)
0.13
" The pharmacokinetic profiles of piroxicam in rat lymph were very similar in both groups."( Pharmacokinetic profile of piroxicam beta-cyclodextrin, in rat plasma and lymph.
Bersani-Amado, CA; Kimura, E; Oga, S; Santos, SR; Sudo, LS, 1997
)
0.3
" Pharmacokinetic investigations have shown the drug to be highly bound to blood proteins, mainly serum albumin, and to have a low brain uptake, explaining its lack of sedative effects."( Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.
Carrupt, PA; Jolliet, P; Morin, C; Morin, D; Pagliara, A; Rihoux, JP; Testa, B; Tillement, JP; Urien, S, 1998
)
0.3
" The analgesic activity of nimesulide was subsequently correlated with its pharmacokinetic profile."( Analgesic efficacy and pharmacokinetics of topical nimesulide gel in healthy human volunteers: double-blind comparison with piroxicam, diclofenac and placebo.
Gupta, SK; Kabir, SR; Sengupta, S; Velpandian, T, 1998
)
0.3
" Peak analgesic effect was observed at 120 min post-treatment, which correlated with the pharmacokinetic profile of the drug in gel formulation."( Analgesic efficacy and pharmacokinetics of topical nimesulide gel in healthy human volunteers: double-blind comparison with piroxicam, diclofenac and placebo.
Gupta, SK; Kabir, SR; Sengupta, S; Velpandian, T, 1998
)
0.3
"The superior analgesic activity of nimesulide (as gel formulation), correlating with its pharmacokinetic profile, indicates that the topical route of administration may be a safe and effective alternative to the presently used oral and rectal routes."( Analgesic efficacy and pharmacokinetics of topical nimesulide gel in healthy human volunteers: double-blind comparison with piroxicam, diclofenac and placebo.
Gupta, SK; Kabir, SR; Sengupta, S; Velpandian, T, 1998
)
0.3
" Pharmacokinetic studies conducted on rats showed that these molecules were able to highly concentrate in joint cartilages but their bioavailability by the oral way was low."( New quaternary ammonium oxicam derivatives targeted toward cartilage: synthesis, pharmacokinetic studies, and antiinflammatory potency.
Giraud, I; Madelmont, JC; Maurizis, JC; Nicolas, C; Ollier, M; Rapp, M; Verny, M, 1999
)
0.3
" An approach to predict pharmacokinetic interactions of lornoxicam from in vitro inhibition data was developed."( Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants.
Kohl, C; Steinkellner, M, 2000
)
0.31
"This study explored the interference by Maytenus aquifolium leaves hydroalcoholic (MALHE) extract, administered orally, on the pharmacokinetic and antiinflammatory activity of piroxicam in rats."( Effect of Maytenus aquifolium extract on the pharmacokinetic and antiinflammatory effectiveness of piroxicam in rats.
Albiero, AL; Bersani-Amado, CA; Caparroz-Assef, SM; Cuman, RK; Kimura, E; Oga, S, 2000
)
0.31
" The pharmacokinetic data were best described by a two-compartment model with first-order absorption."( Comparative population pharmacokinetic-pharmacodynamic analysis for piroxicam-beta-cyclodextrin and piroxicam.
Hu, C; Miller, R; Wang, D; Zheng, J, 2000
)
0.31
" Pharmacokinetic disposition of tenoxicam in this patient cohort was also described."( Tenoxicam i.v. in major gynaecological surgery--pharmacokinetic, pain relief and haematological effects.
Chilvers, M; Jones, RD; Lang, C; Lo, SK; Miles, W; Prankerd, R, 2000
)
0.31
" The study was also extended to determine the pharmacokinetic profile of a newer formulation of meloxicam gel after topical application on depilated skin of rats."( Comparison of analgesic and anti-inflammatory activity of meloxicam gel with diclofenac and piroxicam gels in animal models: pharmacokinetic parameters after topical application.
Bansal, P; Bhardwaj, RK; Gupta, SK; Jaiswal, J; Velpandian, T,
)
0.13
" A positive correlation was found between an increase in the free fraction (% F) of tenoxicam in plasma and a decrease in the plasma elimination half-life in the low creatinine clearance group (40-20 ml/min."( Single- and multiple-dose pharmacokinetics, kidney tolerability and plasma protein binding of tenoxicam in renally impaired patients and healthy volunteers.
Aasarød, K; Guentert, TW; Nilsen, OG; Widerøe, TE, 2001
)
0.31
" Pharmacokinetic parameters of PIRO were determined using noncompartmental analysis."( Single dose pharmacokinetics of piroxicam in cats.
Chun, R; Goatley, MA; Heeb, HL; Hunter, RP; Koch, DE, 2003
)
0.32
" A 2-compartment pharmacokinetic model was used for fitting the plasma concentration versus time data, and the individual model descriptive parameters were used to simulate the plasma tenoxicam concentrations during repeated dosing for 7 consecutive days."( CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians.
Perini, JA; Rondinelli, E; Suarez-Kurtz, G; Vianna-Jorge, R, 2004
)
0.32
" Eight healthy males and eight healthy females participated in the trial, which was conducted in a pharmacokinetic (PK) part followed by a pharmacodynamic (PD) part."( A pharmacokinetic and pharmacodynamic study of desmopressin: evaluating sex differences and the effect of pre-treatment with piroxicam, and further validation of an indirect response model.
Callréus, T; Höglund, P; Lundin, S; Odeberg, JM; Roth, EB, 2004
)
0.32
" An open-label, randomized, single dose, crossover study with a 18 days washout period was conducted in 16 healthy volunteers to compare the pharmacokinetic profile of 20 mg piroxicam freeze-dried tablet (Proxalyoc, Cephalon) with that of 20 mg piroxicam capsule (Feldene, Pfizer)."( Pharmacokinetic profiles of two tablet formulations of piroxicam.
Grangé, V; Rasetti-Escargueil, C, 2005
)
0.33
" There were no significant differences between CYP2C9*1/*2 and CYP2C 9*1/*3 individuals in these pharmacokinetic parameters (P=."( Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam.
Brogliato, AR; Perini, JA; Suarez-Kurtz, G; Vianna-Jorge, R, 2005
)
0.33
" Pharmacokinetic parameters were determined using noncompartmental analysis."( Multiple dose pharmacokinetics and acute safety of piroxicam and cimetidine in the cat.
Chun, R; Corse, M; Garrett, L; Heeb, HL; Hunter, RP; Koch, DE; Moore, L; Pellerin, MA; Radlinsky, M, 2005
)
0.33
"CYP2C9 * 3 greatly affects both the pharmacokinetic profiles of glibenclamide and lornoxicam."( [Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects].
Chen, XY; Guo, YJ; Si, DY; Zhang, YF; Zhong, DF; Zhou, H, 2005
)
0.33
" DRUG-KNT--a pharmacokinetic software developed previously for fitting one and two compartment kinetics using the iterative curve stripping method--was modified and a revised subroutine was incorporated to solve double-peak models."( A simple pharmacokinetics subroutine for modeling double peak phenomenon.
Mahmoudian, M; Mirfazaelian, A, 2006
)
0.33
" Compared with oral administration, maximum plasma concentration (Cmax) was significantly lower, and time to reach Cmax (Tmax) delayed with all formulated tenoxicam TDS."( Pharmacokinetics of formulated tenoxicam transdermal delivery systems.
Chun, I; Gwak, H; Kang, E; Kim, T, 2008
)
0.35
" The aim of this study was to evaluate the effects of CYP2C9*1/*13 on the pharmacokinetic parameters of lornoxicam in healthy individuals."( Effects of the CYP2C9*1/*13 genotype on the pharmacokinetics of lornoxicam.
Bae, JW; Choi, CI; Jang, CG; Kim, MJ; Lee, SY; Park, YS, 2011
)
0.37
" The development of NSAIDs having safer therapeutic profile depends on the better understanding of their mechanisms, physicochemical and pharmacokinetic properties."( Self-organizing molecular field analysis of NSAIDs: assessment of pharmacokinetic and physicochemical properties using 3D-QSPkR approach.
Kumar, M; Sinha, VR; Thareja, S, 2012
)
0.38
" Saliva and plasma samples were collected for 3-5 half-life values of sitagliptin, cinacalcet, metformin, montelukast, tolterodine, hydrochlorothiazide (HCT), lornoxicam, azithromycin, diacerhein, rosuvastatin, cloxacillin, losartan and tamsulosin after oral dosing."( Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system.
Arafat, T; Idkaidek, N, 2012
)
0.38
"PXM was subjected to melt sonocrystallization to obtain product designated as MSCPXM and characterized for various pharmacotechnical parameters, performance characteristics and pharmacokinetic evaluation."( Melt sonocrystallized piroxicam for oral delivery: particle characterization, solid state analysis, and pharmacokinetics.
Gupta, PS; Pathak, K; Sharma, V, 2013
)
0.39
" In vivo pharmacodynamic study was performed using egg albumin- induced pedal edema in rats."( Pharmacodynamics of piroxicam from novel solid lipid microparticles formulated with homolipids from Bos indicus.
Adikwu, MU; Attama, AA; Ibezim, EC; Kenechukwu, FC; Nnamani, PO, 2013
)
0.39
" Pharmacodynamic activity of the Lor-Nio gel was performed by carragenan-induced rat paw model."( Niosomal gel of lornoxicam for topical delivery: in vitro assessment and pharmacodynamic activity.
Kumbhar, D; Vavia, P; Wavikar, P, 2013
)
0.39
" To the authors' knowledge, this study represents the first pharmacokinetic investigation of piroxicam in an avian species."( PHARMACOKINETICS OF PIROXICAM IN CRANES (FAMILY GRUIDAE).
Cox, SK; Doss, GA; Elsmo, B; Franzen-Klein, D; Hartup, BK; Keiper, NL, 2017
)
0.46
"A quantitative prediction of human pharmacokinetic (PK) profiles has become an increasing demand for the reduction of the clinical failure of drug formulations."( Justification of Biowaiver and Dissolution Rate Specifications for Piroxicam Immediate Release Products Based on Physiologically Based Pharmacokinetic Modeling: An In-Depth Analysis.
Jiang, Q; Li, H; Li, J; Li, X; Luo, C; Wang, W; Wang, Y; Wu, C; Wu, W; Yang, Y; Zhang, T; Zhang, Y, 2019
)
0.51
"The present study was aimed to prepare and characterize new cocrystals of lornoxicam (LORX), a BCS class II drug employing 1,3-dimethyl urea (DMU) as a coformer to improve physicochemical, pharmaceutical, and pharmacokinetic performance."( Amelioration of physicochemical, pharmaceutical, and pharmacokinetic properties of lornoxicam by cocrystallization with a novel coformer.
Abbas, N; Afzal, H; Bukhari, NI; Fatima, K; Hussain, A; Latif, S; Shamim, R, 2021
)
0.62
"Lornoxicam physiologically based pharmacokinetic (PBPK) models were developed and validated on the basis of clinical pharmacokinetic results obtained by considering CYP2C9 genetic polymorphisms in healthy adult populations."( Physiologically Based Pharmacokinetic (PBPK) Modeling of Lornoxicam: Exploration of doses for CYP2C9 Genotypes and Patients with Cirrhosis.
Jang, JH; Jeong, SH; Lee, YB, 2022
)
0.72

Compound-Compound Interactions

Cisplatin combined with the cox-inhibitor piroxicam would induce remission more frequently than cisplatin alone in a relevant animal model of human invasive TCC. Administration of gemcitabine failed to provide a longer overall survival time in dogs with TCC of the urinary bladder.

ExcerptReferenceRelevance
"A study of pirprofen (rengasil) combined with small doses of corticosteroids in 93 patients with rheumatoid arthritis during a double blind multicentre testing showed good and satisfactory therapeutic results in 60%."( [Study of pirprofen (rengasil) combined with maintenance doses of corticosteroids in rheumatoid arthritis in a double-blind multicenter trial].
Alekberova, ZS; Kobaladze, SG; Pokryshkin, VI; Taletene, IP; Trofimova, TM, 1986
)
0.27
" Based on the results of these five drug-drug interaction studies and the known biotransformation pathways of nonsteroidal antiinflammatory drugs, it is speculated that the pharmacokinetic interaction, which is unique to diclofenac, is caused by inhibition by cyclosporine of diclofenac's first-pass metabolism."( Cyclosporine and nonsteroidal antiinflammatory drugs: exploring potential drug interactions and their implications for the treatment of rheumatoid arthritis.
Francheteau, P; Gerbeau, C; Guerret, M; Kovarik, JM; Mueller, EA; Tarral, A, 1997
)
0.3
" The purpose of this study was to determine whether cisplatin combined with the cox-inhibitor piroxicam would induce remission more frequently than cisplatin alone in a relevant animal model of human invasive TCC."( Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer.
Adams, LG; Bonney, PL; DeGortari, AE; DeNicola, DB; Glickman, LT; Glickman, NW; Han, C; Knapp, DW; Kuczek, T; Widmer, WR, 2000
)
0.31
" every 21 days) or cisplatin (same dosage) combined with piroxicam (0."( Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer.
Adams, LG; Bonney, PL; DeGortari, AE; DeNicola, DB; Glickman, LT; Glickman, NW; Han, C; Knapp, DW; Kuczek, T; Widmer, WR, 2000
)
0.31
"The objectives of this study were: (a) to determine the antitumor activity and toxicity of a cyclooxygenase inhibitor (piroxicam) combined with cisplatin chemotherapy in dogs with naturally-occurring, invasive transitional cell carcinoma (TCC) of the urinary bladder; and (b) to determine the effects of this treatment on prostaglandin E(2) concentration, tumor cell proliferation and apoptosis, and angiogenesis."( Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.
Bonney, PL; Coffman, KT; Craig, BA; deGortari, AE; Glickman, NW; Knapp, DW; Mohammed, SI; Mutsaers, AJ; Schlittler, DL; Snyder, PW, 2003
)
0.32
"To determine the maximum tolerated dose (MTD) of cisplatin administered with piroxicam, the antitumor activity and toxicity of cisplatin combined with piroxicam in dogs with oral malignant melanoma (OMM) and oral squamous cell carcinoma (SCC), and the effects of piroxicam on the pharmacokinetics of cisplatin in dogs with tumors."( Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs.
Bennett, PF; Boria, PA; Glickman, NW; Knapp, DW; Merkel, BL; Murry, DJ; Mutsaers, AJ; Schlittler, DL; Snyder, PW; Thomas, RM, 2004
)
0.32
" The MTD of cisplatin when administered in combination with piroxicam was 50 mg/m2."( Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs.
Bennett, PF; Boria, PA; Glickman, NW; Knapp, DW; Merkel, BL; Murry, DJ; Mutsaers, AJ; Schlittler, DL; Snyder, PW; Thomas, RM, 2004
)
0.32
"Cisplatin administered in combination with piroxicam had antitumor activity against OMM and SCC."( Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs.
Bennett, PF; Boria, PA; Glickman, NW; Knapp, DW; Merkel, BL; Murry, DJ; Mutsaers, AJ; Schlittler, DL; Snyder, PW; Thomas, RM, 2004
)
0.32
"To evaluate the antitumor activity and toxic effects of a conservative dose of cisplatin administered in combination with piroxicam to dogs with transitional cell carcinoma (TCC) of the urinary bladder."( Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladder.
Bonney, PL; Greenberg, CB; Greene, SN; Knapp, DW; Lucroy, MD, 2007
)
0.34
"Administration of gemcitabine in combination with piroxicam treatment failed to provide a longer overall survival time in dogs with TCC of the urinary bladder, compared with previously reported treatment strategies."( Toxic effects and antitumor response of gemcitabine in combination with piroxicam treatment in dogs with transitional cell carcinoma of the urinary bladder.
Jeglum, AK; Lindner, D; Marconato, L; Nelson, V; Suslak-Brown, L; Zini, E, 2011
)
0.37
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38
"Reported response rates of transitional cell carcinoma (TCC) in dogs to piroxicam in combination with either mitoxantrone or carboplatin are similar; however, it is unknown whether either drug might provide superior duration of response."( Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract transitional cell carcinoma in dogs.
Allstadt, SD; Boostrom, B; Rebhun, RB; Rodriguez, CO; Skorupski, KA, 2015
)
0.42
"This study did not detect a different in outcome in dogs with TCC treated with either mitoxantrone or carboplatin in combination with piroxicam."( Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract transitional cell carcinoma in dogs.
Allstadt, SD; Boostrom, B; Rebhun, RB; Rodriguez, CO; Skorupski, KA, 2015
)
0.42
" The cytotoxic effects of etoposide against canine OSA cell lines, either alone or in combination with piroxicam, have been previously demonstrated in vitro."( Anti-tumour efficacy of etoposide alone and in combination with piroxicam against canine osteosarcoma in a xenograft model.
Choisunirachon, N; Kok, MK; Nakagawa, T; Nishimura, R; Ong, SM; Saeki, K; Tanaka, Y; Yoshitake, R, 2017
)
0.46

Bioavailability

The dissolution of piroxicam is a limiting step in its bioavailability on account of its hydrophobicity. An evaluation of the response-related pharmacokinetics of the three most widely used NSAIDs, diclofenac, indomethacin, and piroXicam, shows some obvious reasons for these differences.

ExcerptReferenceRelevance
" Absorption and elimination of droxicam are independent of the administered dose and the bioavailability of droxicam and piroxicam was equal."( Pharmacokinetic profile of droxicam.
Martínez, L; Sánchez, J, 1991
)
0.28
" The bioavailability of piroxicam was studied in 24 healthy volunteers in a double blind, randomised, cross over study."( Comparative bioavailability of two different rectal preparations of piroxicam in man.
Benkö, S; Grézal, G; Klebovich, I; Nagy, E, 1992
)
0.28
" In this study, the comparative bioavailability of the two compounds was investigated."( Cross-over study of the bioavailability of a new NSAID (droxicam) versus piroxicam in healthy volunteers following single and multiple dose administration.
Bartlett, A; Costa, A; Martinez, L; Roser, R; Sagarra, R; Sanchez, J,
)
0.13
" An in-vivo absorption study was performed on eight male healthy volunteers to compare the bioavailability of piroxicam in presence and absence of casein using plasma data after 100 mg single dose treatment."( Piroxicam-natural polymers interactions.
Abdel-Fatah, IM; Bayomi, MA; el-Shattawy, HH; el-Sherbiny, AI, 1991
)
0.28
" The mean relative bioavailability was 116% for diclofenac plus sucralfate compared to diclofenac alone, and 100% for piroxicam plus sucralfate compared to piroxicam alone."( Study on the interaction between sucralfate and diclofenac/piroxicam in healthy volunteers.
Ungethüm, W, 1991
)
0.28
" Lornoxicam is well absorbed and has a plasma t1/2 in man of 4 hours which is distinctly different from other oxicams."( Overview of the pharmacological properties, pharmacokinetics and animal safety assessment of lornoxicam.
Fellier, H; Mehdi, N; Pruss, TP; Radhofer-Welte, S; Stroissnig, H; Takacs, F; Wendtlandt, W, 1990
)
0.28
" Since pharmacokinetic interactions between antacids and NSAIDs have been reported, it was investigated whether aluminium and magnesium hydroxide (Maalox as oral suspension) or aluminium hydroxide and calcium carbonate (Solugastril as oral gel) influenced the bioavailability of Lornoxicam (rINN), a new potent NSAID from the chemical group of the oxicams."( The effect of concomitantly administered antacids on the bioavailability of lornoxicam, a novel highly potent NSAID.
Dittrich, P; Ferber, HP; Kukovetz, WR; Magometschnigg, D; Mayerhofer, S; Radhofer-Welte, S, 1990
)
0.28
" These results indicate that absorption rate of droxicam has been modified but bioavailability does not suffer modification in conditions of altered gastric emptying."( The influence of gastric emptying on droxicam pharmacokinetics.
Bartlett, A; García-Barbal, J; Martínez, L; Roser, R; Sagarra, R; Sánchez, J, 1989
)
0.28
" A preliminary bioavailability study of two of the lead structures is presented."( Antiinflammatory activity of substituted 6-hydroxypyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-triones. Atypical nonsteroidal antiinflammatory agents.
Blythin, DJ; Bober, LA; Chiu, PJ; Conn, DJ; Domalski, MS; Kaminski, JJ; Solomon, DM; Spitler, J; Verbiar, LL; Wong, SC, 1986
)
0.27
"Present criteria for comparing bioavailability are inadequate when the Cmax and tmax cannot be reliably identified in individual subjects."( Mean apical concentration and duration in the comparative bioavailability of slowly absorbed and eliminated drug preparations.
Carruthers, SG; Freeman, DJ; Pollak, PT, 1988
)
0.27
" The bioavailability of both drugs was equal."( Comparative study of the multiple dose pharmacokinetics and the tolerance of a new NSAID (droxicam) versus piroxicam in healthy volunteers.
Bartlett, A; Costa, A; Estruch, J; García-Barbal, J; Martínez, L; Puig, S; Roser, R; Sagarra, R; Sánchez, J, 1988
)
0.27
" Although comparative bioavailability studies would be required to establish any definitive relationship between dissolution test performance and bioavailability, the failure of most of these products to meet the USP requirement for dissolution indicates formulation differences that could result in altered bioavailability."( Comparative dissolution performance of internationally available piroxicam products.
Barone, JA; Byerly, WG; Colaizzi, JL; Lordi, NG, 1988
)
0.27
"The pharmacokinetics and bioavailability of two piroxicam formulations, 20-mg capsules for oral administration and 20-mg solution for intramuscular injection, were studied in 18 healthy male volunteers."( Pharmacokinetics of intramuscular piroxicam.
Fourtillan, JB, 1987
)
0.27
" 6 These effects of food on tenoxicam bioavailability are unlikely to be of clinical significance during chronic dosing with the drug."( Effect of food and various antacids on the absorption of tenoxicam.
Day, RO; Lam, S; Paull, P; Wade, D, 1987
)
0.27
"1 The pharmacokinetic characteristics and bioavailability of isoxicam were investigated in healthy male volunteers following various routes of administration."( Pharmacokinetics of isoxicam following intravenous, intramuscular, oral and rectal administration in healthy volunteers.
Kölle, EU; Vollmer, KO, 1986
)
0.27
" An evaluation of the response-related pharmacokinetics of the three most widely used NSAIDs, diclofenac, indomethacin, and piroxicam, shows some obvious reasons for these differences: The onset of absorption and the bioavailability of diclofenac can vary considerably, and relevant inter-patient differences are found in the terminal plasma half-life of indomethacin and piroxicam."( Clinical relevance of nonsteroidal anti-inflammatory drug pharmacokinetics.
Brune, K, 1987
)
0.27
" As this absorption is in direct relation to the depth of the lesions, it can be considered from the results of this study that the lesser lesive effect of droxicam on the gastric mucosa when compared to that of piroxicam is due to the fact that, owing to its hydrolysis to piroxicam the absorption rate is slower."( Comparative light and electron microscopic observations of the lesive effects of two non-steroid anti-inflammatory drugs plus stress on rat gastric mucosa.
Castell, O; Colombo, M; Esteve, J; Palacios, G; Roser, R, 1987
)
0.27
" It is concluded that droxicam is a prodrug of piroxicam with a slower rate of absorption, but with the same bioavailability within the range of therapeutic doses."( Pharmacokinetics of droxicam in rat and dog.
Esteve, A; Martínez, L; Roser, R; Sagarra, R, 1986
)
0.27
" An evaluation of the response-related pharmacokinetic parameters of the three presently most widely used NSAID's, namely diclofenac, indomethacin and piroxicam shows some obvious reasons: While the onset of absorption and the bioavailability of diclofenac varies considerably, we find relevant differences in the terminal plasma half-life of indomethacin and particularly piroxicam."( Pharmacokinetic factors as causes of variability in response to non-steroidal anti-inflammatory drugs.
Brune, K, 1985
)
0.27
" The rate of absorption was slower with post-prandial than with pre-prandial administration, resulting in a significantly later time for peak plasma drug levels (4."( The effects of food and of antacid on the single oral dose pharmacokinetics of tenoxicam.
Dixon, JS; Francis, RJ; Harris, PA; Lowe, JR,
)
0.13
" Azapropazone has been found to be well absorbed, and benoxaprofen and fenclofenac somewhat more slowly, so for the latter two drugs their low rate of absorption might also be a factor in their reduced ulcerogenicity."( Structural damage and changes in eicosanoid metabolites in the gastric mucosa of rats and pigs induced by anti-inflammatory drugs of varying ulcerogenicity.
Rainsford, KD, 1986
)
0.27
" This treatment reduced the mean bioavailability of piroxicam by 41."( The effect of activated charcoal on the bioavailability of piroxicam in man.
Laufen, H; Leitold, M, 1986
)
0.27
" It was well absorbed following peroral administration to man, monkey, dog, and rat, reaching peak plasma concentrations in 4-8 hr."( Metabolic disposition of isoxicam in man, monkey, dog, and rat.
Borondy, PE; Michniewicz, BM,
)
0.13
" As a general rule, NSAIDs are well absorbed from the gastrointestinal tract, with the exception of aspirin (and possibly diclofenac, tolfenamic acid and fenbufen) which undergoes presystemic hydrolysis to form salicylic acid."( Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs.
Blackburn, JL; Loewen, GR; Verbeeck, RK,
)
0.13
" These findings combined with the results of the bioavailability tests suggest that the percutaneous application of piroxicam may be exploited to advantage in clinical practice."( Antiinflammatory activity and bioavailability of percutaneous piroxicam.
Acerbi, D; Cadel, S; Pavesi, L; Schiantarelli, P, 1982
)
0.26
"A biopharmaceutics drug classification scheme for correlating in vitro drug product dissolution and in vivo bioavailability is proposed based on recognizing that drug dissolution and gastrointestinal permeability are the fundamental parameters controlling rate and extent of drug absorption."( A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability.
Amidon, GL; Crison, JR; Lennernäs, H; Shah, VP, 1995
)
0.29
" So, it seems to be unreasonable that only serum concentration is taken as a criterion for bioavailability test of piroxicam for local dosage forms, the local drug concentration should also be investigated and evaluated."( [Comparison of concentration of piroxicam in blood and local site after two routes of administration].
Fang, XL; Jiang, XG; Xi, NZ; Zhang, ZR, 1995
)
0.29
" As the inclusion complex of piroxicam-beta-cyclodextrin is wettable and more water soluble, the absorption rate of the drug is increased whilst its other pharmacokinetic characteristics remain unchanged."( Oral bioavailability of CHF1194, an inclusion complex of piroxicam and beta-cyclodextrin, in healthy subjects under single dose and steady-state conditions.
Acerbi, D; Allemon, AM; Deroubaix, X; Lebacq, E; Stockis, A; Ventura, P, 1995
)
0.29
" The absorption rate of piroxicam from the complex, determined using tmax, absorption rate constant (Ka) and plasma concentrations at 15 min and 30 min post-dose, is considerably faster than that for plain piroxicam."( Supermolecular inclusion of piroxicam with beta-cyclodextrin: pharmacokinetic properties in man.
Acerbi, D; Merz, PG; Rietbrock, N; Rietbrock, S; Woodcock, BG, 1993
)
0.29
"Piroxicam-beta-cyclodextrin (PBC), a complex of piroxicam with beta-cyclodextrin, was developed with the aim of improving the hydrosolubility and bioavailability of piroxicam."( Effects of piroxicam-beta-cyclodextrin on the gastrointestinal tract.
Warrington, S, 1993
)
0.29
" This results in an increase in the rate of absorption of the active compound and, consequently, in an earlier onset of analgesic action."( Piroxicam-beta-cyclodextrin in the treatment of acute pain of rheumatic disease.
Franchimont, P; Reginster, JY, 1993
)
0.29
"The bioavailability of two pharmaceutical dosage forms formulated using different polymorphs of tenoxicam were compared."( Bioequivalence of two oral dosage forms prepared from different polymorphic modifications of tenoxicam.
Alkaysi, HN; Badwan, AA; Gharaibeh, AM; Gharaibeh, NM; Salem, MS, 1994
)
0.29
"The bioavailability of tenoxicam (Ro 12-0068, Tilcotil, CAS 59804-37-4) from an effervescent tablet and an instant milk drink formulation relative to the commercial 20 mg tablet was investigated in a randomized cross-over study."( Relative bioavailability of oral dosage forms of tenoxicam.
Banken, L; Defoin, R; Guentert, TW; Schmitt, M; Stebler, T, 1994
)
0.29
" Piroxicam, the most widely used oxicam, is well absorbed after oral administration."( Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.
Brunetto, AV; Mattila, MJ; Olkkola, KT, 1994
)
0.29
" These results indicate that concurrent administration of the antacid does not significantly change the bioavailability and pharmacokinetics of droxicam."( A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics.
Maya, MT; Morais, JA; Pais, JP; Ruas Da Silva, J,
)
0.13
" Bioavailability of piroxicam in plasma is higher after treatment with the inclusion product than with free piroxicam."( Pharmacokinetic profile of piroxicam beta-cyclodextrin, in rat plasma and lymph.
Bersani-Amado, CA; Kimura, E; Oga, S; Santos, SR; Sudo, LS, 1997
)
0.3
"The bioavailability of lornoxicam (CAS 70374-39-9), a novel highly potent anti-inflammatory and analgesic agent, was studied in healthy volunteers after single doses of a new oral formulation (8 mg granules) in comparison to tablets (8 mg)."( Absorption of oral lornoxicam in healthy volunteers using a granular formulation in comparison with standard tablets.
Bareggi, SR; Benvenuti, C; Gambaro, V; Valenti, M, 1997
)
0.3
" This method was used successfully in several thousand samples of pharmacokinetic and bioavailability studies in animals and in humans."( Determination of the novel non-steroidal anti-inflammatory drug lornoxicam and its main metabolite in plasma and synovial fluid.
Dittrich, P; Radhofer-Welte, S, 1998
)
0.3
" There was no significant change in the bioavailability of theses NSAIDs during omeprazole therapy in this study."( Lack of drug-drug interaction between three different non-steroidal anti-inflammatory drugs and omeprazole.
Andersson, T; Bredberg, E; Lagerström, PO; Naesdal, J; Wilson, I, 1998
)
0.3
"The purpose of this research was to determine the effect of major compositional changes on the bioavailability of piroxicam from immediate-release formulations filled in hard gelatin capsules."( The impact of formulation and process changes on in vitro dissolution and the bioequivalence of piroxicam capsules.
Augsburger, L; Bigora, S; Goskonda, S; Lesko, LJ; Piscitelli, DA; Propst, C; Schwartz, P; Young, D, 1998
)
0.3
" In a model-based analysis, an increase of (S)-phenprocoumon and (R)-phenprocoumon bioavailability of 14% [95% CI (9%, 19%)] and 6% (2%, 10%) and a decrease of their clearances by 15% (8%, 21%) and 6% (0%, 13%) was obtained."( Opposite effects of lornoxicam co-administration on phenprocoumon pharmacokinetics and pharmacodynamics.
Fattinger, KE; Masche, UP; Meier, PJ; Rentsch, KM; von Felten, A, 1999
)
0.3
" While these results cannot be used to draw clinical conclusions without bioavailability data, they should nonetheless be kept in mind by healthcare practitioners."( Comparative potency and dissolution performance of internationally available piroxicam products.
Barone, JA, 1992
)
0.28
"Microparticulate polymeric delivery systems have been suggested as a possible approach to improve the low bioavailability characteristics shown by standard ophthalmic vehicles (collyria)."( Pectin microspheres as ophthalmic carriers for piroxicam: evaluation in vitro and in vivo in albino rabbits.
Chetoni, P; Conte, U; Giunchedi, P; Saettone, MF, 1999
)
0.3
" Pharmacokinetic studies conducted on rats showed that these molecules were able to highly concentrate in joint cartilages but their bioavailability by the oral way was low."( New quaternary ammonium oxicam derivatives targeted toward cartilage: synthesis, pharmacokinetic studies, and antiinflammatory potency.
Giraud, I; Madelmont, JC; Maurizis, JC; Nicolas, C; Ollier, M; Rapp, M; Verny, M, 1999
)
0.3
" The results showed no significant difference in piroxicam bioavailability with simultaneous application of MALHE."( Effect of Maytenus aquifolium extract on the pharmacokinetic and antiinflammatory effectiveness of piroxicam in rats.
Albiero, AL; Bersani-Amado, CA; Caparroz-Assef, SM; Cuman, RK; Kimura, E; Oga, S, 2000
)
0.31
" Piroxicam-beta-cyclodextrin (PBCD) was developed for pain indication by virtue of the increased absorption rate of piroxicam."( Comparative population pharmacokinetic-pharmacodynamic analysis for piroxicam-beta-cyclodextrin and piroxicam.
Hu, C; Miller, R; Wang, D; Zheng, J, 2000
)
0.31
" This corresponds to a relative bioavailability of 55."( Intranasal delivery of tenoxicam in rat.
Abimon, VD; Raghavan, CV, 2001
)
0.31
" The absorption rate of TEN increased in parallel with increasing OA concentration, due to the alteration of the stratum corneum caused by this enhancer."( Combined effect of oleic acid and propylene glycol on the percutaneous penetration of tenoxicam and its retention in the skin.
Arellano, A; Larrucea, E; Santoyo, S; Ygartua, P, 2001
)
0.31
" Solid dispersion capsule PNC1 (containing 1:5--drug-carrier ratio solid dispersion) and the corresponding physical mixture capsule PNC1A were used for bioavailability studies in healthy human volunteers."( Dissolution, bioavailability and ulcerogenic studies on piroxicam-nicotinamide solid dispersion formulations.
Balasubramaniam, J; Kumar, MT; Pandit, JK; Verma, MM, 2003
)
0.32
" PIRO is well absorbed in the cat with a median bioavailability (F) of 80% (range 64-124%)."( Single dose pharmacokinetics of piroxicam in cats.
Chun, R; Goatley, MA; Heeb, HL; Hunter, RP; Koch, DE, 2003
)
0.32
" Oral bioavailability of 20 mg piroxicam in GL, CD, and PP was compared after administration of a single dose to eight healthy volunteers."( Enhanced bioavailability of piroxicam using Gelucire 44/14 and labrasol: in vitro and in vivo evaluation.
Baykara, T; Karataş, A; Ozkan, SA; Ozkan, Y; Savaşer, A; Yüksel, N, 2003
)
0.32
" Cyclooxygenase (COX) converts EPA intracellularly into various inflammatory mediators that may affect the bioavailability of this fatty acid for inducing apoptosis in the cancer cells."( Synergistic action of piroxicam on the eicosapentaenoic acid-induced apoptosis is associated with enhanced down-regulation of anti-apoptotic Bcl-2 expression but not promoted activation of pro-apoptotic Bid protein.
Chiu, LC; Ooi, VE; Tong, KF, 2004
)
0.32
" The in vivo delivery of CF by electroporation in mice demonstrated the potential of HPCD for sustaining the transdermal absorption rate of hydrophilic molecules."( Cyclodextrin enhanced transdermal delivery of piroxicam and carboxyfluorescein by electroporation.
Hui, SW; Murthy, SN; Sen, A; Zhao, YL, 2004
)
0.32
" Although the bioavailability of the two formulations was similar, the administration of piroxicam as a freeze-dried tablet gave a much faster absorption rate during the first hour after dosing than the capsule formulation."( Pharmacokinetic profiles of two tablet formulations of piroxicam.
Grangé, V; Rasetti-Escargueil, C, 2005
)
0.33
" These physicochemical results indicate that solid molecular dispersions based on PHEMA hydrogels can effectively enhance the dissolution and therefore should be potentially useful in improving the oral bioavailability of poorly water-soluble drugs."( Solid molecular dispersions of poorly water-soluble drugs in poly(2-hydroxyethyl methacrylate) hydrogels.
Lee, PI; Zahedi, P, 2007
)
0.34
"To enhance the dissolution and oral bioavailability of poorly water soluble piroxicam, the piroxicam-loaded hyaluronic microspheres were prepared with various ratios of piroxicam, sodium hyaluronate and polyethylene glycol 4000 (PEG) using a spray dryer, and their physicochemical properties such as shape, size, drug-loading efficiency and dissolution were investigated."( Enhanced oral bioavailability of piroxicam in rats by hyaluronate microspheres.
Choi, HG; Kim, JH; Kim, JO; Lee, MH; Lyoo, WS; Piao, MG; Yong, CS, 2007
)
0.34
" The bioavailability of pellets (containing 50 mg hydrochlorothiazide) was determined after oral administration to 6 dogs."( Immediate release of poorly soluble drugs from starch-based pellets prepared via extrusion/spheronisation.
Dukić-Ott, A; Foreman, P; Remon, JP; Vervaet, C, 2007
)
0.34
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
" The aqueous solubility and bioavailability of piroxicam in piroxicam-loaded microcapsule in rats were then evaluated compared to piroxicam powder."( Preparation and in vivo evaluation of piroxicam-loaded gelatin microcapsule by spray drying technique.
Choi, HG; Han, SS; Jang, KY; Kim, DD; Kim, JA; Kim, JO; Lee, YB; Li, DX; Lyoo, WS; Piao, MG; Woo, JS; Yang, CW; Yong, CS; Yoo, BK, 2008
)
0.35
"Self-microemulsifying drug delivery systems (SMEDDS) were developed to overcome the problems of delivery and administration of piroxicam, a drug with low bioavailability and gastrointestinal irritation, The in vitro properties of it were assessed."( [Design and in vitro evaluation of self-microemulsifying drug delivery systems for piroxicam].
Nie, SF; Pan, WS; Sun, JY; Wang, J; Wang, Y; Zhou, XT, 2008
)
0.35
" PCA processing could provide an effective pharmaceutical formulation technology to improve the bioavailability of poorly water-soluble drug."( Formation and characterization of solid dispersions of piroxicam and polyvinylpyrrolidone using spray drying and precipitation with compressed antisolvent.
Li, J; Wang, W; Winstead, DA; Wu, K, 2009
)
0.35
" Collected results suggest that the proposed one-pot process can be used to prepare polymer based composites to increase bioavailability of low solubility drugs without utilization of toxic solvents and under mild temperature conditions."( A one-pot method to enhance dissolution rate of low solubility drug molecules using dispersion polymerization in supercritical carbon dioxide.
Filardo, G; Galia, A; Scialdone, O; Spanò, T, 2009
)
0.35
" These "in combo" PAMPA data were used to predict the human absolute bioavailability of the ampholytes."( The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
Avdeef, A; Sun, N; Tam, KY; Tsinman, O, 2010
)
0.36
"An attempt has been made in the present research to formulate piroxicam into bioadhesive ocular inserts with an objective to sustain drug release, reduce frequency of dosing, and enhance ocular bioavailability of piroxicam."( Piroxicam bioadhesive ocular inserts: physicochemical characterization and evaluation in prostaglandin-induced inflammation.
Gilhotra, N; Gilhotra, RM; Mishra, DN, 2009
)
0.35
"Formulation was found promising, as it sustained the drug release and enhanced the ocular bioavailability of piroxicam as compared to piroxicam eye drops."( Piroxicam bioadhesive ocular inserts: physicochemical characterization and evaluation in prostaglandin-induced inflammation.
Gilhotra, N; Gilhotra, RM; Mishra, DN, 2009
)
0.35
" Although there are generic formulations of oral piroxicam marketed in Mexico, a literature search did not identify published data concerning the bioavailability of these formulations in the Mexican population."( Relative bioavailability of two oral formulations of piroxicam 20 mg: a single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Mexican adult volunteers.
Burke-Fraga, V; Cariño, L; González-de la Parra, M; Lopez-Gamboa, M; Palma-Aguirre, JA, 2010
)
0.36
"The aims of this study were to determine the bioequivalence of a generic (test) and a reference formulation of oral piroxicam 20 mg and to generate data regarding the oral bioavailability of this drug in a Mexican population."( Relative bioavailability of two oral formulations of piroxicam 20 mg: a single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Mexican adult volunteers.
Burke-Fraga, V; Cariño, L; González-de la Parra, M; Lopez-Gamboa, M; Palma-Aguirre, JA, 2010
)
0.36
" To show the importance of physicochemical properties, the classic QSAR and CoMFA of neonicotinoids and prediction of bioavailability of pesticides in terms of membrane permeability in comparison with drugs are described."( Importance of physicochemical properties for the design of new pesticides.
Akamatsu, M, 2011
)
0.37
"The aim of this study was to gain understanding about the effects of different solid-state forms of a poorly water-soluble piroxicam on drug dissolution and oral bioavailability in rats."( Solid-state dependent dissolution and oral bioavailability of piroxicam in rats.
Aaltonen, J; Heinämäki, J; Kogermann, K; Laidmäe, I; Lust, A; Meos, A; Palo, M; Veski, P, 2013
)
0.39
"The dissolution of piroxicam is a limiting step in its bioavailability on account of its hydrophobicity."( Pharmacodynamics of piroxicam from novel solid lipid microparticles formulated with homolipids from Bos indicus.
Adikwu, MU; Attama, AA; Ibezim, EC; Kenechukwu, FC; Nnamani, PO, 2013
)
0.39
" Furthermore, the dose related bioavailability was determined by investigating the experimental saturation concentrations for different doses."( Dissolution testing of amorphous solid dispersions.
Jeeger, K; Kogermann, K; Naelapää, K; Penkina, A; Predbannikova, K; Rantanen, J; Veski, P, 2013
)
0.39
" The extent of piroxicam absorption seems not to depend on manufacturing conditions or excipients, so the risk of bioinequivalence in terms of area under the curve (AUC) is very low, but the rate of absorption (i."( Biowaiver monographs for immediate release solid oral dosage forms: piroxicam.
Abrahamsson, B; Barends, DM; Dressman, JB; Groot, DW; Kopp, S; Kulinich, JI; Langguth, P; Polli, JE; Ramenskaya, GV; Shah, VP; Shohin, IE, 2014
)
0.4
"The present work was performed aiming to develop a new solid self-emulsifying system (SMEDDS) for poorly water-soluble drug Lornoxicam and evaluate the bioavailability in Wister rats by oral gavage."( Preparation and pharmacokinetics evaluation of oral self-emulsifying system for poorly water-soluble drug Lornoxicam.
Guo, Y; Li, F; Pan, W; Song, S; Yang, X; Zhang, X; Zhao, Q, 2015
)
0.42
" The primary factor leading to increased bioavailability is the administration of the drug in a pre-dissolved state thereby avoiding the dissolution limiting step."( Development of self emulsifying lipid formulations of BCS class II drugs with low to medium lipophilicity.
Belotti, S; Chavant, Y; Chevrier, S; Demarne, F; Dumont, C; Jannin, V; Michenaud, M, 2015
)
0.42
"To determine if a novel electrospraying technique could be applied to an oral drug delivery system for improving the solubility and oral bioavailability of poorly water-soluble piroxicam; the nanospheres were generated with drug and polyvinylpyrrolidone (PVP) using electrospraying technique; and their physicochemical properties, solubility, release and pharmacokinetics were evaluated in comparison with piroxicam powder."( Novel piroxicam-loaded nanospheres generated by the electrospraying technique: physicochemical characterisation and oral bioavailability evaluation.
Cho, KH; Choi, HG; Din, FU; Kim, DW; Kim, JO; Lim, SJ; Mustapha, O; Park, JH; Rashid, R; Woo, KB; Yong, CS; Youn, YS; Yousaf, AM, 2016
)
0.43
"Drug solubility and lymphatic transport enhancements are two main pathways to improve drug oral bioavailability for microemulsions."( Microemulsions containing long-chain oil ethyl oleate improve the oral bioavailability of piroxicam by increasing drug solubility and lymphatic transportation simultaneously.
Guo, Q; Hu, H; Li, P; Song, J; Wang, K; Wu, C; Xing, Q; Xu, D; You, X, 2016
)
0.43
" It shows limited solubility in the gastric pH, delayed bioavailability and pharmacodynamic effects with aggravated gastric side effects (due to longer residence in the stomach wall)."( Comparative study on the in vitro performance of blister molded and conventional lornoxicam immediate release liquitablets: accelerated stability study and anti-inflammatory and ulcerogenic effects.
Badawi, AA; El-Setouhy, DA; Gamiel, AA; Labib, DA; Osman, AS, 2017
)
0.46
"The obtained results ratify that S-sSNEDDS is a promising drug delivery system to enhance the oral bioavailability of piroxicam."( Nanoemulsifying drug delivery system to improve the bioavailability of piroxicam.
Abd El-Gawad, AE; Borg, T; Motawea, A; Tarshoby, M, 2017
)
0.46
"Microemulsion was prepared using several concentrations of selected oil (pine oil), surfactant (cre- mophor RH40), co-surfactant (isopropanol) and water to improve bioavailability by increasing solubility and permeability of lomoxicam, which was then incorporated to carbomer 940 gel base to fabricate microemulsion based gel (MEBG) to sustained permeability for transdermal delivery."( A QUALITY BY DESIGN APPROACH: FABRICATION, CHARACTERIZATION AND EVALUATION OF OPTIMIZED TRANSDERMAL THERAPEUTIC SYSTEM FOR ANTIRHEUMATIC LORNOXICAM.
Ali, A; Khalid, N; Khan, JA; Naeem, M; Nawaz, Z; Pervaiz, F; Yousup, M, 2017
)
0.46
"Evaluation of drug precipitation is important in order to address challenges regarding low and variable bioavailability of poorly water-soluble drugs, to assess potential risk of patient safety with infusion therapy, and to explore injectable in situ suspension-forming drug delivery systems."( UV-vis Imaging of Piroxicam Supersaturation, Precipitation, and Dissolution in a Flow-Through Setup.
Chapman, A; Goodall, DM; Jensen, H; Larsen, SW; Petersen, NJ; Sun, Y; Østergaard, J, 2018
)
0.48
" Compound 12g with MIC values of 5 μg/ml as a representative may possess better oral bioavailability and indicated high permeability by the parallel artificial membrane permeation assay of the blood-brain barrier (PAMPA-BBB)."( Discovery of novel anti-tuberculosis agents with pyrrolo[1,2-a]quinoxaline-based scaffold.
An, Q; Deng, Y; Liu, P; Luo, Y; Sang, Z; Tang, Y; Wang, T; Yang, T; Yang, Y; Zhang, T, 2018
)
0.48
"Co-amorphous drug delivery systems are a promising approach to improve the dissolution rate and therefore potentially the oral bioavailability of poorly-water soluble drugs."( Aspartame as a co-former in co-amorphous systems.
Grohganz, H; Knuhtsen, A; Löbmann, K; Pedersen, DS; Rades, T; Schnitzkewitz, J; Wu, W, 2018
)
0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" The study concludes that binary solid dispersion with Solutol has effectively increased the solubility of piroxicam that in turn has increased its dissolution rate, therefore useful in enhancing the bioavailability of this poorly soluble drug."( Effect of low melting hydrophilic carriers on the solubility and dissolution rate of Piroxicam using solid dispersion technique.
Abbas, N; Arshad, MS; Bukhari, NI; Farrukh, M; Hussain, A; Irfan, M, 2019
)
0.51
"The knowledge on human serum albumin (HSA) binding is of utmost importance as it affects pharmacokinetic behavior and bioavailability of drugs."( Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
Bajusz, D; Balogh, GT; Dargó, G; Müller, J; Simon, K, 2020
)
0.56
" The intent of this study was to ameliorate the bioavailability of the drug by employing a solubility-enhancing encapsulation technique."( Electrospun Gelatin Nanocontainers for Enhanced Biopharmaceutical Performance of Piroxicam: In Vivo and In Vitro Investigations.
Anwer, K; Din, FU; Ghori, MU; Hussain, T; Jamshaid, T; Khan, IU; Mehmood, Y; Mustapha, O; Shafique, S; Shahzad, Y; Yousaf, AM; Yousafi, QUA; Zhao, L, 2020
)
0.56
" Evaluation of solubility and release rate in water and assessment of bioavailability in rats were carried out in comparison with piroxicam plain drug powder (PPDP)."( Electrospun Gelatin Nanocontainers for Enhanced Biopharmaceutical Performance of Piroxicam: In Vivo and In Vitro Investigations.
Anwer, K; Din, FU; Ghori, MU; Hussain, T; Jamshaid, T; Khan, IU; Mehmood, Y; Mustapha, O; Shafique, S; Shahzad, Y; Yousaf, AM; Yousafi, QUA; Zhao, L, 2020
)
0.56
" Amelioration in bioavailability of piroxicam with the aforementioned PLGN formulation was fourfold that of PPDP."( Electrospun Gelatin Nanocontainers for Enhanced Biopharmaceutical Performance of Piroxicam: In Vivo and In Vitro Investigations.
Anwer, K; Din, FU; Ghori, MU; Hussain, T; Jamshaid, T; Khan, IU; Mehmood, Y; Mustapha, O; Shafique, S; Shahzad, Y; Yousaf, AM; Yousafi, QUA; Zhao, L, 2020
)
0.56
" Adsorption on mesoporous silicas increases their bioavailability when administered orally."( Improved solubility of lornoxicam by inclusion into SBA-15: Comparison of loading methods.
Bilski, P; Dadej, A; Dadej, D; Jelińska, A; Józkowiak, M; Pawełczyk, A; Piotrowska-Kempisty, H; Woźniak-Braszak, A; Łażewska, D, 2022
)
0.72
"Intra-articular (IA) injection is grasping much interest due to the poor drug bioavailability at the targeted site of action which minimizes the effect of the orally administered moiety."( Artificial intelligence-assisted development of
Ammar, HO; El Hoffy, NM; Ibrahim, M; Mansour, SM; Yacoub, AS, 2022
)
0.72
" Mucoadhesive buccal tablets containing LRX -loaded solid lipid nanoparticles (SLNs) were developed to enhance the drug solubility and bioavailability and achieve a controlled release pattern for a better anti-inflammatory effect."( Design, characterization and in vivo performance of solid lipid nanoparticles (SLNs)-loaded mucoadhesive buccal tablets for efficient delivery of Lornoxicam in experimental inflammation.
Abd-Allah, SM; E Eissa, J; El-Dakroury, WA; F Asaad, G; K Hosny, S; S Mohamed, S; Sallah, SK; Swellam, SM; Zewail, MB, 2022
)
0.72
"42 fold enhancement in the relative bioavailability of PXM-NS10 as compared to commercial tablets."( Formulation and evaluation of Piroxicam nanosponge for improved internal solubility and analgesic activity.
Abdoun, SA; Alail, JA; Aljumah, RS; Alkhalifah, SA; Aloqla, RM; Alzughaibi, DA; Gaber, DA; Radwan, MA, 2023
)
0.91

Dosage Studied

The objective of this study is to evaluate and compare the analgesic efficacy of Piroxicam Fast Dissolving Dosage Formulation (FDDF) administered sublingually either preoperatively or postoperatively with aspirin and placebo. The elimination of piroXicam is impaired in some elderly patients, resulting in a high interindividual variability in average steady state levels.

ExcerptRelevanceReference
" After human Tenon's fibroblast cell lines were established, a complete dose-response curve was done for the representative compounds for 8 days."( Effect of steroids and nonsteroidal antiinflammatory agents on human ocular fibroblast.
Lee, DA; Nguyen, KD, 1992
)
0.28
" Tenoxicam plasma concentrations measured during once daily dosing before and after haemodialysis showed that tenoxicam does not accumulate."( The effect of haemodialysis on the pharmacokinetics of tenoxicam in patients with end-stage renal disease.
al-Ghamdi, MS; al-Mohanna, FA; al-Mustafa, ZH; al-Saeed, IS, 1992
)
0.28
" All four muscles from the topically dosed shoulder exhibit two distinct peaks, the first at 4 hr and a later one at 12 hr (which coincides with the topical Cpmax)."( Local enhanced topical delivery (LETD) of drugs: does it truly exist?
Francoeur, ML; McNeill, SC; Potts, RO, 1992
)
0.28
" Upper endoscopies were performed at the baseline and at the end of each 2-week dosing arm of the study."( A pharmacokinetic and endoscopic comparison of an oral and an experimental buccal piroxicam formulation.
Brater, DC; Figueroa, N; Greene, P; Mueller, BA; Rex, DK, 1992
)
0.28
" Compared with many other NSAIDs, tenoxicam offers certain advantages in that it is conveniently administered once daily and dosage adjustment is not required in the elderly or in patients with renal or hepatic impairment."( Tenoxicam. An update of its pharmacology and therapeutic efficacy in rheumatic diseases.
Clissold, SP; Todd, PA, 1991
)
0.28
"3 mg/kg piroxicam q24h per os, the accepted canine dosage prior to this trial."( Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors.
Bottoms, GD; Chan, TC; Knapp, DW; Richardson, RC; Teclaw, R, 1992
)
0.28
" The 5-lipoxygenase inhibitor diethylcarbamazine and the LTD4/LTE4 receptor antagonist LY 171883 markedly reduced mortality in dose-response fashion."( Effects of some nonsteroidal anti-inflammatory agents on experimental radiation pneumonitis.
Gross, NJ; Holloway, NO; Narine, KR, 1991
)
0.28
" Since the tolerance was good, we recommend midday as an optimal once-a-day dosing time."( [Chronotherapy of tenoxicam].
Chaouat, D; Chaouat, Y; Delcambre, B; Kahn, MF; Le Goff, P; Manfredi, R; Maugars, Y; Reinberg, A; Valat, JP,
)
0.13
" Tenoxicam concentrations were measured in plasma (10 samples) and synovial fluid (6 samples) over a 24-hour dosage interval at steady state in 10 subjects with arthritis who had been taking the drug at a dosage of 20 mg/day for at least 2 weeks."( The pharmacokinetics of total and unbound concentrations of tenoxicam in synovial fluid and plasma.
Day, RO; Graham, S; Handel, M; Williams, KM, 1991
)
0.28
" Our observations are based on the results of a 13 week routine experiment (control group and dosage groups 5-, 50- and 700 mg/kg per day UH-A 46 XX) and on a special open-ended reversibility study (control group and dosage groups 50- and 700 mg/kg)."( Experimental pancytopenia of the peripheral blood with granulocytopoietic bone marrow hyperplasia in the beagle-dog.
Bauer, M; Busch, U; Meister, H; Schneider, P, 1990
)
0.28
" The dosage for piroxicam was 40 mg on the first and second day of the menstrual cycle, and if necessary an additional 20 mg on the third day."( [Piroxicam versus naproxen in primary dysmenorrhea].
Saltveit, T, 1989
)
0.28
" Therefore, no dosage adjustment of this drug is necessary in elderly patients to achieve similar plasma concentrations following standard dosing in young subjects."( Effect of age on the pharmacokinetics of tenoxicam in comparison to other non-steroidal anti-inflammatory drugs (NSAIDs).
Guentert, TW; Schmitt, M, 1989
)
0.28
" Gastroscopy was performed at base-line after the dosing period of 14 days and again after a follow-up period of 14 days without any treatment."( [Gastroduodenal tolerance of tenoxicam versus diclofenac-Na: an endoscopy double-blind controlled study in healthy probands].
Dammann, HG; Marinis, E; Müller, P; Simon, B,
)
0.13
" In this study, four NSAIDs were investigated for their phototoxicity potential in human volunteers using an oral dosing protocol."( Photosensitizing potential of certain nonsteroidal anti-inflammatory agents.
Kaidbey, KH; Mitchell, FN, 1989
)
0.28
" Gastric tolerance was assessed by endoscopy, which was performed at base-line, after the 14 day dosing period and after a 14 day follow-up period without treatment."( Comparison of the gastroduodenal tolerance of tenoxicam and diclofenac Na. A double-blind, endoscopically controlled study in healthy volunteers.
Dammann, HG; Leucht, U; Müller, P; Simon, B, 1989
)
0.28
" To ensure the human therapeutic dose, each drug was given twice a day per os in 3 different dosage regimes."( Impact of NSAIDS on murine antigen induced arthritis. I. Investigation of antiinflammatory and chondroprotective effects.
de Vries, BJ; van den Berg, WB, 1989
)
0.28
" 4 It was concluded that patients with hepatic insufficiency do not require a systematic modification of drug dosage but that long-term treatment should be employed with caution in these patients."( Pharmacokinetics of isoxicam in hepatic disease.
Cuisinaud, G; Ferry, N; Ouzan, D; Sassard, J; Trepo, C, 1986
)
0.27
" Except for a few patients with injection site pain, the side-effect profile was similar to that established with the oral dosage form."( Intramuscular piroxicam, a new dosage form, in the treatment of acute musculoskeletal disorders.
Kilgour, M; Wiseman, RL, 1985
)
0.27
" Using data from a study of three dosage forms of piroxicam, we propose an alternative approach which decreases the influence of sampling bias and analytical error on the identification of the apex of the concentration-time curve and provides a simple tool for describing the shape of the curve around the apex."( Mean apical concentration and duration in the comparative bioavailability of slowly absorbed and eliminated drug preparations.
Carruthers, SG; Freeman, DJ; Pollak, PT, 1988
)
0.27
"The presence of piroxicam in breast milk was determined by HPTLC during initial and long term dosing in 4 women treated for arthritis."( Piroxicam in breast milk after long-term treatment.
Laufen, H; Matheson, I; Ostensen, M, 1988
)
0.27
"9 h) with no significant difference between the single and multiple dosage regimens."( Single and multiple dose pharmacokinetics of tenoxicam in the elderly.
Am, T; Bückert, A; Eckert, M; Heizmann, P; Løge, I; Nilsen, OG; Thue, E; Unnvik, J; Walstad, RA, 1988
)
0.27
" Tiaprofenic acid was administered orally at a dosage of 900 mg daily for 14 days and piroxicam at a dosage of 40 mg daily."( Comparative double-blind study of tiaprofenic acid versus piroxicam in the treatment of osteoarthritis of the knee.
Di Giorgio, E; Maccagno, A; Sebastian, O, 1988
)
0.27
" The piroxicam dosage was 40 mg once daily for two days and then 20 mg daily for an additional five days."( Piroxicam and naproxen in acute sports injuries.
Gabor, I; Lereim, P, 1988
)
0.27
" Piroxicam has the advantage that once-daily dosage is sufficient to provide efficacy equal to or better than these comparative agents."( Toleration and safety of piroxicam.
Heynen, G, 1987
)
0.27
"Patient acceptance of medications often depends upon individual and cultural preferences for particular dosage forms."( Piroxicam: new dosage forms.
Guttadauria, M; Norris, E, 1987
)
0.27
" Transient mild or moderate gastrointestinal symptoms, in 8% of patients at a dosage of 20mg daily, are the most frequently reported side effects."( Tenoxicam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
Gonzalez, JP; Todd, PA, 1987
)
0.27
" The low elimination rate of tenoxicam allows for a once-daily dosage (20 mg) regimen."( Overview on the pharmacokinetics of tenoxicam.
Guentert, TW; Heintz, RC; Joly, R, 1987
)
0.27
" The substantial differences in dissolution performance observed among the piroxicam oral dosage forms tested have implications concerning the equivalency and standards of multisource products available on the international market, and should be taken into account by health care providers worldwide."( Comparative dissolution performance of internationally available piroxicam products.
Barone, JA; Byerly, WG; Colaizzi, JL; Lordi, NG, 1988
)
0.27
" Mefenamic acid was given at a dosage of 500 mg 3-times daily and piroxicam as a single daily dose of 20 mg, for a maximum of 10 days."( A double-blind comparison of mefenamic acid and piroxicam in acute soft tissue injuries.
Haig, G, 1988
)
0.27
" We may conclude that this model is adequate and precise for selecting the most appropriate galenic dosage form for an active compound in terms of its clinical efficacy when topically administered."( UV-induced erythema model: a tool in dermatopharmacology for testing the topical activity of non-steroidal anti-inflammatory agents in man.
Barbanoj, MJ; Izquierdo, I; Jané, F; Lauroba, J; Moreno, J; Torrent, J, 1988
)
0.27
" Furthermore, the half-lives after repeated dosing were not different from those found after single doses of 400 mg."( The pharmacokinetics of isoxicam in elderly patients with rheumatoid arthritis.
Buchanan, WW; Grace, EM; Rosenfeld, JM; Sweeney, GD, 1987
)
0.27
" The elimination of piroxicam is impaired in some elderly patients, resulting in a high interindividual variability in average steady state levels following a standard 20 mg/day dosage regimen."( Clinical pharmacokinetics of piroxicam.
Blocka, KL; Richardson, CJ; Verbeeck, RK, 1986
)
0.27
" 3 Twenty plasma samples were collected over 15 days following dosing with tenoxicam."( Effect of food and various antacids on the absorption of tenoxicam.
Day, RO; Lam, S; Paull, P; Wade, D, 1987
)
0.27
" The urinary excretion profile of furosemide was not significantly changed by concurrent dosing of tenoxicam."( Study on the possible interaction between tenoxicam and furosemide.
Hartmann, D; Kleinbloesem, CH; Lücker, PW; Vetter, G, 1987
)
0.27
" However, there was no strong dose-response relation."( [Modulation of the oxidative metabolism of granulocytes by nonsteroidal anti-inflammatory agents].
Kapp, A; Schöpf, E, 1987
)
0.27
" 2 Dose-response studies were performed to delineate a suppressive (high) and non-suppressive (low) dose of isoxicam prior to studying these doses in combination with aspirin."( The effect of isoxicam-aspirin combinations on the polyurethane sponge implantation model in the rat.
Brooks, PM; Garrett, R; Manthey, B; Vernon-Roberts, B, 1986
)
0.27
" 4 It is concluded that isoxicam is suitable for use in once daily dosage and that there are no clinically significant differences in its pharmacokinetics between young and elderly subjects."( A comparison of isoxicam pharmacokinetics in young and elderly subjects.
Blake, D; Darragh, AS; Frank, GJ; George, CF; Hosie, J; Renwick, AG; van Marle, W, 1986
)
0.27
" The corresponding "in vivo" study was undertaken and plasma samples were collected during the ninth dosing interval."( Bioavailability of piroxicam: oral and rectal multiple application in humans.
Janezic, A; Jerman, P; Karba, R; Kmetec, V; Kozjek, F; Mrhar, A; Primozic, S, 1987
)
0.27
"In this histological study it has been demonstrated that a single-dose administration of piroxicam, at the same dosage (4 mg/kg) as droxicam, has a greater erosive potential on the gastric mucosa of rats later exposed to cold stress."( Comparative light and electron microscopic observations of the lesive effects of two non-steroid anti-inflammatory drugs plus stress on rat gastric mucosa.
Castell, O; Colombo, M; Esteve, J; Palacios, G; Roser, R, 1987
)
0.27
" Thus no dosage adjustment should be necessary and the usual daily dose of tenoxicam may be administered once daily also to patients with renal failure."( Pharmacokinetics of tenoxicam in patients with impaired renal function.
Descoeudres, C; Frey, FJ; Guentert, TW; Heizmann, P; Horber, FF; Weidekamm, E, 1986
)
0.27
" FBLs for both isoxicam and piroxicam were only slightly higher than baseline for the first 3 drug dosing days, confirming the results of a previously published 4-day study of piroxicam, but FBL subsequently steadily increased, with maxima occurring for most subjects receiving isoxicam in 2 or 3 weeks and for most subjects receiving piroxicam in 3 or 4 weeks."( Fecal blood loss during isoxicam and piroxicam administration for 28 days.
Anslow, JA; Araujo, P; Darke, A; Hooper, JW; Martin, WS, 1985
)
0.27
" Patients then took regular medication until they had reached steady-state for chronic dosing (20 mg/day) when a further pharmacokinetic profile was performed."( Single and multiple oral dose pharmacokinetics of tenoxicam in the elderly.
Allen, JG; Bird, HA; Dixon, JS; Francis, RJ; Hill, J; Le Gallez, P; Wright, V, 1985
)
0.27
" Patients showed significantly better compliance with a once daily dosage regimen."( A double blind comparison of piroxicam and enteric coated ASA in rheumatoid arthritis. A Cooperative Multicenter Canadian trial.
, 1985
)
0.27
" Piroxicam was comparable to indomethacin with respect to efficacy and offered better toleration and a simplified dosage regimen."( Piroxicam vs indomethacin: a double blind multicenter comparative study in osteoarthritis. A Canadian Multicenter Study.
, 1985
)
0.27
" Dosage was then reduced to 200 mg a day for all patients."( Long-term studies of isoxicam in the treatment of rheumatoid arthritis.
Reese, RW, 1985
)
0.27
" During a six-week, double-blind, placebo-controlled phase involving 176 patients, isoxicam at a dosage of 200 mg once daily was significantly superior to placebo in parameters (knee) of night pain, pain on walking, starting pain, pain on motion, swelling, tenderness, maximal extension, maximal flexion, and limitation of range of motion, and in the parameter (hip) of pain on walking."( Six-week, double-blind, placebo-controlled and long-term, open-label multicenter study of isoxicam in treatment of degenerative joint disease.
Posner, SL, 1985
)
0.27
"6 percent with isoxicam, at a dosage greater than 200 mg per day; 14."( Evaluation of the safety of isoxicam.
Burch, FX, 1985
)
0.27
" Among patients who received only the recommended dosage of 200 mg per day, the frequencies of all reactions were lower than among the entire population and were similar between the two age groups."( Adverse effects of isoxicam in relation to age.
Williams, PI, 1985
)
0.27
" The maximum recommended dosage for ibuprofen, a widely prescribed drug for the treatment of rheumatoid arthritis, has increased from 400 mg three or four times a day (at the time of its introduction) to 2,400 mg per day at present."( A double-blind comparative study of piroxicam and ibuprofen in the treatment of rheumatoid arthritis.
McLaughlin, GE, 1985
)
0.27
"Since the initial marketing in the early 1970s of the nonsteroidal anti-inflammatory agents of the propionic acid type, there has been a gradual escalation of the dosage recommendation for each of these drugs."( Double-blind crossover comparison of piroxicam and naproxen in the treatment of active osteoarthritis.
Hodge, RH, 1985
)
0.27
" In equivalent once-daily dosage (20 mg), tenoxicam was found to be at least as effective as piroxicam in combating the symptoms of the above arthritic disorders and, even in relatively high dosages of 30 and 40 mg exhibited excellent tolerance, producing fewer adverse reactions than piroxicam."( Clinical evaluation of tenoxicam in osteoarthrosis, rheumatoid arthritis and ankylosing spondylitis.
Josenhants, G; Standel, W, 1985
)
0.27
" Another advantage of piroxicam is its low effective dosage level achieved by a single daily dose."( [Treatment of rheumatoid arthritis. Open parallel study with the non-steroidal antirheumatics piroxicam and diclofenac].
Rohde, J; Schwegler, F; Standel, W, 1980
)
0.26
" Dose-response relationships for inhibition of 45Ca uptake were identical with controls in mitochondria isolated from normal or essential fatty acid-deficient Long-Evans rats even though PGE synthesis in essential fatty acid-deficient was only 20% of that in normal rats."( Prostaglandin-independent inhibition of calcium transport by nonsteroidal anti-inflammatory drugs: differential effects of carboxylic acids and piroxicam.
Burch, RM; Halushka, PV; Wise, WC, 1983
)
0.27
" Plasma concentrations of tilcotil showed that the drug's half-life was approximately 50 hours, compatible with once daily dosage, and steady state concentrations on multiple dosing were reached after 10 to 12 days."( Gastro-intestinal blood loss with high dose tilcotil (Ro 12-0068) and aspirin: an open crossover clinical trial and pharmacokinetic assessment in normal volunteers.
Bird, HA; Galloway, DB; Lowe, JR; McEvoy, M; Pickup, ME; Taylor, P; Wright, V, 1983
)
0.27
" 92 patients received piroxicam in a daily dosage of 4 capsules (40 mg) during the first two days, then 20 mg during the following days."( Double blind comparative study of piroxicam and indomethacin in acute locomotor affections linked with sports activity.
Commandre, F, 1983
)
0.27
" once or twice daily dosage schedule), side effects and cost."( Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs.
Blackburn, JL; Loewen, GR; Verbeeck, RK,
)
0.13
" For this the dosage of diclofenac was reduced to 100 mg/d."( Diclofenac and piroxicam in a double-blind trial results and methodological problems. Working Party of the Society for Rheumatology of the GDR for the Testing of Anti-rheumatic Drugs.
Friedländer, R; Häntzschel, H; Hüge, W; Keitel, W; Keysser, M; Seidel, W; Tanner, E; Wächter, G; Weber, J; Wille, R, 1984
)
0.27
" The dosage of piroxicam was 40 mg for the first 2 days and 20 mg daily thereafter."( A double blind, placebo controlled study of piroxicam in the management of acute musculoskeletal disorders.
Dodd, GD; Lacey, PH; Shannon, DJ, 1984
)
0.27
" Initial dosage ranged from 10 to 40 mg piroxicam and all but a few patients continued treatment with 20 mg once daily."( A multi-centre study of piroxicam in the treatment of osteoarthritis and rheumatoid arthritis in general practice.
Gow, PJ, 1983
)
0.27
" Piroxicam was given in a dosage of 20mg once daily and ibuprofen 400mg three times a day."( Comparative study of piroxicam and ibuprofen in rheumatoid arthritis.
Alam, MN; Kabir, MZ, 1983
)
0.27
" Piroxicam is currently marketed in 20 mg capsules and once daily dosing has proven effective for many patients."( Pharmacology, clinical efficacy, and adverse effects of piroxicam, a new nonsteroidal anti-inflammatory agent.
Dahl, SL; Ward, JR,
)
0.13
" Due to the long plasma half life, once daily dosing provides continuous exposure to drug, with concentrations fluctuating less than twofold."( Pharmacokinetics of piroxicam in man.
Hobbs, DC, 1983
)
0.27
" For diclofenac, indometacin and piroxicam proposals for a more rational procedure of their dose-response relationship determination are discussed."( [Transsynovial kinetics and correlation of dosage and effect of non-steroidal anti-rheumatic agents].
Fenner, H, 1982
)
0.26
" Piroxicam, a member of a new class of non-steroidal anti-inflammatory agents, possesses a long plasma half-life permitting a once-a-day dosage regimen in osteo-arthrosis, rheumatoid arthritis, ankylosing spondylitis, acute musculoskeletal disorders and acute gout."( An evaluation of piroxicam, a new non-steroidal anti-inflammatory agent. A multicentre trial.
Tweddell, ED; Willcocks, WA, 1981
)
0.26
" NSAID dose-response curves produced using the two indices of damage showed that intestinal permeability is as sensitive and reproducible as ulceration, although changes could not be detected before visible ulceration occurred."( Assessment of intestinal permeability changes induced by nonsteroidal anti-inflammatory drugs in the rat.
Ford, J; Houston, JB; Martin, SW, 1995
)
0.29
" Intestinal permeability was measured in rats given diclofenac either by sc bolus or iv infusion and dose-response data compared."( Concentration-response relationships for three nonsteroidal anti-inflammatory drugs in the rat intestine.
Ford, J; Houston, JB, 1995
)
0.29
" So, it seems to be unreasonable that only serum concentration is taken as a criterion for bioavailability test of piroxicam for local dosage forms, the local drug concentration should also be investigated and evaluated."( [Comparison of concentration of piroxicam in blood and local site after two routes of administration].
Fang, XL; Jiang, XG; Xi, NZ; Zhang, ZR, 1995
)
0.29
" Dose-response studies indicated that bolus regional administration of S-(+)-ibuprofen increased potency 30-fold compared with systemic administration and could be further improved 10-fold by regional infusion, whereas regional administration of piroxicam showed no therapeutic advantage."( Pharmacodynamic comparison of regional drug delivery for non-steroidal anti-inflammatory drugs, using the rat air-pouch model of inflammation.
Brennan, BS; Houston, JB; Martin, SW; Rowland, M; Stevens, AJ, 1995
)
0.29
" Heart rate (EHR) after 5 min of exercise by bicycle ergometry (constant 75W), and parameters of renal function were assessed before (baseline) and during concomitant dosing of atenolol and tenoxicam."( Study on the possible interaction between tenoxicam and atenolol in hypertensive patients.
Güzelhan, C; Hartmann, D; Horsch, AK; Lingenfelder, M; Stief, G, 1995
)
0.29
"The pharmacokinetic profile of total and free methotrexate (MTX) and the effect of piroxicam on MTX pharmacokinetics was studied in 20 rheumatoid arthritis patients receiving a stable dosage of MTX (10 mg/week)."( Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients.
Acquaviva, P; Bernard, JC; Bologna, C; Bressolle, F; Combe, B; Edno, L; Lafforgue, P; Sany, J, 1995
)
0.29
" Product characteristics, such as tolerability, efficacy, and dosing regimen, are more significant factors of compliance than patient or disease characteristics."( Patient compliance with tenoxicam in family practice.
Gordon, DA; Kalish, GH; Kraag, GR; Ménard, HA; Russell, AS,
)
0.13
"The bioavailability of two pharmaceutical dosage forms formulated using different polymorphs of tenoxicam were compared."( Bioequivalence of two oral dosage forms prepared from different polymorphic modifications of tenoxicam.
Alkaysi, HN; Badwan, AA; Gharaibeh, AM; Gharaibeh, NM; Salem, MS, 1994
)
0.29
" Plasma concentrations after dosing were determined with a specific HPLC method."( Relative bioavailability of oral dosage forms of tenoxicam.
Banken, L; Defoin, R; Guentert, TW; Schmitt, M; Stebler, T, 1994
)
0.29
" creatinine clearance 88 +/- 13 ml min-1), and (3) elderly patients with renal insufficiency (creatinine clearance 60 +/- 10 ml min-1) following the administration of piroxicam 20 mg as a single dose and after chronic dosing of 20 mg once daily for 4 weeks."( The pharmacokinetics of piroxicam in elderly persons with and without renal impairment.
Brater, DC; Figueroa, NL; Hall, SD; Rudy, AC, 1994
)
0.29
" Isoxicam potentiated the anticoagulant effect of warfarin, necessitating a 20% dosage reduction."( Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.
Brunetto, AV; Mattila, MJ; Olkkola, KT, 1994
)
0.29
" The results demonstrated that, while indomethacin is effective in decreasing the formation of heterotopic bone, piroxicam--when used in the dosage previously demonstrated to have no deleterious effect on healing bone--is not."( Effect of two nonsteroidal antiinflammatory drugs on heterotopic bone formation in a rabbit model.
Fakhouri, AJ; Moed, BR; Nallamothu, B; Resnick, RB; Wagner, RA, 1994
)
0.29
" Plasma concentrations after dosing were determined by a specific HPLC method."( Bioavailability of intramuscularly administered tenoxicam.
Guentert, TW; Stebler, T, 1993
)
0.29
" These studies showed that penetration of the radiolabel occurred in subcutaneous and muscle tissue only under the dosed sites and not at the remote sites, ruling out systemic absorption as a prerequisite for local delivery."( Topical penetration of piroxicam is dependent on the distribution of the local cutaneous vasculature.
Francoeur, ML; Inman, AO; McNeill, SC; Monteiro-Riviere, NA; Riviere, JE, 1993
)
0.29
" The methods have been applied to the routine determination of the drug in dosage forms."( Flow-injection spectrophotometric determination of piroxicam.
Albero, MI; Garcia, MS; Rodriguez, J; Sánchez-Pedreño, C, 1993
)
0.29
"Open, non comparative study to evaluate the efficacy and safety of piroxicam Fast Dissolving Dosage Form (FDDF) for sublingual administration in treatment of reacutized osteoarthritis."( [Clinical experience with the use of piroxicam in fast-dissolving sublingual capsules in acute recurrent osteoarthritis].
Bancheri, C; Bogliolo, A; Brundisini, B; Gospodinoff, L; Lucentini, L; Minisola, G; Perpignano, G; Porzio, F, 1993
)
0.29
"Diclofenac/misoprostol at twice daily dosing is associated with significantly fewer gastroduodenal ulcers than either piroxicam or naproxen."( Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis.
Bruyn, GA; Geis, GS; Melo Gomes, JA; Roth, SH; Woods, EM; Zeeh, J, 1993
)
0.29
"In this study we evaluated the efficacy of a new preparation (Fast Dissolving Dosage Form--FDDF) of piroxicam (40 mg in a single sublingual dose) in the acute treatment of migraine."( Effectiveness of a piroxicam fast dissolving formulation sublingually administered in the symptomatic treatment of migraine without aura.
Altavilla, T; Micieli, G; Nappi, G; Tassorelli, C; Viotti, E, 1993
)
0.29
" Dosage increases were permitted after a 2-week trial period."( Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis.
DeLapp, RE; Lister, BJ; Poland, M, 1993
)
0.29
" There was a linear dose-response curve that was steeper in women than in men."( Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs.
Dobson, A; Henry, D; Turner, C, 1993
)
0.29
"Open non comparative study for the evaluation of the efficacy and tolerability of the new piroxicam formulation, the Fast Dissolving Dosage Form tablets for sublingual administration in the treatment of primary dysmenorrhea."( [Primary dysmenorrhea treated with sublingual piroxicam].
Ciccarelli, A; Ragni, N,
)
0.13
" The results were compared with those obtained treating a similar group of patients with tenoxicam, at the same dosage of 20 mg/day, orally administered."( [Efficacy of and tolerance to a new NSAID in the treatment of arthrosis: droxicam. Randomized study versus tenoxicam].
Chevallard, M; Colombo, B; Venegoni, C, 1993
)
0.29
" Ten patients with GI haemorrhage, who had ingested piroxicam (and no other NSAID), within the preceding 64 h, at the same dosage and on no new medication for the past 14 days, had blood taken at presentation for measurement of piroxicam concentrations."( Are systemic levels of non steroidal anti inflammatory drugs relevant to acute upper gastrointestinal haemorrhage?
Rawlins, MD; Wynne, HA, 1993
)
0.29
" It was also demonstrable after subcutaneous dosing or when injury was measured by a change in mucosal potential difference."( Gastric mucosal adaptation to diclofenac injury.
Cook, GA; Elliott, SL; Giraud, AS; Skeljo, MV; Yeomans, ND, 1996
)
0.29
" We recorded patients' dosing histories with electronic monitors for an average of 225 days (range 55-379) in 34 recipients of piroxicam and 31 recipients of tenoxicam."( Compliance monitoring of NSAID drug therapy in ankylosing spondylitis, experiences with an electronic monitoring device.
de Klerk, E; van der Linden, SJ, 1996
)
0.29
" administered orally over two 7-day dosing periods."( Gastrointestinal tolerability of lornoxicam compared to that of naproxen in healthy male volunteers.
Aabakken, L; Frenzel, W; Osnes, M, 1996
)
0.29
"An open-label, noncomparative study of the efficacy and tolerability of a once-daily piroxicam fast-dissolving dosage form (FDDF) comprised 157 patients aged 15 to 76 years (56."( Piroxicam fast-dissolving dosage form in the treatment of patients with acute low back pain.
Englert, R; Fontanesi, G; Müller, P; Ott, H; Rehn, L; Silva, H,
)
0.13
" This effect appeared to be dose-dependent, with patients in the lornoxicam 4 mg or morphine 10 mg groups recording significantly lower TOTPAR0-4 scores than patients in the higher dosage groups of these drugs."( Pain control after dental surgery: a double-blind, randomised trial of lornoxicam versus morphine.
Bang, U; Ersbøll, AK; Hansen, HJ; Ingerslev, J; Larsen, U; Nielsen, O; Nørholt, SE; Sindet-Pedersen, S, 1996
)
0.29
" Gastroscopy was performed at base-line and after the dosing period of 14 days."( [Comparative endoscopic study of gastroduodenal tolerance of piroxicam-beta-cyclodextrin vs piroxicam].
Müller, P; Simon, B,
)
0.13
" IB showed a dose-response relationship which appeared to plateau at doses of 50 and 100 mg/kg."( Effects of the combined oral administration of NSAIDs and dextromethorphan on behavioral symptoms indicative of arthritic pain in rats.
Caruso, FS; Frenk, H; Lu, J; Mao, J; Mayer, DJ; Price, DD, 1996
)
0.29
" Both UV derivative spectrophotometric and HPLC approaches were followed for confirming the purity of tenoxicam in bulk and tablets dosage form."( Simultaneous determination of tenoxicam and 2-aminopyridine using derivative spectrophotometry and high-performance liquid chromatography.
Abdine, HH; Barary, MH; Blaih, SM; el Kersh, AM; el Sayed, MA; el Walily, AF, 1997
)
0.3
"To assess the possible therapeutic effect of 40 mg sublingual piroxicam (fast-dissolving dosage form, FDDF) compared with intramuscular 75 mg diclofenac, as a reference drug, on acute renal colic in a randomized, double-blind controlled clinical trial."( Piroxicam fast-dissolving dosage form vs diclofenac sodium in the treatment of acute renal colic: a double-blind controlled trial.
Echarte, JL; Gelabert, A; Iglesias, ML; Mínguez, S; Nogués, X; Pedro-Botet, J; Supervía, A, 1998
)
0.3
" The possibility of an association between absorption kinetics from dosage forms in humans and Caco-2 monolayer permeability may allow for a direct kinetic interpretation of human oral absorption from Caco-2 monolayer permeability values."( Human drug absorption kinetics and comparison to Caco-2 monolayer permeabilities.
Ginski, MJ; Polli, JE, 1998
)
0.3
" 2'5' oligoadenylate synthetase activity (2'5' AS) was dosed in mononuclear cells before and at 3-month treatment intervals in 28 patients."( Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferon.
Abergel, A; Bacq, Y; Bailly, F; Barnoud, R; Baud, M; Bresson-Hadni, S; Causse, X; Chousterman, S; Combis, JM; Girardin, MF; Hamici, L; Hicham, T; Leroy, V; Maynard-Muet, M; Minello, A; Oberti, F; Raabe, JJ; Tran, A; Zarski, JP, 1998
)
0.3
"The objective of this study is to evaluate and compare the analgesic efficacy of Piroxicam Fast Dissolving Dosage Formulation (FDDF) administered sublingually either preoperatively or postoperatively with that of aspirin and placebo."( Postoperative pain control by single doses of piroxicam administered sublingually and aspirin.
Alpaslan, C; Alpaslan, G; Uğar, D, 1997
)
0.3
"The aim of the present study was to compare the analgesic efficacy of piroxicam-FDDF (fast dissolving dosage form) with naproxen sodium, following bilateral removal of impacted third molars."( The postoperative analgesic efficacy and safety of piroxicam (FDDF) and naproxen sodium.
Apaydin, S; Gomel, M; Köse, T; Selçuk, E; Tuglular, I, 1998
)
0.3
"Diclofenac, naproxen, and piroxicam can be administered together with omeprazole 20 mg daily without need for dosage alteration."( Lack of drug-drug interaction between three different non-steroidal anti-inflammatory drugs and omeprazole.
Andersson, T; Bredberg, E; Lagerström, PO; Naesdal, J; Wilson, I, 1998
)
0.3
" NS-398 and nimesulide dosing did not reduce thromboxane B2 production from platelets isolated from rats with carrageenin-induced pleurisy, demonstrating that at the doses used, cyclooxygenase 2 inhibitors did not inhibit cyclooxygenase 1, as platelets contain only this isoform."( Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation.
Gilroy, DW; Tomlinson, A; Willoughby, DA, 1998
)
0.3
" This figure is far from satisfactory and not acceptable for the treatment of cancer pain at this dosage and schedule."( Sublingual piroxicam for cancer pain.
Altundağ, K; Asil, M; Tekuzman, G; Yalçin, S, 1998
)
0.3
" The results of this study are part of the research database that supports SUPAC-IR, an FDA guidance that provides relaxed testing and filing requirements for scale-up and post-approval changes to immediate-release oral solid dosage forms."( The impact of formulation and process changes on in vitro dissolution and the bioequivalence of piroxicam capsules.
Augsburger, L; Bigora, S; Goskonda, S; Lesko, LJ; Piscitelli, DA; Propst, C; Schwartz, P; Young, D, 1998
)
0.3
" The substantial differences observed in this study regarding performance of piroxicam dosage forms available worldwide have possible implications in terms of product equivalency and standards at an international level."( Comparative potency and dissolution performance of internationally available piroxicam products.
Barone, JA, 1992
)
0.28
"While the analysis of in vitro dissolution-in vivo absorption relationships from oral solid dosage forms provides biopharmaceutical insight and regulatory benefit, no well developed method exists to predict dissolution-absorption relationships a priori to human studies."( Prediction of dissolution-absorption relationships from a dissolution/Caco-2 system.
Ginski, MJ; Polli, JE, 1999
)
0.3
" To directly evaluate the ability of 5-ASA to suppress intestinal tumors, we studied several formulations of 5-ASA (free acid, sulfasalazine, and Pentasa) at multiple oral dosage levels [500, 2400, 4800, and 9600 parts/million (ppm)] in the adenomatous polyposis coli (Apc) mouse model of multiple intestinal neoplasia (Min)."( Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse.
Gendler, SJ; Hirsch, RE; Leighton, JA; Morrow, JD; Ritland, SR; Weaver, AL, 1999
)
0.3
"The influence of different solvents (propylene glycol, glycerol, ethanol), as well as different technological procedures (melting, rapid and slow cooling), on the formation of polymorphous piroxicam modifications was examined in the course of the elaboration of a "soft-patch" type of semisolid pharmaceutical dosage form."( Examination of the polymorphism of piroxicam in connection with the preparation of a new "soft-patch" type pharmaceutical dosage form.
Balogh, E; Csóka, G; Farkas, E; Marton, S; Rácz, I, 1999
)
0.3
" The methods have been applied to the routine determination of the drug in dosage forms."( Flow-injection spectrophotometric methods for the determination of tenoxicam.
Albero, MI; García, MS; Gimenez, MJ; Sánchez-Pedreño, C, 1999
)
0.3
" Because of gastrointestinal disorders, dermatological dosage forms are recommended most."( In vitro release studies of piroxicam from oil-in-water creams and hydroalcoholic gel topical formulations.
Mehramizi, A; Rafiee-Tehrani, M, 2000
)
0.31
" These results suggest a dissolution/Caco-2 system to be an experimentally based tool that may predict dissolution-absorption relationships from oral solid dosage forms, and hence the relative contributions of dissolution and permeation to oral drug absorption kinetics."( Prediction of dissolution-absorption relationships from a continuous dissolution/Caco-2 system.
Ginski, MJ; Polli, JE; Taneja, R, 1999
)
0.3
"A floating type dosage form (FDF) of piroxicam in hollow polycarbonate (PC) microspheres capable of floating on simulated gastric and intestinal fluids was prepared by a solvent evaporation technique."( A floating-type oral dosage form for piroxicam based on hollow polycarbonate microspheres: in vitro and in vivo evaluation in rabbits.
Jayakrishnan, A; Joseph, NJ; Lakshmi, S, 2002
)
0.31
"To study the efficacy of piroxicam fast-dissolving dosage form in reducing postoperative pain after simple lumbar spine surgery."( The clinical efficacy of piroxicam fast-dissolving dosage form for postoperative pain control after simple lumbar spine surgery: a double-blinded randomized study.
Jaovisidha, S; Laohacharoensombat, W; Pookarnjanamorakot, C, 2002
)
0.31
" In addition to a normal postoperative analgesic regimen, each patient received placebo or piroxicam fast-dissolving dosage form (2 tablets administered sublingually 1 to 3 hours before surgery)."( The clinical efficacy of piroxicam fast-dissolving dosage form for postoperative pain control after simple lumbar spine surgery: a double-blinded randomized study.
Jaovisidha, S; Laohacharoensombat, W; Pookarnjanamorakot, C, 2002
)
0.31
"Sublingual administration of piroxicam fast-dissolving dosage form after simple spine surgery is effective and efficient in relief of postoperative pain."( The clinical efficacy of piroxicam fast-dissolving dosage form for postoperative pain control after simple lumbar spine surgery: a double-blinded randomized study.
Jaovisidha, S; Laohacharoensombat, W; Pookarnjanamorakot, C, 2002
)
0.31
" The proposed methods have been successfully applied to the determinations of PPH and PX in various dosage forms."( Indirect spectrophotometric determination of propranolol hydrochloride and piroxicam in pure and pharmaceutical formulations.
Gowda, BG; Melwanki, MB; Seetharamappa, J, 2002
)
0.31
"The present study was undertaken to investigate, if the non-steroidal anti-inflammatory drug (NSAID) piroxicam (CAS 36322-90-4) Fast-Dissolving Dosage Form (FDDF) can be absorbed in the oral mucosa."( Studies of piroxicam absorption by oral mucosa.
Cruz, M; Diez-Ortego, I; Egido, J; Herrero-Beaumont, G; Largo, R; Navarro, A; Palacios, I; Sanchez-Pernaute, O; Solans, A, 2002
)
0.31
"Open trial was carried out on different dosage schedules of lornoxicam (4 or 8 mg bid and 4mg tid) administered for six to twelve months."( [Long term study on the efficacy and safety of lornoxicam in rheumatoid arthritis].
Focherini, MC; Frizziero, L; Reta, M; Rocchi, P; Valentini, M, 2002
)
0.31
" The twice a day dosage of lornoxicam revealed to be appropriate."( [Analgesic dose range finding of lornoxicam compared to diclofenac. Crossover double blind study in rheumatoid arthritis].
Di Munno, O; Pasero, GP,
)
0.13
" STUDY MEDICATION: once daily dosage of either tenidap 40 mg, tenidap 120 mg or piroxicam 20mg."( Arthroscopic evaluation of potential structure-modifying drug in osteoarthritis of the knee. A multicenter, randomized, double-blind comparison of tenidap sodium vs piroxicam.
Alava, S; Ayral, X; Beaulieu, A; Dougados, M; Genant, HK; Kirkpatrick, J; Mackillop, N; Pippingskiöld, P; Will, RK, 2003
)
0.32
"These results suggest that the newly developed dosage form of piroxicam is effective and well tolerated in the treatment of patients with chronic BP."( Efficacy and tolerability of piroxicam-beta-cyclodextrin in the outpatient management of chronic back pain.
Buran, I; Gazdik, F; Gogolak, I; Mihal, A; Pijak, MR; Turcani, P; Turcaniova, Z, 2002
)
0.31
" The results were evaluated by comparing with pure piroxicam filled into hard gelatin capsules (PP) and a commercially available tablet dosage form containing a piroxicam:beta-cyclodextrin complex (CD)."( Enhanced bioavailability of piroxicam using Gelucire 44/14 and labrasol: in vitro and in vivo evaluation.
Baykara, T; Karataş, A; Ozkan, SA; Ozkan, Y; Savaşer, A; Yüksel, N, 2003
)
0.32
" The developed methods were successfully applied to the determination of LOX, TEX, and MEX in bulk powder, laboratory-prepared mixtures containing different percentages of degradation products, and pharmaceutical dosage forms."( Stability-indicating chromatographic methods for the determination of some oxicams.
Abdel Fattah, Lel-S; Salama, NN; Taha, EA,
)
0.13
" A 2-compartment pharmacokinetic model was used for fitting the plasma concentration versus time data, and the individual model descriptive parameters were used to simulate the plasma tenoxicam concentrations during repeated dosing for 7 consecutive days."( CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians.
Perini, JA; Rondinelli, E; Suarez-Kurtz, G; Vianna-Jorge, R, 2004
)
0.32
" First, dose-response relationships of each of diclofenac, piroxicam and alpha-tocopherol were evaluated using bone marrow lymphocytes counts and monoamines levels in plasma, brain and spleen."( Effects of diclofenac, piroxicam and alpha-tocopherol on monoaminelymphopoietic interfacing in mice.
Hamed, MR; Hasan, WA; Hassanein, NM, 2004
)
0.32
" Although the bioavailability of the two formulations was similar, the administration of piroxicam as a freeze-dried tablet gave a much faster absorption rate during the first hour after dosing than the capsule formulation."( Pharmacokinetic profiles of two tablet formulations of piroxicam.
Grangé, V; Rasetti-Escargueil, C, 2005
)
0.33
"Drugs were separately, orally once daily dosed to pregnant rats from day 8 to 21 (GD1=plug day)."( Comparison of developmental toxicity of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats--DFU and piroxicam study.
Burdan, F, 2005
)
0.33
" Thirty patients were randomly assigned to three groups and treated for 3 days, before impacted lower third molar removal, as follows: (1) sublingual piroxicam-FDDF (fast dissolving dosage formulation) 20 mg/day; (2) oral azithromycin 500 mg/day; (3) piroxicam-FDDF 20 mg/day plus azithromycin 500 mg/day."( Clinical evaluation of piroxicam-FDDF and azithromycin in the prevention of complications associated with impacted lower third molar extraction.
Antonioli, L; Blandizzi, C; Cei, S; Colucci, R; Corsi, L; Del Tacca, M; Fornai, M; Gabriele, M; Graziani, F; Tonelli, M, 2005
)
0.33
" The cats were dosed for 10 days followed by at least a 2-week washout period between trials."( Multiple dose pharmacokinetics and acute safety of piroxicam and cimetidine in the cat.
Chun, R; Corse, M; Garrett, L; Heeb, HL; Hunter, RP; Koch, DE; Moore, L; Pellerin, MA; Radlinsky, M, 2005
)
0.33
" Further studies are required to determine whether a higher dosage of tenoxicam is beneficial to reduce uterine cramping pain in multiparous women."( Differential analgesic effect of tenoxicam on post-cesarean uterine cramping pain between primiparous and multiparous women.
Chen, SY; Lin, CJ; Sun, WZ; Yeh, HM; Yeh, YC, 2005
)
0.33
" It is possible, however, that local or topical treatment or altered dosing regimens may offer alternative approaches to the use of these drugs as antineoplastic agents."( The in vitro effects of piroxicam and meloxicam on canine cell lines.
Argyle, DJ; Chambers, G; Gault, E; Knottenbelt, C, 2006
)
0.33
" Dogs underwent laser ablation of the primary tumor and were treated with mitoxantrone at a dosage of 5 mg/m2)every 3 weeks for 4 treatments."( Evaluation of carbon dioxide laser ablation combined with mitoxantrone and piroxicam treatment in dogs with transitional cell carcinoma.
Payton, ME; Tangner, CH; Upton, ML, 2006
)
0.33
" The suggested procedures could be used for the determination of the above mentioned drugs in pure and dosage forms as well as in the presence of their degradation products."( Spectrofluorimetric and spectrophotometric stability-indicating methods for determination of some oxicams using 7-chloro-4-nitrobenz-2-oxa-1,3-diazole (NBD-Cl).
Fattah, Lel-S; Salama, NN; Taha, EA, 2006
)
0.33
" Application of the method for the determination of the drug in the dosage form (Feledene capsules and tablets and also piroxicam gel), without any interference, from the excipients, resulted in acceptable deviation from the stated concentrations."( Electrochemical monitoring of piroxicam in different pharmaceutical forms with multi-walled carbon nanotubes paste electrode.
Abbaspour, A; Mirzajani, R, 2007
)
0.34
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.
Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A,
)
0.13
" Thus, the hyaluronic microsphere developed using spray-drying technique with sodium hyaluronate and PEG was a more effective oral dosage form for poorly water soluble piroxicam."( Enhanced oral bioavailability of piroxicam in rats by hyaluronate microspheres.
Choi, HG; Kim, JH; Kim, JO; Lee, MH; Lyoo, WS; Piao, MG; Yong, CS, 2007
)
0.34
"To investigate the therapeutic effect of the fast-dissolving dosage form (FDDF) of sublingual piroxicam on renal colic compared with the intramuscular (IM) injection form of the same agent in a randomized, double-blind, placebo-controlled clinical trial."( Double-blind, placebo-controlled, randomized clinical trial of sublingual or intramuscular piroxicam in the treatment of renal colic. A comparative study.
Altay, B; Horasanli, K; Kendirci, M; Miroglu, C; Sarica, K; Tanriverdi, O, 2007
)
0.34
" In phase II, the cumulative NBI in phase II decreased with the increase in lornoxicam dosage, but the difference was not significant when the dosage above 180 microg."( [Effects of preemptively injected intrathecal lornoxicam on behavior and c-fos protein expression of rat with formalin hurting].
Chen, X; Liu, H; Xiao, H; Yang, BX; Yang, Y, 2008
)
0.35
" This effect is correlated with the dosage of lornoxicam and has ceiling phenomenon."( [Effects of preemptively injected intrathecal lornoxicam on behavior and c-fos protein expression of rat with formalin hurting].
Chen, X; Liu, H; Xiao, H; Yang, BX; Yang, Y, 2008
)
0.35
" The droplet size and dissolution of optimal formulation were determined to prove that the dosage form is a useful delivery system for piroxicam."( [Design and in vitro evaluation of self-microemulsifying drug delivery systems for piroxicam].
Nie, SF; Pan, WS; Sun, JY; Wang, J; Wang, Y; Zhou, XT, 2008
)
0.35
" Every other day dosing was tolerated better than daily dosing."( Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas.
Dow, SW; Elmslie, RE; Glawe, P,
)
0.13
" The adequate condition for the chromatographic determination of these compounds in pharmaceutical dosage forms was established based on the different retention behaviors of the species."( Determination of pKa values of nonsteroidal antiinflammatory drug-oxicams by RP-HPLC and their analysis in pharmaceutical dosage forms.
Alsancak, G; Demiralay, EC; Ozkan, SA, 2009
)
0.35
" The dosage of study treatment was 8-24 mg/day LNX, 100-150 mg/day diclofenac or placebo."( Efficacy and safety of lornoxicam compared with placebo and diclofenac in acute sciatica/lumbo-sciatica: an analysis from a randomised, double-blind, multicentre, parallel-group study.
Geertsen, MS; Herrmann, WA, 2009
)
0.35
"A simple, reliable and selective differential pulse (DP) and square wave (SW) voltammetric methods at glassy carbon (GC) and boron-doped diamond (BDD) electrodes of lornoxicam in pharmaceutical dosage form and in spiked human serum samples have been developed and evaluated."( Applications of carbon based electrodes for voltammetric determination of lornoxicam in pharmaceutical dosage form and human serum.
Bozal, B; Uslu, B, 2010
)
0.36
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" The inhibition of oedema formation increased with increasing dosage from 25 to 100mg/kg."( Analgesic effects and anti-inflammatory properties of the crude methanolic extract of Schwenckia americana Linn (Solanaceae).
Abdullahi, N; Adebisi, I; Chika, A; Jimoh, AO; Umar, MT, 2011
)
0.37
"There is a need for an improved process understanding of solid dosage pharmaceuticals."( Role of excipients on solid-state properties of piroxicam during processing.
Christensen, NP; Cornett, C; Rantanen, J, 2012
)
0.38
" Five dose-escalating cohorts, up to and including approved label dosage for toceranib and standard dosage for piroxicam, were completed without observing a frequency of dose-limiting AEs necessitating cohort closure."( Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study.
Chon, E; Kubicek, LN; McCartan, L; Vail, DM, 2012
)
0.38
"In vitro dissolution methodologies that adequately capture the oral bioperformance of solid dosage forms are critical tools needed to aid formulation development."( Mechanistic analysis of solute transport in an in vitro physiological two-phase dissolution apparatus.
Amidon, GE; Amidon, GL; Gao, P; Mudie, DM; Ping, H; Shi, Y, 2012
)
0.38
" Form II had the significantly higher solubility and dissolution and would be the suitable polymorph for the preparation of oral and injectable dosage forms of lornoxicam."( Characterization of two polymorphs of lornoxicam.
Fan, W; Gao, J; Gao, Y; Qian, S; Tan, X; Zhang, J, 2013
)
0.39
" However, FT-IR can be used to obtain information on the compounds chemical structure and conformation, and ToF-SIMS provides sensitivity in cases, where the entire solid dosage form is contaminated with foreign matter."( Foreign matter identification from solid dosage forms.
Bjørneboe, K; Haugshøj, KB; Pajander, J; Rantanen, J; Wahlberg, P, 2013
)
0.39
"The purpose of this study was to formulate printable dosage forms for a poorly soluble drug (piroxicam; PRX) and to gain understanding of critical parameters to be considered during development of such dosage forms."( A step toward development of printable dosage forms for poorly soluble drugs.
Fors, D; Genina, N; Peltonen, J; Raijada, D; Rantanen, J; Sandler, N; Wisaeus, E, 2013
)
0.39
"Literature and experimental data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage forms containing piroxicam in the free acid form are reviewed."( Biowaiver monographs for immediate release solid oral dosage forms: piroxicam.
Abrahamsson, B; Barends, DM; Dressman, JB; Groot, DW; Kopp, S; Kulinich, JI; Langguth, P; Polli, JE; Ramenskaya, GV; Shah, VP; Shohin, IE, 2014
)
0.4
" It suggested that this S-SMEDDS could be used as a successful oral solid dosage form to improve the solubility and bioavailability of poorly water-soluble drug Lornoxicam as well."( Preparation and pharmacokinetics evaluation of oral self-emulsifying system for poorly water-soluble drug Lornoxicam.
Guo, Y; Li, F; Pan, W; Song, S; Yang, X; Zhang, X; Zhao, Q, 2015
)
0.42
"Floating dosage forms with prolonged gastric residence time have garnered much interest in the field of oral delivery."( Modulating drug release from gastric-floating microcapsules through spray-coating layers.
Lee, WL; Loo, SC; Tan, CN; Tan, JW, 2014
)
0.4
"The assessment of the solid-state stability of active pharmaceutical ingredient (API) and/or excipients in solid dosage forms during manufacturing and storage is mandatory for safeguarding quality of the final products."( Monitoring of multiple solid-state transformations at tablet surfaces using multi-series near-infrared hyperspectral imaging and multivariate curve resolution.
Alexandrino, GL; Amigo, JM; Khorasani, MR; Poppi, RJ; Rantanen, J, 2015
)
0.42
" Microemulsion formulations were found to be superior in controlling inflammation as compared to conventional topical dosage forms and showed efficacy equivalent to oral formulation."( Microemulsion-Based Topical Hydrogels of Tenoxicam for Treatment of Arthritis.
Goindi, S; Kalra, A; Narula, M, 2016
)
0.43
" Water-soluble and water-dispersible surfactants are able to dissolve the target dose of each drug in the dosage form and efficiently keep it in solution during dispersion."( Development of self emulsifying lipid formulations of BCS class II drugs with low to medium lipophilicity.
Belotti, S; Chavant, Y; Chevrier, S; Demarne, F; Dumont, C; Jannin, V; Michenaud, M, 2015
)
0.42
" The permeation of the drug was evaluated using an inverted Franz diffusion cell technique that allowed the dosage form to be directly applied onto the substrate with required volume of saliva."( Formulation and evaluation of sublingual delivery of piroxicam using thermosensitive polymer with an inverted Franz diffusion cell.
Banga, AK; Sivaraman, A, 2016
)
0.43
"The transdermal dosage forms presented a limited usage for a long time, for it was believed that the stratum corneum, the outermost layer of epidermis, made it impracticable the permeation of medications through the skin."( Ex vivo Skin Permeation Evaluation of An Innovative Transdermal Vehicle Using Nimesulide and Piroxicam as Model Drugs.
Brandao, MAF; de Oliveira Ferreira, A; Pelisson E Silva, TCC; Pereira, RO; Polonini, HC; Raposo, NRB, 2017
)
0.46
" A single-oral solid dosage form (8 mg/tablet), randomized, open-label, 2-way crossover study was conducted on 30 healthy male volunteers."( Lornoxicam Immediate-Release Tablets: Formulation and Bioequivalence Study in Healthy Mediterranean Volunteers Using a Validated LC-MS/MS Method.
Bustami, R; Jaradat, N; Mousa, A; Zaid, AN, 2017
)
0.46
"Printing technology has been shown to enable flexible fabrication of solid dosage forms for personalized drug therapy."( Development of Oromucosal Dosage Forms by Combining Electrospinning and Inkjet Printing.
Heinämäki, J; Kogermann, K; Laidmäe, I; Meos, A; Palo, M; Preis, M; Sandler, N, 2017
)
0.46
"Formulation of injectable In situ forming implant (ISI) systems of lornoxicam for dental and postoperative pain management to decrease dosing frequency and increase patient compliance."( Polymeric and Non Polymeric Injectable In-situ Forming Implant Systems for Sustained Delivery of Lornoxicam: In vitro and In vivo Evaluation.
Aziz, MY; Halim, SAA; Yehia, SA, 2018
)
0.48
" The ability for intestinal mucus to stabilize drug supersaturation and delay drug precipitation is potentially useful in enhancing the absorption of orally dosed compounds from drug delivery systems that generate supersaturation within the gastrointestinal tract (e."( Intestinal mucus is capable of stabilizing supersaturation of poorly water-soluble drugs.
Carrier, RL; Lerkvikarn, S; Lock, J; Nguyen, N; Semin, T; Yeap, YY, 2019
)
0.51
" A successful therapeutic outcome often requires the use of commercially manufactured medications that are not produced in the doses or dosage forms tolerated by veterinary patients or are unavailable to, unaffordable for, and/or inaccessible by owners."( Compounded Cyclophosphamide and Piroxicam for the Treatment of a Canine Peripheral Nerve Sheath Tumor: A Case Report.
Batson, SL; Daleo, C; Pope, G,
)
0.13
" The purpose of the study was to develop new PC loaded gastro-protective polymer hybrid microspheres (PHM) with subsequent conversion to tablet dosage form having modified dissolution rate and improved bioavailability."( Piroxicam loaded polymer hybrid microspheres based tablets with modified release kinetics: Development, characterization and in vivo evaluation.
Ahmad, N; Amin, F; Asghar, M; Elhissi, A; Hamid, HA; Hussain, Z; Jan, SU; Khan, BA; Khan, S; Minhas, MU; Noor Shah, SM; Shah, SMH; Shah, SWA; Shahid, M; Sohail, M, 2021
)
0.62
" Finally, the developed sensing system was validated as per ICH guidelines and it was proved to be accurate and precise and applied successfully for quantitative determination of the two cited drugs in their capsule dosage forms with excellent percentage recoveries reaching to 97."( Microanalysis of Two Members of Oxicam Drugs by Quenching the Fluorescence of Newly Isolated Carbonaceous Materials From Incense Ash.
Ghany, NA; Helmy, MI; Ramzy, E; Rizk, M; Toubar, S, 2021
)
0.62
"Semi-solid extrusion (SSE) 3D printing enables flexible designs and dose sizes to be printed on demand and is a suitable tool for fabricating personalized dosage forms."( Personalizing oral delivery of nanoformed piroxicam by semi-solid extrusion 3D printing.
Kaasalainen, M; Lakio, S; Manandhar, S; Mathiyalagan, R; Rosenholm, JM; Sandler, N; Sjöholm, E; Wang, X, 2023
)
0.91
" The study outcomes support the potential of nanoforming for producing fast-acting dosage forms of poorly soluble drugs."( Small is Powerful: Demonstration of the Impact of Nanoformed Piroxicam in a Controlled Clinical Study.
Andrade, G; Evans, P; Hӕggström, E; Lakio, S; McDermott, J; Roe, C; Sandler, N; Smith, DJ, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
analgesicAn agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms.
cyclooxygenase 1 inhibitorA cyclooxygenase inhibitor that interferes with the action of cyclooxygenase 1.
non-steroidal anti-inflammatory drugAn anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitorA compound or agent that combines with cyclooxygenases (EC 1.14.99.1) and thereby prevents its substrate-enzyme combination with arachidonic acid and the formation of icosanoids, prostaglandins, and thromboxanes.
antirheumatic drugA drug used to treat rheumatoid arthritis.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
benzothiazine
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
monocarboxylic acid amideA carboxamide derived from a monocarboxylic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Piroxicam Action Pathway2967

Protein Targets (84)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency3.55190.003245.467312,589.2998AID2517
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency35.48130.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency23.73590.177814.390939.8107AID2147
LuciferasePhotinus pyralis (common eastern firefly)Potency29.67890.007215.758889.3584AID1224835; AID588342
thioredoxin reductaseRattus norvegicus (Norway rat)Potency2.66790.100020.879379.4328AID588453
15-lipoxygenase, partialHomo sapiens (human)Potency19.95260.012610.691788.5700AID887
phosphopantetheinyl transferaseBacillus subtilisPotency35.48130.141337.9142100.0000AID1490
RAR-related orphan receptor gammaMus musculus (house mouse)Potency22.14290.006038.004119,952.5996AID1159521; AID1159523
ATAD5 protein, partialHomo sapiens (human)Potency32.64270.004110.890331.5287AID504466
NFKB1 protein, partialHomo sapiens (human)Potency0.01000.02827.055915.8489AID895; AID928
GLS proteinHomo sapiens (human)Potency35.48130.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency20.59620.000811.382244.6684AID686978
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency26.04390.001022.650876.6163AID1224838; AID1224893
EWS/FLI fusion proteinHomo sapiens (human)Potency36.20920.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency3.16230.28189.721235.4813AID2326
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency40.21820.003041.611522,387.1992AID1159553; AID1159555
pregnane X nuclear receptorHomo sapiens (human)Potency21.88860.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency38.60230.000229.305416,493.5996AID743069; AID743075
GVesicular stomatitis virusPotency13.08550.01238.964839.8107AID1645842
ParkinHomo sapiens (human)Potency7.30780.819914.830644.6684AID720572
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency50.11870.707936.904389.1251AID504333
arylsulfatase AHomo sapiens (human)Potency0.10691.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency14.73330.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency28.34380.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency69.21790.001723.839378.1014AID743083
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency44.042019.739145.978464.9432AID1159509
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.00890.540617.639296.1227AID2364; AID2528
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency25.11890.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency6.30960.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency16.06440.00636.904339.8107AID883
chromobox protein homolog 1Homo sapiens (human)Potency50.11870.006026.168889.1251AID488953
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency14.12540.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency12.74480.000323.4451159.6830AID743066
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency18.85410.65619.452025.1189AID927
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency53.97590.000627.21521,122.0200AID743202; AID743219
gemininHomo sapiens (human)Potency4.10950.004611.374133.4983AID624296
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency1.25890.031610.279239.8107AID884; AID885
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency39.81070.00419.962528.1838AID2675
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency17.78280.251215.843239.8107AID504327
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency3.16230.00106.000935.4813AID944
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Interferon betaHomo sapiens (human)Potency13.08550.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency13.08550.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Alpha-synucleinHomo sapiens (human)Potency5.80480.56239.398525.1189AID652106
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency16.06440.00638.235039.8107AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Disintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)Potency18.85411.584913.004325.1189AID927
TAR DNA-binding protein 43Homo sapiens (human)Potency25.11891.778316.208135.4813AID652104
GABA theta subunitRattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency13.08550.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency13.08550.01238.964839.8107AID1645842
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency37.93300.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Solute carrier family 22 member 6Rattus norvegicus (Norway rat)Ki52.00001.60005.744010.0000AID681340
Prostaglandin G/H synthase 1 Bos taurus (cattle)IC50 (µMol)65.00000.00051.41288.2000AID160709
Prostaglandin G/H synthase 2 Bos taurus (cattle)IC50 (µMol)65.00000.00050.57393.4000AID160709
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Prostaglandin G/H synthase 1Ovis aries (sheep)IC50 (µMol)21.00000.00032.177410.0000AID162151
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)1,000.00000.00011.753610.0000AID428564
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)50.00000.00002.800510.0000AID1210069
Polyunsaturated fatty acid 5-lipoxygenaseRattus norvegicus (Norway rat)IC50 (µMol)100.00000.00462.018210.0000AID6865
Prostaglandin G/H synthase 1Homo sapiens (human)IC50 (µMol)68.72540.00021.557410.0000AID1330175; AID161468; AID625243
Prostaglandin G/H synthase 2Homo sapiens (human)IC50 (µMol)136.64170.00010.995010.0000AID1330173; AID162666
Prostaglandin G/H synthase 2 Rattus norvegicus (Norway rat)IC50 (µMol)0.10000.00291.786810.0000AID160881
Cytochrome P450 2J2Homo sapiens (human)IC50 (µMol)50.00000.01202.53129.4700AID1210069
Solute carrier family 22 member 6Homo sapiens (human)IC50 (µMol)20.50000.27004.53069.9000AID681160
Solute carrier family 22 member 6Homo sapiens (human)Ki19.80000.03003.20437.8200AID678821
Prostaglandin G/H synthase 1 Rattus norvegicus (Norway rat)IC50 (µMol)0.10000.00291.823210.0000AID160881
Solute carrier family 22 member 8Homo sapiens (human)Ki602.44000.04004.22979.0000AID678814; AID681372
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Solute carrier family 22 member 11Homo sapiens (human)Ki107.80000.20002.57716.1500AID678972
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (311)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1 Bos taurus (cattle)
cellular oxidant detoxificationProstaglandin G/H synthase 1 Bos taurus (cattle)
meiotic spindle organizationProstaglandin G/H synthase 2 Bos taurus (cattle)
prostaglandin biosynthetic processProstaglandin G/H synthase 2 Bos taurus (cattle)
ovarian cumulus expansionProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of protein phosphorylationProstaglandin G/H synthase 2 Bos taurus (cattle)
response to oxidative stressProstaglandin G/H synthase 2 Bos taurus (cattle)
cyclooxygenase pathwayProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of embryonic developmentProstaglandin G/H synthase 2 Bos taurus (cattle)
cellular response to interleukin-1Prostaglandin G/H synthase 2 Bos taurus (cattle)
cellular oxidant detoxificationProstaglandin G/H synthase 2 Bos taurus (cattle)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of oocyte maturationProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of meiotic cell cycle process involved in oocyte maturationProstaglandin G/H synthase 2 Bos taurus (cattle)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processCytochrome P450 2J2Homo sapiens (human)
icosanoid metabolic processCytochrome P450 2J2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2J2Homo sapiens (human)
regulation of heart contractionCytochrome P450 2J2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2J2Homo sapiens (human)
linoleic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
organic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to hypoxiaDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
neutrophil mediated immunityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
germinal center formationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of leukocyte chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch receptor processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell population proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to xenobiotic stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of T cell chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
signal releaseDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
B cell differentiationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell growthDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to lipopolysaccharideDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of chemokine productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
regulation of mast cell apoptotic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
T cell differentiation in thymusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
wound healing, spreading of epidermal cellsDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
spleen developmentDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell motilityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
defense response to Gram-positive bacteriumDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cellular response to high density lipoprotein particle stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
commissural neuron axon guidanceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of cold-induced thermogenesisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
monoatomic anion transportSolute carrier family 22 member 6Homo sapiens (human)
response to organic cyclic compoundSolute carrier family 22 member 6Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 6Homo sapiens (human)
organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transportSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 6Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 6Homo sapiens (human)
renal tubular secretionSolute carrier family 22 member 6Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 8Homo sapiens (human)
response to toxic substanceSolute carrier family 22 member 8Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 8Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 8Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 8Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 11Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 11Homo sapiens (human)
organic anion transportSolute carrier family 22 member 11Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 11Homo sapiens (human)
urate metabolic processSolute carrier family 22 member 11Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 11Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (127)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1 Bos taurus (cattle)
heme bindingProstaglandin G/H synthase 1 Bos taurus (cattle)
metal ion bindingProstaglandin G/H synthase 1 Bos taurus (cattle)
peroxidase activityProstaglandin G/H synthase 2 Bos taurus (cattle)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2 Bos taurus (cattle)
heme bindingProstaglandin G/H synthase 2 Bos taurus (cattle)
metal ion bindingProstaglandin G/H synthase 2 Bos taurus (cattle)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
monooxygenase activityCytochrome P450 2J2Homo sapiens (human)
iron ion bindingCytochrome P450 2J2Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
isomerase activityCytochrome P450 2J2Homo sapiens (human)
linoleic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
hydroperoxy icosatetraenoate isomerase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 5,6-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
heme bindingCytochrome P450 2J2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2J2Homo sapiens (human)
endopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
interleukin-6 receptor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
integrin bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
peptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metallopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
SH3 domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytokine bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
PDZ domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
tumor necrosis factor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metal ion bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
protein bindingSolute carrier family 22 member 6Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
chloride ion bindingSolute carrier family 22 member 6Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 8Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 11Homo sapiens (human)
protein bindingSolute carrier family 22 member 11Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 11Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 11Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier family 22 member 11Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (65)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1 Bos taurus (cattle)
nuclear inner membraneProstaglandin G/H synthase 2 Bos taurus (cattle)
nuclear outer membraneProstaglandin G/H synthase 2 Bos taurus (cattle)
endoplasmic reticulum membraneProstaglandin G/H synthase 2 Bos taurus (cattle)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2J2Homo sapiens (human)
extracellular exosomeCytochrome P450 2J2Homo sapiens (human)
cytoplasmCytochrome P450 2J2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2J2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cell-cell junctionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
focal adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
ruffle membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Golgi membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
endoplasmic reticulum lumenDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytosolDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell surfaceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
actin cytoskeletonDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
apical plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane raftDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
caveolaSolute carrier family 22 member 6Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 6Homo sapiens (human)
protein-containing complexSolute carrier family 22 member 6Homo sapiens (human)
plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 8Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
external side of plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 11Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (525)

Assay IDTitleYearJournalArticle
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347087qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Confirmatory Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347088qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): Viability assay - Alamar blue signal for LCMV Confirmatory Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347084qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Confirmatory Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347081qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Confirmatory Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID5985271-Octanol-sodium citrate buffer distribution coefficient, log D of the compound at pH 5.5 by shake-flask method2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.
AID481440Dissociation constant, pKa of the compound2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID169635Compound is evaluated for gastric ulceration in rats at a dose of 10 mg/kg.; 5 out of 12 is lesioned1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and antiinflammatory activities of 3-(3,5-di-tert-butyl-4-hydroxybenzylidene)pyrrolidin-2-ones.
AID1319973Permeability of the compound by PAMPA assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Synthesis and biological evaluation of N-cyanoalkyl-, N-aminoalkyl-, and N-guanidinoalkyl-substituted 4-aminoquinoline derivatives as potent, selective, brain permeable antitrypanosomal agents.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID26287Partition coefficient (logD3.0)1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.
AID26548compound was evaluated for reverse occurs for the rate constant(log K-1) at pH 7.41998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.
AID453204Permeability in human skin after 48 hrs by Franz cell permeability assay2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.
AID193235Compound was evaluated for edema density in adjuvant-induced arthritis model in rats at a dose of 3 mg/kg (Experiment # 2)1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and antiinflammatory activities of 3-(3,5-di-tert-butyl-4-hydroxybenzylidene)pyrrolidin-2-ones.
AID181667Compound is evaluated for inhibitory effect on the generation of Prostaglandin E2 (PGE2) from rat synovial cells1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and antiinflammatory activities of 3-(3,5-di-tert-butyl-4-hydroxybenzylidene)pyrrolidin-2-ones.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID374372Antiinflammatory against carrageenan-induced paw edema in Sprague-Dawley rat assessed as remaining paw edema at 10 mg/kg, sc administered 30 mins before carrageenan challenge measured after 3 hrs by plethysmometer relative to control2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Synthesis and pharmacological evaluation of 2-substituted benzo[b]thiophenes as anti-inflammatory and analgesic agents.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID481444Octanol-water partition coefficient, log P of the compound2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID185568Percent inhibition was determined in vivo in male Dawley rats at a dose of 10 mg/kg by rat carrageenan-induced hyperalgesia assay1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID137946Antinociceptive activity in the mouse writhing test after intraperitoneal dose of 5 mg/kg2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
New benzo[h][1,6]naphthyridine and azepino[3,2-c]quinoline derivatives as selective antagonists of 5-HT4 receptors: binding profile and pharmacological characterization.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID481441Aqueous diffusivity at 37C2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID229957IC50 ratio measured as the IC50 values of COX-1 to that of COX-2.1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Antiinflammatory 4,5-diarylpyrroles. 2. Activity as a function of cyclooxygenase-2 inhibition.
AID1480943Permeability of the compound at pH 7.4 at 5 mg/ml after 18 hrs by PAMPA-BBB assay2017European journal of medicinal chemistry, Apr-21, Volume: 130Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
AID472062Antiosteoarthritis activity in bovine articular chondrocytes assessed as inhibition of IL1-induced reduction of aggrecan mRNA expression at 0.1 uM after 5 days by Northern blot analysis relative to control2010European journal of medicinal chemistry, Jan, Volume: 45, Issue:1
New quaternary ammonium oxicam derivatives: synthesis and in vitro antiosteoarthritis evaluation.
AID1192730Permeability of the compound by PAMPA2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease.
AID189996Dose at which 50% of the rats had a positive gastrointestinal irritation / ulceration on a quantal all-or-none basis.1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and analgesic activity of pemedolac (cis-1-ethyl-1,3,4,9-tetrahydro-4-(phenylmethyl)pyrano[3,4-b]ind ole-1- acetic acid).
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID625277FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID467613Volume of distribution at steady state in human2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID266763Membrane retention in 70% silicon-30% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID1636268Permeability of the compound at pH 7.4 after 18 hrs by PAMPA-BBB assay2016Bioorganic & medicinal chemistry, 10-15, Volume: 24, Issue:20
Design, synthesis and biological evaluation of N-methyl-N-[(1,2,3-triazol-4-yl)alkyl]propargylamines as novel monoamine oxidase B inhibitors.
AID1292330Permeability of the compound at 100 ug/ml after 18 hrs by PAMPA-BBB assay2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID364307Activity at PPARgamma in human Caco-2 cells assessed as luciferase activity at 1000 uM relative to control2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
NSAIDs revisited: putative molecular basis of their interactions with peroxisome proliferator-activated gamma receptor (PPARgamma).
AID1427528Permeability of the compound at 100 ug/ml after 18 hrs by PAMPA2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
AID599064Plasma protein binding in human2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1524751Analgesic activity in formalin-induced nociception Albino Swiss CD-1 mouse model assessed as time spent on licking formalin injected hind paw during neurogenic phase at 10 mg/kg, ip pretreated for 30 mins followed by formalin induction measured up to 5 mi2019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Synthesis and pharmacological evaluation of novel arylpiperazine oxicams derivatives as potent analgesics without ulcerogenicity.
AID1524771Ulcerogenic activity in Wistar (Krf:(WI) WU) rat assessed as change in gastric mucosa at 25 mg/kg measured after 24 hrs by stereo microscopic analysis2019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Synthesis and pharmacological evaluation of novel arylpiperazine oxicams derivatives as potent analgesics without ulcerogenicity.
AID1773264Permeability of the compound at 100 ug/ml incubated for 18 hrs by PAMPA2021European journal of medicinal chemistry, Nov-05, Volume: 223Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.
AID1336731Permeability of compound at 100 ug/ml after 18 hrs by PAMPA2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID310931Partition coefficient, log P of the compound2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID1453097Effective permeability of the compound at 100 ug/ml incubated for 18 hrs by PAMPA-BBB assay2017Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12
Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
AID176213Effective dose was determined in vivo in male Dawley rats by rat carrageenan-induced foot pad edema assay1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).
AID1071344Permeability of the compound by BBB-PAMPA2014European journal of medicinal chemistry, Feb-12, Volume: 731,2,3,4-Tetrahydrobenzo[h][1,6]naphthyridines as a new family of potent peripheral-to-midgorge-site inhibitors of acetylcholinesterase: synthesis, pharmacological evaluation and mechanistic studies.
AID28234% absorbed in human GI-tract2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID26541compound was evaluated for reverse occurs for the rate constant(log K-1) at pH 1.01998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1529179Dissociation constant, pKa2 of compound in aqueous medium by UV-pH titration based spectrophotometric analysis2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID604744Displacement of radiolabeled dansylsarcosine from fatty acid containing human serum albumin site 2 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID1173449Effective permeability of the compound by PAMPA assay2014Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23
Synthesis and antiprotozoal activity of oligomethylene- and p-phenylene-bis(methylene)-linked bis(+)-huprines.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1524752Analgesic activity in formalin-induced nociception Albino Swiss CD-1 mouse model assessed as time spent on licking formalin injected hind paw during neurogenic phase at 20 mg/kg, ip pretreated for 30 mins followed by formalin induction measured up to 5 mi2019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Synthesis and pharmacological evaluation of novel arylpiperazine oxicams derivatives as potent analgesics without ulcerogenicity.
AID1324013Permeability of the compound at 100 ug/ml after 16 hrs by PAMPA-BBB method2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson's disease.
AID135327BBB penetration classification2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
AID374385Analgesic activity in Sprague-Dawley rat assessed as change in latency time required to elicit jumping or hind paw licking at 10 mg/kg, sc administered 1 hr prior testing measured after 2 hrs of post dose by hot plate method relative to basal level2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Synthesis and pharmacological evaluation of 2-substituted benzo[b]thiophenes as anti-inflammatory and analgesic agents.
AID428564Inhibition of CYP3A42009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.
AID192123Antiinflammatory activity on Zymosan-induced rat's paw edema(ZPE) after peroral administration of 100 mg/kg dose with control swelling of 55.1%1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
A novel synthesis and potent antiinflammatory activity of 4-hydroxy-2(1H)-oxo-1-phenyl-1,8-naphthyridine-3-carboxamides.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID162666Tested for inhibitory activity against Prostaglandin G/H synthase 2 from human1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Antiinflammatory 4,5-diarylpyrroles. 2. Activity as a function of cyclooxygenase-2 inhibition.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1330175Inhibition of COX-1 (unknown origin) using arachidonic acid as substrate preincubated for 2 mins followed by substrate addition in presence of TMPD by spectrophotometric analysis2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Synthesis, COX-1/2 inhibition activities and molecular docking study of isothiazolopyridine derivatives.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1167634Blood brain permeability of the compound at donor and acceptor by PAMPA assay2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Design, synthesis and evaluation of novel tacrine-(β-carboline) hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID1129167Permeability of the compound by PAMPA2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis.
AID1056992Permeability of the compound by PAMPA2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
AID1091956Apparent hydrophobicity, log D of the compound in Octanol-buffer2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID1545418Antiinflammatory activity in Swiss mouse assessed as inhibition of TPA-induced ear edema at 1 mg/ear applied topically and measured 4 hrs post-TPA challenge relative to control2019Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7
Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances.
AID1330773Effective permeability of the compound by PAMPA2016European journal of medicinal chemistry, Nov-10, Volume: 123Rational modification of donepezil as multifunctional acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.
AID1330172Inhibition of COX-1 (unknown origin) using arachidonic acid as substrate preincubated for 7 to 10 mins followed by substrate addition in presence of TMPD by spectrophotometric analysis2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Synthesis, COX-1/2 inhibition activities and molecular docking study of isothiazolopyridine derivatives.
AID472063Antiosteoarthritis activity in bovine articular chondrocytes assessed as inhibition of IL1-induced reduction of aggrecan mRNA expression at 1 uM after 5 days by Northern blot analysis relative to control2010European journal of medicinal chemistry, Jan, Volume: 45, Issue:1
New quaternary ammonium oxicam derivatives: synthesis and in vitro antiosteoarthritis evaluation.
AID160881In vitro inhibitory activity against Prostaglandin G/H synthase in rat neutrophils1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Antiinflammatory activity of substituted 6-hydroxypyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-triones. Atypical nonsteroidal antiinflammatory agents.
AID1496041Effective permeability of the compound by PAMPA-BBB assay2018Bioorganic & medicinal chemistry letters, 06-15, Volume: 28, Issue:11
Discovery of novel anti-tuberculosis agents with pyrrolo[1,2-a]quinoxaline-based scaffold.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1879297Permeability of compound by PAMPA-BBB assay2022Bioorganic & medicinal chemistry letters, 04-01, Volume: 61Design, synthesis, biological evaluation and molecular modeling of N-isobutyl-N-((2-(p-tolyloxymethyl)thiazol-4yl)methyl)benzo[d][1,3] dioxole-5-carboxamides as selective butyrylcholinesterase inhibitors.
AID1392732Effective permeability of the compound at 25 ug/ml after 18 hrs by PAMPA
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1201747Permeability of the compound by PAMPA2015European journal of medicinal chemistry, May-05, Volume: 95Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease.
AID192268Antiinflammatory activity on Zymosan-induced rat's paw edema(ZPE) after peroral administration of 3 mg/kg dose with control swelling of 55.1%1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
A novel synthesis and potent antiinflammatory activity of 4-hydroxy-2(1H)-oxo-1-phenyl-1,8-naphthyridine-3-carboxamides.
AID1534777Effective permeability of the compound at 100 mg/ml incubated for 16 hrs by PAMPA-BBB assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Synthesis and evaluation of isoprenylation-resveratrol dimer derivatives against Alzheimer's disease.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1330170Inhibition of COX-1 (unknown origin) using arachidonic acid as substrate preincubated up to 6 mins followed by substrate addition in presence of TMPD by spectrophotometric analysis2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Synthesis, COX-1/2 inhibition activities and molecular docking study of isothiazolopyridine derivatives.
AID374373Antiinflammatory against carrageenan-induced paw edema in Sprague-Dawley rat assessed as remaining paw edema at 10 mg/kg, sc administered 30 mins before carrageenan challenge measured after 1 hr by plethysmometer relative to control2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Synthesis and pharmacological evaluation of 2-substituted benzo[b]thiophenes as anti-inflammatory and analgesic agents.
AID1272447Cytotoxicity against human THP1 cells assessed as cell viability at 20 uM after 48 hrs by trypan blue dye exclusion assay2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Three-component, one-pot synthesis of benzo[6,7]cyclohepta[1,2-b]pyridine derivatives under catalyst free conditions and evaluation of their anti-inflammatory activity.
AID1703582Permeability of the compound at pH 7.4 measured after 6 hrs by PAMPA method2020European journal of medicinal chemistry, Oct-01, Volume: 203Discovery of novel berberine derivatives with balanced cholinesterase and prolyl oligopeptidase inhibition profile.
AID1378880Effective permeability of the compound at 25 ug/ml after 18 hrs by PAMPA-BBB assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer's disease.
AID1524770Acute toxicity in ip dosed Albino Swiss CD-1 mouse measured for 24 hrs2019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Synthesis and pharmacological evaluation of novel arylpiperazine oxicams derivatives as potent analgesics without ulcerogenicity.
AID1377752Effective permeability of the compound at 25 ug/ml by PAMPA assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents.
AID467612Fraction unbound in human plasma2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID761962Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced IL-1beta secretion preincubated for 1 hr prior PMA-challenge measured after 48 hrs by ELISA2013European journal of medicinal chemistry, Aug, Volume: 66Novel 2-(2,4-dioxo-1,3-thiazolidin-5-yl)acetamides as antioxidant and/or anti-inflammatory compounds.
AID137947Antinociceptive activity in the mouse writhing test before administration of the compound2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
New benzo[h][1,6]naphthyridine and azepino[3,2-c]quinoline derivatives as selective antagonists of 5-HT4 receptors: binding profile and pharmacological characterization.
AID128316Analgesic activity against acetic acid induced writhing test in mouse after peroral administration1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
4-Hydroxy-3-quinolinecarboxamides with antiarthritic and analgesic activities.
AID160403Inhibition of human Prostaglandin G/H synthase 2 at 1 ug/mL expressed as mean percent inhibition of control PGE-2 production1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity.
AID767491Equilibrium solubility of the compound by shake-flask method2013Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18
Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.
AID678821TP_TRANSPORTER: inhibition of Ochratoxin A uptake in OAT1-expressing S2 cells2001Life sciences, Sep-21, Volume: 69, Issue:18
Characterization of ochratoxin A transport by human organic anion transporters.
AID1201746Permeability of the compound after 16 hrs by PAMPA2015European journal of medicinal chemistry, May-05, Volume: 95Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1272446Anti-inflammatory activity in human THP1 cells assessed as inhibition of PMA-induced MCP-1 production after 48 hrs by ELISA2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Three-component, one-pot synthesis of benzo[6,7]cyclohepta[1,2-b]pyridine derivatives under catalyst free conditions and evaluation of their anti-inflammatory activity.
AID175768Delayed Type hypersensitivity (DTH) is measured by increase in ear thickness 24 hours after antigen injection into pinna1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Antiinflammatory activity of substituted 6-hydroxypyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-triones. Atypical nonsteroidal antiinflammatory agents.
AID1091955Dissociation constant, pKa of the compound at pH 7.32011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID177225Antiinflammatory activity against carrageenan-induced foot edema in rat after peroral administration1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
4-Hydroxy-3-quinolinecarboxamides with antiarthritic and analgesic activities.
AID1585850Effective permeability of the compound in PBS/EtOH at 100 ug/ml after 18 hrs by PAMPA2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1072116Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced TNF-alpha secretion incubated for 2 hrs prior to PMA challenge measured after 48 hrs by ELISA2014European journal of medicinal chemistry, Mar-21, Volume: 75Synthesis of novel 1,2-benzothiazine 1,1-dioxide-3-ethanone oxime N-aryl acetamide ether derivatives as potent anti-inflammatory agents and inhibitors of monocyte-to-macrophage transformation.
AID481439Absolute bioavailability in human2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID160709Inhibition of bovine Prostaglandin G/H synthase after oral administration1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
4-Hydroxy-3-quinolinecarboxamides with antiarthritic and analgesic activities.
AID1846854Analgesic activity in hot plate induced thermal pain Swiss albino mouse model assessed as change in latency at 10 mg/kg, po measured at 1 to 2 hrs relative to control2021European journal of medicinal chemistry, Oct-05, Volume: 221Contemporary advances of cyclic molecules proposed for inflammation.
AID180934Ulcerogenic potential was assessed in a rat model by the enhancement of stress-induced gastric mucosal lesions after oral administration1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Analogues and derivatives of tenoxicam. 1. Synthesis and antiinflammatory activity of analogues with different residues on the ring nitrogen and the amide nitrogen.
AID161682Highest percent inhibition against Prostaglandin G/H synthase 1 observed on IC50 curve; Range 80-90%1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity.
AID1056993Permeability of the compound at 100 mg/mL after 10 hrs by PAMPA2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
AID28925Highest effective permeability across hexadecane membrane (pH 4-8)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID1171415Aqueous solubility of the compound at pH 6.5 after 48 hrs by shake-flask method2014ACS medicinal chemistry letters, Nov-13, Volume: 5, Issue:11
Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers.
AID176730Dose causing an analgesic effect in 50% of rats (Randall-Selitto assay)1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and analgesic activity of pemedolac (cis-1-ethyl-1,3,4,9-tetrahydro-4-(phenylmethyl)pyrano[3,4-b]ind ole-1- acetic acid).
AID173626Ulcerogenic effect after oral administration (gastric ulcer)1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
4-Hydroxy-3-quinolinecarboxamides with antiarthritic and analgesic activities.
AID26563compound was evaluated for rate constant of transfer (log K1) at pH 7.41998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.
AID1378334Permeability of the compound by PAMPA2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
AID1334754Permeability of the compound at 25 ug/ml after 18 hrs by PAMPA assay2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1330177Selectivity ratio of IC50 for COX-2 (unknown origin) to IC50 for COX-1 (unknown origin)2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Synthesis, COX-1/2 inhibition activities and molecular docking study of isothiazolopyridine derivatives.
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID427197Membrane permeability dissolved in PBS/EtOH (70:30) mixture by PAMPA-BBB assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
AID1633668Permeability of the compound at pH 7.4 PBS buffer at 100 uM measured upto 6 hrs by PAMPA-BBB assay2019ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4
Novel Sustainable-by-Design HDAC Inhibitors for the Treatment of Alzheimer's Disease.
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID374388Analgesic activity in Swiss albino mouse assessed as inhibition of acetic acid-induced abdominal constriction at 10 mg/kg, sc administered 30 mins prior to acetic acid challenge measured for 30 mins relative to control2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Synthesis and pharmacological evaluation of 2-substituted benzo[b]thiophenes as anti-inflammatory and analgesic agents.
AID540235Phospholipidosis-negative literature compound
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID266766Dissociation constant, pKa of the compound2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1311930Permeability of the compound at 50 ug/ml in 70:30 PBS:EtOH by PAMPA-BBB assay2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Synthesis and evaluation of multi-target-directed ligands for the treatment of Alzheimer's disease based on the fusion of donepezil and melatonin.
AID1352675Effective permeability at 25 ug/ml after 18 hrs by PAMPA2018European journal of medicinal chemistry, Feb-25, Volume: 146Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID243647In vitro inhibitory activity against ovine cyclooxygenase-1 (COX-1) at 200 uM; Inactive2004Journal of medicinal chemistry, Sep-23, Volume: 47, Issue:20
Novel cyclooxygenase-1 inhibitors discovered using affinity fingerprints.
AID1384013Effective permeability of the compound dissolved in PBS containing 1% F-127 at 100 uM after 3 to 6 hrs by PAMPA2018European journal of medicinal chemistry, Apr-25, Volume: 150The concept of hybrid molecules of tacrine and benzyl quinolone carboxylic acid (BQCA) as multifunctional agents for Alzheimer's disease.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1437175Permeability of the compound by PAMPA2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
AID225499Dose causing 50% inhibition of writhing in mouse (PBQ writhing test)1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and analgesic activity of pemedolac (cis-1-ethyl-1,3,4,9-tetrahydro-4-(phenylmethyl)pyrano[3,4-b]ind ole-1- acetic acid).
AID1311209Effective permeability of the compound at 100 uM at pH 7.4 after 3 to 6 hrs by PAMPA2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Design, synthesis and in vitro evaluation of benzothiazole-based ureas as potential ABAD/17β-HSD10 modulators for Alzheimer's disease treatment.
AID1444095Effective permeability of the compound at pH 7.4 at 25 ug/ml after 18 hrs by PAMPA-BBB assay2017European journal of medicinal chemistry, Apr-21, Volume: 130Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
AID1347981Permeability of the compound at pH 7.4 at 25 ug/ml after 18 hrs by PAMPA-BBB assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID192104Antiinflammatory activity on Carrageenan rat's paw edema(CPE) after peroral administration of 10 mg/kg dose with control swelling of 75.8%1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
A novel synthesis and potent antiinflammatory activity of 4-hydroxy-2(1H)-oxo-1-phenyl-1,8-naphthyridine-3-carboxamides.
AID1529184Protein binding in immobilized human serum albumin by HPLC analysis2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID1524753Analgesic activity in formalin-induced nociception Albino Swiss CD-1 mouse model assessed as time spent on licking formalin injected hind paw during neurogenic phase at 30 mg/kg, ip pretreated for 30 mins followed by formalin induction measured up to 5 mi2019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Synthesis and pharmacological evaluation of novel arylpiperazine oxicams derivatives as potent analgesics without ulcerogenicity.
AID1365649Permeability of the compound at 100 mg/ml after 16 hrs by BBB-PAMPA method2017Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
Design, synthesis, and evaluation of salicyladimine derivatives as multitarget-directed ligands against Alzheimer's disease.
AID680172TP_TRANSPORTER: inhibition of MTX uptake (MTX: 1 uM, Piroxicam: 1000 uM) in OAT4-expressing S2 cells2002The Journal of pharmacology and experimental therapeutics, Aug, Volume: 302, Issue:2
Characterization of methotrexate transport and its drug interactions with human organic anion transporters.
AID26545compound was evaluated for reverse occurs for the rate constant(log K-1) at pH 3.01998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.
AID192860Antiinflammatory activity expressed as minimum effective dose was screened by using adjuvant-induced local hyperthermia in rats1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and antiinflammatory activities of 3-(3,5-di-tert-butyl-4-hydroxybenzylidene)pyrrolidin-2-ones.
AID184310Compound was evaluated for the inhibition of adjuvant-induced arthritis model in rats at a dose of 1 mg/kg1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and antiinflammatory activities of 3-(3,5-di-tert-butyl-4-hydroxybenzylidene)pyrrolidin-2-ones.
AID1161578Permeability of the compound by PAMPA-BBB assay2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Shogaol-huprine hybrids: dual antioxidant and anticholinesterase agents with β-amyloid and tau anti-aggregating properties.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1625123Permeability of the compound in pH 7.4 PBS at 200 uL after 18 hrs by PAMPA-BBB assay2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
AID659472Effective permeability across porcine polar brain lipid after 4 hrs by PAMPA2012Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4
5-imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3.
AID1444094Permeability of the compound in PBS/EtOH at 100 ug/ml after 18 hrs by PAMPA-BBB assay2017European journal of medicinal chemistry, Apr-21, Volume: 130Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
AID28679Partition coefficient (logD6.8)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID1524762Sedative activity in Albino Swiss CD-1 mouse assessed as inhibition of locomotor activity by measuring reduction in number of light beam crossings at 30 mg/kg, ip treated for 30 mins measured for next 30 mins relative to control2019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Synthesis and pharmacological evaluation of novel arylpiperazine oxicams derivatives as potent analgesics without ulcerogenicity.
AID25571Dissociation constant (pKa)1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Discovery of the hemifumarate and (alpha-L-alanyloxy)methyl ether as prodrugs of an antirheumatic oxindole: prodrugs for the enolic OH group.
AID193233Compound was evaluated for edema density in adjuvant-induced arthritis model in rats at a dose of 1 mg/kg (Experiment # 2)1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and antiinflammatory activities of 3-(3,5-di-tert-butyl-4-hydroxybenzylidene)pyrrolidin-2-ones.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID182560Compound was tested for the inhibition of Zymosan-induced rat's paw edema(ZPE) after peroral administration of 3 mg/kg dose1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
A novel synthesis and potent antiinflammatory activity of 4-hydroxy-2(1H)-oxo-1-phenyl-1,8-naphthyridine-3-carboxamides.
AID1465314Effective permeability of the compound by PAMPA2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Design, synthesis and biological evaluation of 2-acetyl-5-O-(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID178490Antiinflammatory activity in the rat foot edema at the dose of 0.32-10 mg/kg po1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
1,2-Dihydro-1-oxopyrrolo[3,2,1-kl]phenothiazine-2-carboxamides and congeners, dual cyclooxygenase/5-lipoxygenase inhibitors with antiinflammatory activity.
AID453203Lipophilicity, log D of the compound2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.
AID169643Compound is evaluated for gastric ulceration in rats at a dose of 3 mg/kg.; 1 out of 6 is lesioned1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and antiinflammatory activities of 3-(3,5-di-tert-butyl-4-hydroxybenzylidene)pyrrolidin-2-ones.
AID681340TP_TRANSPORTER: inhibition of PAH uptake in Xenopus laevis oocytes1999Molecular pharmacology, May, Volume: 55, Issue:5
Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes.
AID1072114Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced MCP-1 secretion incubated for 2 hrs prior to PMA challenge measured after 72 hrs by ELISA2014European journal of medicinal chemistry, Mar-21, Volume: 75Synthesis of novel 1,2-benzothiazine 1,1-dioxide-3-ethanone oxime N-aryl acetamide ether derivatives as potent anti-inflammatory agents and inhibitors of monocyte-to-macrophage transformation.
AID1190185Permeability of the compound after 16 hrs by PAMPA2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Multifunctional coumarin derivatives: monoamine oxidase B (MAO-B) inhibition, anti-β-amyloid (Aβ) aggregation and metal chelation properties against Alzheimer's disease.
AID176728Dose causing 50% inhibition of edema by carrageenan paw edema assay.1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and analgesic activity of pemedolac (cis-1-ethyl-1,3,4,9-tetrahydro-4-(phenylmethyl)pyrano[3,4-b]ind ole-1- acetic acid).
AID1072115Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced IL-8 secretion incubated for 2 hrs prior to PMA challenge measured after 48 hrs by ELISA2014European journal of medicinal chemistry, Mar-21, Volume: 75Synthesis of novel 1,2-benzothiazine 1,1-dioxide-3-ethanone oxime N-aryl acetamide ether derivatives as potent anti-inflammatory agents and inhibitors of monocyte-to-macrophage transformation.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID183351Compound was tested in vivo for antiinflammatory activity against chronic adjuvant arthritic rat by therapeutic inhibition 2 degree paw after peroral administration of 5 mg/kg of dose1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Antiinflammatory activity of substituted 6-hydroxypyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-triones. Atypical nonsteroidal antiinflammatory agents.
AID1330173Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate preincubated for 2 mins followed by substrate addition in presence of TMPD by spectrophotometric analysis relative to control2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Synthesis, COX-1/2 inhibition activities and molecular docking study of isothiazolopyridine derivatives.
AID1900247Permeability of the compound at pH 7.4 PBS/EtOH buffer (70:30) by PAMPA-BBB assay2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy.
AID1427527Effective permeability of the compound at pH 7.4 after 18 hrs by PAMPA2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
AID678972TP_TRANSPORTER: inhibition of Ochratoxin A uptake in OAT4-expressing S2 cells2002Biochimica et biophysica acta, Jun-12, Volume: 1590, Issue:1-3
Role of human organic anion transporter 4 in the transport of ochratoxin A.
AID1524759Analgesic activity in ip dosed formalin-induced nociception Albino Swiss CD-1 mouse model assessed as reduction in time spent on licking formalin injected hind paw during inflammatory phase pretreated for 30 mins followed by formalin induction measured af2019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Synthesis and pharmacological evaluation of novel arylpiperazine oxicams derivatives as potent analgesics without ulcerogenicity.
AID1545415Antiinflammatory activity in po dosed Wistar rat assessed as reduction in carrageenan-induced paw edema pretreated for 1 hr followed by carrageenan challenge and measured over 2 to 4 hrs post carrageenan challenge by plethysmography2019Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7
Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances.
AID26560compound was evaluated for rate constant of transfer (log K1) at pH 3.01998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1511119Permeability of the compound at 25 ug/ml by PAMPA-BBB assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID15712ClogP value of the compound; nd ='no data'1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID1295107Permeability of the compound at 100 ug/ml by PAMPA-BBB assay2016Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10
Design, synthesis and evaluation of novel ferulic acid-memoquin hybrids as potential multifunctional agents for the treatment of Alzheimer's disease.
AID192847Compound is evaluated for mean ulcer index in rats at a dose of 30 mg/kg1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and antiinflammatory activities of 3-(3,5-di-tert-butyl-4-hydroxybenzylidene)pyrrolidin-2-ones.
AID681798TP_TRANSPORTER: inhibition of Ochratoxin A uptake (OTA: 1 uM, Piroxicam: 1000 uM) in Xenopus laevis oocytes1999The Journal of pharmacology and experimental therapeutics, Jun, Volume: 289, Issue:3
Transport of ochratoxin A by renal multispecific organic anion transporter 1.
AID1529178Dissociation constant, pKa1 of compound in aqueous medium by UV-pH titration based spectrophotometric analysis2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID472059Antiosteoarthritis activity in bovine articular chondrocytes assessed as induction of aggrecan mRNA expression at 0.1 uM after 5 days by Northern blot analysis relative to control2010European journal of medicinal chemistry, Jan, Volume: 45, Issue:1
New quaternary ammonium oxicam derivatives: synthesis and in vitro antiosteoarthritis evaluation.
AID637605Permeability of the compound by PAMPA2012European journal of medicinal chemistry, Feb, Volume: 48A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1378333Permeability of the compound in PBS/EtOH at 100 mg/ml after 16 hrs by PAMPA2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1623120Effective permeability of the compound by BBB-PAMPA method2019European journal of medicinal chemistry, Feb-01, Volume: 163Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID1404015Permeability of the compound after 2.5 hrs by PAMPA2018European journal of medicinal chemistry, Feb-10, Volume: 145Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors.
AID427196Membrane permeability by PAMPA-BBB assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID445445Permeability at pH 6.5 by PAMPA method2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID1261398Antitumor activity against mouse EAT implanted in Balb/C mouse assessed as change in paw volume at 40 mg/kg, po administered on day 3 post tumor inoculation measured on day 3 by plethysmometer analysis (Rvb = 40.2 +/- 7.0%)2015European journal of medicinal chemistry, Nov-02, Volume: 104Synthesis of thiophene-thiosemicarbazone derivatives and evaluation of their in vitro and in vivo antitumor activities.
AID384956Dissociation constant, pKa of the compound2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
Molecular characteristics for solid-state limited solubility.
AID1230204Permeability of the compound by PAMPA-BBB assay2015Journal of natural products, Jun-26, Volume: 78, Issue:6
In Vitro Inhibitory Effects of 8-O-Demethylmaritidine and Undulatine on Acetylcholinesterase and Their Predicted Penetration across the Blood-Brain Barrier.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID192119Antiinflammatory activity on Zymosan-induced rat's paw edema(ZPE) after peroral administration of 10 mg/kg dose with control swelling of 55.1%1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
A novel synthesis and potent antiinflammatory activity of 4-hydroxy-2(1H)-oxo-1-phenyl-1,8-naphthyridine-3-carboxamides.
AID288193Flux ionization constant, pKa of the membrane permeability coefficient of the compound2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID21264Effective permeability measured in human.1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID767495Aqueous solubility of the compound in Britton-Robinson buffer at pH 6.5 after 48 hrs by shake-flask method2013Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18
Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.
AID173598Anti-inflammatory activity was assessed by estimating threshold pain response after oral administration to rats1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Analogues and derivatives of tenoxicam. 1. Synthesis and antiinflammatory activity of analogues with different residues on the ring nitrogen and the amide nitrogen.
AID1529180Binding affinity to human serum albumin assessed as dissociation constant pKa1 at 1:1 ratio by UV-pH titration based spectrophotometric analysis (Rvb = 3.87 No_unit)2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID266771Permeability in human skin2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID177164In vivo effective dose required for antiinflammatory activity in rat adjuvant arthritis model1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Antiinflammatory 4,5-diarylpyrroles. 2. Activity as a function of cyclooxygenase-2 inhibition.
AID183500Antiinflammatory activity of compound expressed as percentage inhibition of carrageenan edema 4 hr after an oral dose of 33 mg/kg.1981Journal of medicinal chemistry, Jan, Volume: 24, Issue:1
Synthesis and antiinflammatory activity of metabolites of piroxicam.
AID1261403Antitumor activity against mouse EAT implanted in Balb/C mouse assessed as change in paw volume at 40 mg/kg, po administered on day 3 post tumor inoculation measured on day 6 by plethysmometer analysis (Rvb = 86.1 +/- 5.7%)2015European journal of medicinal chemistry, Nov-02, Volume: 104Synthesis of thiophene-thiosemicarbazone derivatives and evaluation of their in vitro and in vivo antitumor activities.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID288184Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID6865Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
4-Hydroxy-3-quinolinecarboxamides with antiarthritic and analgesic activities.
AID311367Permeability coefficient in human skin2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID469403Permeability across PAMPA membrane 2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1765292Permeability of compound by PAMPA-BBB assay2021European journal of medicinal chemistry, Oct-15, Volume: 222Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
AID182194Antiinflammatory activity against collagen II arthritis in rats, activity% inhibition in injected paw edema1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Antiinflammatory activity of substituted 6-hydroxypyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-triones. Atypical nonsteroidal antiinflammatory agents.
AID182561Compound was tested for the inhibition of Zymosan-induced rat's paw edema(ZPE) after peroral administration of 30 mg/kg dose1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
A novel synthesis and potent antiinflammatory activity of 4-hydroxy-2(1H)-oxo-1-phenyl-1,8-naphthyridine-3-carboxamides.
AID1319976Permeability of the compound at 25 ug/ml at 7.4 pH after 18 hrs by PAMPA2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Synthesis and biological evaluation of N-cyanoalkyl-, N-aminoalkyl-, and N-guanidinoalkyl-substituted 4-aminoquinoline derivatives as potent, selective, brain permeable antitrypanosomal agents.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1414493Permeability of the compound at 100 uM after 3 to 6 hrs by PAMPA assay2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Pyridinium Oximes with Ortho-Positioned Chlorine Moiety Exhibit Improved Physicochemical Properties and Efficient Reactivation of Human Acetylcholinesterase Inhibited by Several Nerve Agents.
AID1529182Protein binding in plasma (unknown origin)2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID639368Permeability of the compound by PAMPA assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease.
AID176168Compound was tested in vivo for antiinflammatory activity against rats by RPAR(reverse passive Arthus reaction) synovitis method1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Antiinflammatory activity of substituted 6-hydroxypyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-triones. Atypical nonsteroidal antiinflammatory agents.
AID604741Displacement of radiolabeled warfarin from fatty acid-free human serum albumin site 1 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID288185Permeability coefficient through artificial membrane in presence of stirred water layer2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID510240Antiinflammatory activity in BALB/C mouse assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, ip administered 30 mins before carrageenan challenge measured before 48 hrs by plethysmometer2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Effect of goniothalamin on the development of Ehrlich solid tumor in mice.
AID678814TP_TRANSPORTER: inhibition of Ochratoxin A uptake in OAT3-expressing S2 cells2001Life sciences, Sep-21, Volume: 69, Issue:18
Characterization of ochratoxin A transport by human organic anion transporters.
AID1091957Apparent permeability of the compound by PAMPA2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1480942Permeability of the compound at pH 7.4 at 1 mg/ml after 4 hrs by PAMPA-BBB assay2017European journal of medicinal chemistry, Apr-21, Volume: 130Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
AID1666036Effective permeability by PAMPA-BBB penetration assay2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Discovery and Biological Evaluation of a Novel Highly Potent Selective Butyrylcholinsterase Inhibitor.
AID1183278Permeability of the compound by PAMPA2014European journal of medicinal chemistry, Sep-12, Volume: 84Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting β-amyloid, tau, and cholinesterase pathologies.
AID1272445Anti-inflammatory activity in human THP1 cells assessed as inhibition of PMA-induced IL-1beta production after 48 hrs by ELISA2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Three-component, one-pot synthesis of benzo[6,7]cyclohepta[1,2-b]pyridine derivatives under catalyst free conditions and evaluation of their anti-inflammatory activity.
AID192116Antiinflammatory activity on Carrageenan rat's paw edema(CPE) after peroral administration of 3 mg/kg dose with control swelling of 75.8%1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
A novel synthesis and potent antiinflammatory activity of 4-hydroxy-2(1H)-oxo-1-phenyl-1,8-naphthyridine-3-carboxamides.
AID1352674Effective permeability at 25 ug/ml after 16 hrs by PAMPA2018European journal of medicinal chemistry, Feb-25, Volume: 146Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID1210069Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID288194Intrinsic artificial membrane permeability coefficient, log P0 of the compound2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID604743Displacement of radiolabeled warfarin from fatty acid containing human serum albumin site 1 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID481446Effective permeability across human jejunum2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID176212Effective dose was determined in vivo in male lewis rats by rat adjuvant-induced arthritis assay1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).
AID1529181Binding affinity to human serum albumin assessed as dissociation constant pKa2 at 1:1 ratio by UV-pH titration based spectrophotometric analysis (Rvb = 11.56 No_unit)2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID182553Compound was tested for the inhibition of Carrageenan rat's paw edema(CPE) after peroral administration of 3 mg/kg dose1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
A novel synthesis and potent antiinflammatory activity of 4-hydroxy-2(1H)-oxo-1-phenyl-1,8-naphthyridine-3-carboxamides.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID349880Permeability across porcine brain lipid coated polyvinylidene fluoride membrane by PAMPA2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID1753998Permeability of the compound in PBS/EtOH buffer (7:3) incubated for 16 hrs by UV plate reader based PAMPA-BBB assay2021European journal of medicinal chemistry, Jul-05, Volume: 219Synthesis and evaluation of multi-target-directed ligands with BACE-1 inhibitory and Nrf2 agonist activities as potential agents against Alzheimer's disease.
AID1708807Permeability of compound in PBS/EtOH buffer (70:30) at 25 ug/ml incubated for 16 hrs by UV plate reader based PAMPA-BBB2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors.
AID1324014Permeability of the compound at 25 ug/ml after 18 hrs by PAMPA-BBB method2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson's disease.
AID678720Metabolic stability in human liver microsomes assessed as low signal/noise ratio (S/N of 1 to 10) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1625122Permeability of the compound in pH 7.4 PBS/EtOH at 100 ug/ml after 18 hrs by PAMPA-BBB assay2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
AID161468Concentration of drug that causes a 50% decrease in the maximal inhibition of Prostaglandin G/H synthase 1 activity as measured by PGE-2 production (''++'' indicates 80-90% inhibition)1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID481442Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID183195Compound was tested in vivo for antiinflammatory activity against chronic adjuvant arthritic rat by prophylactic inhibition 1 degree paw after peroral administration of 2 mg/kg of dose1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Antiinflammatory activity of substituted 6-hydroxypyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-triones. Atypical nonsteroidal antiinflammatory agents.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID161166Inhibition of Prostaglandin G/H synthase activity in sheep seminal vesicle was determined1993Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
3,4-Dihydroxychalcones as potent 5-lipoxygenase and cyclooxygenase inhibitors.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID187881Antiinflammatory activity on the development of collagen II arthritis in rats, measured based on animals positive for arthritis by the presence of bone lesions1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Antiinflammatory activity of substituted 6-hydroxypyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-triones. Atypical nonsteroidal antiinflammatory agents.
AID178129Anti-arthritis activity against adjuvant-induced arthritis in rats after peroral administration1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
4-Hydroxy-3-quinolinecarboxamides with antiarthritic and analgesic activities.
AID395325Lipophilicity, log P by microemulsion electrokinetic chromatography2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID173627Ulcerogenic effect after oral administration (intestinal ulcer)1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
4-Hydroxy-3-quinolinecarboxamides with antiarthritic and analgesic activities.
AID1585851Effective permeability of the compound by PAMPA2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID184311Compound was evaluated for the inhibition of adjuvant-induced arthritis model in rats at a dose of 3 mg/kg1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and antiinflammatory activities of 3-(3,5-di-tert-butyl-4-hydroxybenzylidene)pyrrolidin-2-ones.
AID1495957Effective permeability of the compound in PBS/ethanol buffer after 12 hrs by PAMPA2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Design, synthesis and evaluation of vilazodone-tacrine hybrids as multitarget-directed ligands against depression with cognitive impairment.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1529187Binding affinity to human serum albumin assessed as change in dissociation constant pKa2 of compound in aqueous medium to presence of human serum albumin by UV-pH titration based spectrophotometric analysis2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID1534778Effective permeability of the compound at 25 ug/ml incubated for 18 hrs by PAMPA-BBB assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Synthesis and evaluation of isoprenylation-resveratrol dimer derivatives against Alzheimer's disease.
AID1413458Permeability of the compound by PAMPA
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1524757Analgesic activity in formalin-induced nociception Albino Swiss CD-1 mouse model assessed as time spent on licking formalin injected hind paw during inflammatory phase at 20 mg/kg, ip pretreated for 30 mins followed by formalin induction measured after 152019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Synthesis and pharmacological evaluation of novel arylpiperazine oxicams derivatives as potent analgesics without ulcerogenicity.
AID1568812Permeability of the compound in pH 7.4 PBS/EtOH at 100 ug/ml by PAMPA-BBB assay2019European journal of medicinal chemistry, Sep-15, Volume: 178Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID26590pKa values of the compound; nm= 'not measured'1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
AID231760Ratio of carrageenan paw edema ED50/Randall-Sellitto ED501988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and analgesic activity of pemedolac (cis-1-ethyl-1,3,4,9-tetrahydro-4-(phenylmethyl)pyrano[3,4-b]ind ole-1- acetic acid).
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1378879Effective permeability of the compound at 100 mg/ml after 16 hrs by UV based PAMPA-BBB assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer's disease.
AID1421885Effective permeability of the compound at 1 mg/ml after 4 hrs by BBB-PAMPA method2018European journal of medicinal chemistry, Oct-05, Volume: 158Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
AID1142451Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced IL-1beta secretion preincubated for 2 hrs followed by PMA challenge measured after 48 hrs by ELISA2014European journal of medicinal chemistry, Jun-10, Volume: 80Synthesis of novel 1,2,3-triazole substituted-N-alkyl/aryl nitrone derivatives, their anti-inflammatory and anticancer activity.
AID182562Compound was tested for the inhibition of arachidonic acid-induced rat's paw edema(APE) after peroral administration of 10 mg/kg dose1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
A novel synthesis and potent antiinflammatory activity of 4-hydroxy-2(1H)-oxo-1-phenyl-1,8-naphthyridine-3-carboxamides.
AID1198140Permeability of the compound in PBS and EtOH by PAMPA method2015European journal of medicinal chemistry, Mar-26, Volume: 93Multifunctional tacrine-trolox hybrids for the treatment of Alzheimer's disease with cholinergic, antioxidant, neuroprotective and hepatoprotective properties.
AID1524758Analgesic activity in formalin-induced nociception Albino Swiss CD-1 mouse model assessed as time spent on licking formalin injected hind paw during inflammatory phase at 30 mg/kg, ip pretreated for 30 mins followed by formalin induction measured after 152019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Synthesis and pharmacological evaluation of novel arylpiperazine oxicams derivatives as potent analgesics without ulcerogenicity.
AID677462Dissociation constant, pKa of the compound2012European journal of medicinal chemistry, Jul, Volume: 53Self-organizing molecular field analysis of NSAIDs: assessment of pharmacokinetic and physicochemical properties using 3D-QSPkR approach.
AID472060Antiosteoarthritis activity in bovine articular chondrocytes assessed as induction of aggrecan mRNA expression at 1 uM after 5 days by Northern blot analysis relative to control2010European journal of medicinal chemistry, Jan, Volume: 45, Issue:1
New quaternary ammonium oxicam derivatives: synthesis and in vitro antiosteoarthritis evaluation.
AID416541Antinociceptive activity against acetic acid-induced writhing in NMRI mouse assessed as number of stretches at 5 mg/kg, ip by writhing test2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Novel antagonists of serotonin-4 receptors: synthesis and biological evaluation of pyrrolothienopyrazines.
AID1517838Permeability of the compound in pH 7.4 PBS/EtOH at 25 ug/ml after 18 hrs by PAMPA-BBB assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID161837Inhibition of human Prostaglandin G/H synthase 1 at 10 ug/mL expressed as mean percent inhibition of control PGE-2 production1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity.
AID192846Compound is evaluated for mean ulcer index in rats at a dose of 3 mg/kg1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and antiinflammatory activities of 3-(3,5-di-tert-butyl-4-hydroxybenzylidene)pyrrolidin-2-ones.
AID374371Antiinflammatory against carrageenan-induced paw edema in Sprague-Dawley rat assessed as remaining paw edema at 10 mg/kg, sc administered 30 mins before carrageenan challenge measured after 2 hrs by plethysmometer relative to control2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Synthesis and pharmacological evaluation of 2-substituted benzo[b]thiophenes as anti-inflammatory and analgesic agents.
AID1292332Permeability of the compound at 25 ug/ml after 18 hrs by PAMPA-BBB assay2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID169636Compound is evaluated for gastric ulceration in rats at a dose of 100 mg/kg; NT means not tested1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and antiinflammatory activities of 3-(3,5-di-tert-butyl-4-hydroxybenzylidene)pyrrolidin-2-ones.
AID1330171Inhibition of COX-1 (unknown origin) using arachidonic acid as substrate preincubated for 1 to 2 mins followed by substrate addition in presence of TMPD by spectrophotometric analysis relative to control2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Synthesis, COX-1/2 inhibition activities and molecular docking study of isothiazolopyridine derivatives.
AID1909448Permeability of the compound by PAMPA-BBB assay2022European journal of medicinal chemistry, Jun-05, Volume: 236Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
AID1384014Effective permeability of the compound dissolved in PBS at 100 uM after 3 to 6 hrs by PAMPA2018European journal of medicinal chemistry, Apr-25, Volume: 150The concept of hybrid molecules of tacrine and benzyl quinolone carboxylic acid (BQCA) as multifunctional agents for Alzheimer's disease.
AID1437174Permeability of the compound in PBS/EtOH at 100 ug/ml after 18 hrs by PAMPA2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
AID761961Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced MCP-1 secretion preincubated for 1 hr prior PMA-challenge measured after 48 hrs by ELISA2013European journal of medicinal chemistry, Aug, Volume: 66Novel 2-(2,4-dioxo-1,3-thiazolidin-5-yl)acetamides as antioxidant and/or anti-inflammatory compounds.
AID192278Compound was tested for the inhibition of arachidonic acid-induced rat's paw edema(APE) after peroral administration of 10 mg/kg dose with control swelling of 51.6%1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
A novel synthesis and potent antiinflammatory activity of 4-hydroxy-2(1H)-oxo-1-phenyl-1,8-naphthyridine-3-carboxamides.
AID1557184Permeability of the compound at 25 ug/ml by PAMPA-BBB assay2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID635079Permeability of the compound after 2.5 hrs by PAMPA-BBB assay2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model.
AID681425TP_TRANSPORTER: inhibition of E1S uptake (E1S: 40 uM, Piroxicam: 1000 uM) in Xenopus laevis oocytes1999The Journal of biological chemistry, May-07, Volume: 274, Issue:19
Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain.
AID1436079Permeability of compound at 25 ug/ml after 18 hrs by PAMPA2017European journal of medicinal chemistry, Jan-27, Volume: 126Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
AID177007Anti-inflammatory activity was assessed by estimating kaolin-induced edema in rat hind paw, by administering orally1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Analogues and derivatives of tenoxicam. 1. Synthesis and antiinflammatory activity of analogues with different residues on the ring nitrogen and the amide nitrogen.
AID1223490Apparent permeability across human differentiated Caco2 cells2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID395328Lipophilicity, log P of the compound2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID1570001Permeability of compound at 100 ug/ml measured after dilution with PBS/EtOH (70:30) at pH 7.4 after 18 hrs by PAMPA-BBB assay2019European journal of medicinal chemistry, Oct-15, Volume: 180Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
AID1568822Effective permeability of the compound at 25 ug/ml incubated for 18 hrs by PAMPA-BBB assay2019European journal of medicinal chemistry, Sep-15, Volume: 178Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1264447Permeability of the compound by PAMPA method2015European journal of medicinal chemistry, Nov-13, Volume: 105Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity.
AID26290Partition coefficient (logD7.4)1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID182551Compound was tested for the inhibition of Carrageenan rat's paw edema(CPE) after peroral administration of 10 mg/kg dose1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
A novel synthesis and potent antiinflammatory activity of 4-hydroxy-2(1H)-oxo-1-phenyl-1,8-naphthyridine-3-carboxamides.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID1390040Effective permeability of the compound at 100 ug/ml after 18 hrs by PAMPA-BBB assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
AID161836Inhibition of human Prostaglandin G/H synthase 1 at 1 ug/mL expressed as mean percent inhibition of control PGE-2 production1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity.
AID604742Displacement of radiolabeled dansylsarcosine from fatty acid-free human serum albumin site 2 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID182558Compound was tested for the inhibition of Zymosan-induced rat's paw edema(ZPE) after peroral administration of 10 mg/kg dose1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
A novel synthesis and potent antiinflammatory activity of 4-hydroxy-2(1H)-oxo-1-phenyl-1,8-naphthyridine-3-carboxamides.
AID1694879Permeability of compound after 16 hrs by PAMPA-BBB assay2020RSC medicinal chemistry, Feb-01, Volume: 11, Issue:2
Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
AID187882Antiinflammatory activity on the development of collagen II arthritis in rats, measured based on animals positive for arthritis by the presence of paw edema1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Antiinflammatory activity of substituted 6-hydroxypyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-triones. Atypical nonsteroidal antiinflammatory agents.
AID1374215Effective permeability of the compound in PBS/EtOH at 100 ug/ml after 18 hrs by PAMPA-BBB assay2018Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
AID177018Antiinflammatory activity was evaluated in rat carrageenan foot edema assay in experiment 11987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and antiinflammatory activities of 3-(3,5-di-tert-butyl-4-hydroxybenzylidene)pyrrolidin-2-ones.
AID1413459Permeability of the compound at 50 ug/ml after 16 hrs by PAMPA
AID1495958Effective permeability of the compound in PBS/ethanol buffer2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Design, synthesis and evaluation of vilazodone-tacrine hybrids as multitarget-directed ligands against depression with cognitive impairment.
AID445446Oral bioavailability in human2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID177781Analgesic activity was evaluated in the rat flection pain test1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and antiinflammatory activities of 3-(3,5-di-tert-butyl-4-hydroxybenzylidene)pyrrolidin-2-ones.
AID183215Compound was tested in vivo for antiinflammatory activity against chronic adjuvant arthritic rat by therapeutic inhibition 1 degree paw after peroral administration of 5 mg/kg of dose1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Antiinflammatory activity of substituted 6-hydroxypyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-triones. Atypical nonsteroidal antiinflammatory agents.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1330183Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate preincubated with enzyme followed by substrate addition measured after 1 to 10 mins in presence of TMPD by spectrophotometric analysis2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Synthesis, COX-1/2 inhibition activities and molecular docking study of isothiazolopyridine derivatives.
AID1623078Effective permeability of the compound at 100 ug/ml after 10 hrs by BBB-PAMPA method2019European journal of medicinal chemistry, Feb-01, Volume: 163Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID1230203Permeability of the compound using PDVF membrane after 2 hrs 45 mins by PAMPA-BBB assay2015Journal of natural products, Jun-26, Volume: 78, Issue:6
In Vitro Inhibitory Effects of 8-O-Demethylmaritidine and Undulatine on Acetylcholinesterase and Their Predicted Penetration across the Blood-Brain Barrier.
AID1524756Analgesic activity in formalin-induced nociception Albino Swiss CD-1 mouse model assessed as time spent on licking formalin injected hind paw during inflammatory phase at 10 mg/kg, ip pretreated for 30 mins followed by formalin induction measured after 152019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Synthesis and pharmacological evaluation of novel arylpiperazine oxicams derivatives as potent analgesics without ulcerogenicity.
AID26556compound was evaluated for rate constant of transfer (log K1) at pH 1.01998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.
AID310932Permeability across human Skin2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID1487425Aqueous solubility of the compound in buffer at pH 6.4 after 48 hrs UV spectroscopy based shake flask method2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Discovery of novel dengue virus entry inhibitors via a structure-based approach.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID7119In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M1993Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
3,4-Dihydroxychalcones as potent 5-lipoxygenase and cyclooxygenase inhibitors.
AID1421886Effective permeability of the compound at 25 ug/ml after 18 hrs by BBB-PAMPA method2018European journal of medicinal chemistry, Oct-05, Volume: 158Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
AID161835Inhibition of human Prostaglandin G/H synthase 1 at 0.1 ug/mL expressed as mean percent inhibition of control PGE-2 production1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1331427Equilibrium solubility of the compound in Britton-Robinson buffer stirred for 6 hrs followed by sedimentation for 18 hrs by saturation shake flask based UV-vis spectroscopy
AID177020Antiinflammatory activity was evaluated in rat carrageenan foot edema assay in experiment 31987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and antiinflammatory activities of 3-(3,5-di-tert-butyl-4-hydroxybenzylidene)pyrrolidin-2-ones.
AID1529186Binding affinity to human serum albumin assessed as change in dissociation constant pKa1 of compound in aqueous medium to presence of human serum albumin by UV-pH titration based spectrophotometric analysis2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID455986Permeability across human Caco-2 cells2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID1365650Permeability of the compound at pH 7.4 by BBB-PAMPA2017Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
Design, synthesis, and evaluation of salicyladimine derivatives as multitarget-directed ligands against Alzheimer's disease.
AID1480849Permeability of the compound at pH 7.4 after 18 hrs by PAMPA-BBB assay2017European journal of medicinal chemistry, Apr-21, Volume: 130Design, synthesis and evaluation of 2-arylethenyl-N-methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment.
AID310933Permeability across PAMPA membrane after 7 hrs2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID374374Antiinflammatory against carrageenan-induced paw edema in Sprague-Dawley rat assessed as remaining paw edema at 10 mg/kg, sc administered 30 mins before carrageenan challenge measured after 4 hrs by plethysmometer relative to control2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Synthesis and pharmacological evaluation of 2-substituted benzo[b]thiophenes as anti-inflammatory and analgesic agents.
AID5985261-Octanol-water distribution coefficient, log D of the compound at pH 7.4 by shake-flask method2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.
AID1465293Effective permeability of the compound at 100 ug/ml by PAMPA-BBB assay2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
AID183203Compound was tested in vivo for antiinflammatory activity against chronic adjuvant arthritic rat by prophylactic inhibition 2 degree paw after peroral administration of 2 mg/kg of dose1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Antiinflammatory activity of substituted 6-hydroxypyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-triones. Atypical nonsteroidal antiinflammatory agents.
AID1167550Permeability of the compound in 70:30 PBS:EtOH by PAMPA-BBB assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Discovery of indanone derivatives as multi-target-directed ligands against Alzheimer's disease.
AID266764Membrane permeability, CA(t)/CD(0) in 70% silicon-30% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID467611Dissociation constant, pKa of the compound2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID183497Antiinflammatory activity of compound expressed as percentage inhibition of carrageenan edema 4 hr after an oral dose of 10 mg/kg.1981Journal of medicinal chemistry, Jan, Volume: 24, Issue:1
Synthesis and antiinflammatory activity of metabolites of piroxicam.
AID160404Inhibition of human Prostaglandin G/H synthase 2 at 10 ug/mL expressed as mean percent inhibition of control PGE-2 production1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity.
AID681372TP_TRANSPORTER: inhibition of MTX uptake in OAT3-expressing S2 cells2002The Journal of pharmacology and experimental therapeutics, Aug, Volume: 302, Issue:2
Characterization of methotrexate transport and its drug interactions with human organic anion transporters.
AID190376Concentration at which gastric damage will occur was determined in rat1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).
AID1524755Analgesic activity in formalin-induced nociception Albino Swiss CD-1 mouse model assessed as time spent on licking formalin injected hind paw during inflammatory phase at 5 mg/kg, ip pretreated for 30 mins followed by formalin induction measured after 15 2019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Synthesis and pharmacological evaluation of novel arylpiperazine oxicams derivatives as potent analgesics without ulcerogenicity.
AID1866897Permeability for across blood brain barrier by PAMPA2022European journal of medicinal chemistry, Apr-15, Volume: 234Development of 5-hydroxyl-1-azabenzanthrone derivatives as dual binding site and selective acetylcholinesterase inhibitors.
AID177019Antiinflammatory activity was evaluated in rat carrageenan foot edema assay in experiment 21987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and antiinflammatory activities of 3-(3,5-di-tert-butyl-4-hydroxybenzylidene)pyrrolidin-2-ones.
AID374383Analgesic activity in Sprague-Dawley rat assessed as change in latency time required to elicit jumping or hind paw licking at 10 mg/kg, sc administered 1 hr prior testing measured after 1 hr of post dose by hot plate method relative to basal level2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Synthesis and pharmacological evaluation of 2-substituted benzo[b]thiophenes as anti-inflammatory and analgesic agents.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID288192Partition coefficient, log P of the compound2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID28924Effective permeability (Pe) across a hexadecane membrane (pH 6.8)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID1347980Permeability of the compound in PBS/EtOH at 100 ug/ml after 12 hrs by PAMPA-BBB assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID172967Antiinflammatory activity by immune response to collagen II antigen in rats antibody titer was determined by passive hemagglutinination1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Antiinflammatory activity of substituted 6-hydroxypyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-triones. Atypical nonsteroidal antiinflammatory agents.
AID1545417Antiinflammatory activity in Wistar rat model of Freund's adjuvant-induced arthritis assessed as inhibition of arthritis by measuring reduction in paw volume at 75 mg/kg, po administered once daily for 8 days starting from day 7 post Freund's adjuvant tre2019Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7
Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances.
AID266765Effective permeability coefficient in 70% silicon-30% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID26284Partition coefficient (logD1.0)1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID160412Percentage inhibition of Prostaglandin G/H synthase 2 activity as measured by PGE-2 production at 100 uM1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity.
AID1261413Antitumor activity against mouse EAT implanted in Balb/C mouse assessed as change in paw volume at 40 mg/kg, po administered on day 3 post tumor inoculation measured on day 12 by plethysmometer analysis (Rvb = 125.5 +/- 7.5%)2015European journal of medicinal chemistry, Nov-02, Volume: 104Synthesis of thiophene-thiosemicarbazone derivatives and evaluation of their in vitro and in vivo antitumor activities.
AID1436078Permeability of compound at 100 ug/ml after 18 hrs by PAMPA2017European journal of medicinal chemistry, Jan-27, Volume: 126Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
AID169647Compound is evaluated for gastric ulceration in rats at a dose of 30 mg/kg.; 7 out of 12 is lesioned1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and antiinflammatory activities of 3-(3,5-di-tert-butyl-4-hydroxybenzylidene)pyrrolidin-2-ones.
AID1524750Analgesic activity in formalin-induced nociception Albino Swiss CD-1 mouse model assessed as time spent on licking formalin injected hind paw during neurogenic phase at 5 mg/kg, ip pretreated for 30 mins followed by formalin induction measured up to 5 min2019Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8
Synthesis and pharmacological evaluation of novel arylpiperazine oxicams derivatives as potent analgesics without ulcerogenicity.
AID1500949Passive permeability of the compound at 100 uM after 6 hrs by PAMPA2017European journal of medicinal chemistry, Oct-20, Volume: 139Hydroxy-substituted trans-cinnamoyl derivatives as multifunctional tools in the context of Alzheimer's disease.
AID11902Maximal blood concentration after oral administration of a 30 umol/kg dose of compound1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
New quaternary ammonium oxicam derivatives targeted toward cartilage: synthesis, pharmacokinetic studies, and antiinflammatory potency.
AID1377751Effective permeability of the compound after 2.5 hrs at 25 degC by PAMPA assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents.
AID178754Inhibitory activity in the adjuvant induced arthritis model of chronic inflammation in rat1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
1,2-Diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active antiinflammatory agents.
AID1330174Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition presence of TMPD by spectrophotometric analysis relative to control2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Synthesis, COX-1/2 inhibition activities and molecular docking study of isothiazolopyridine derivatives.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1545416Antiinflammatory activity in Wistar rat assessed as inhibition of cotton pellet-induced granuloma at 75 mg/kg, po administered daily for 7 days and measured on day 8 relative to control2019Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7
Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances.
AID1709005Permeability of compound at 100 uM at pH 7.4 by PAMPA assay2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Synthesis and Pharmacological Evaluation of Novel Non-nucleotide Purine Derivatives as P2X7 Antagonists for the Treatment of Neuroinflammation.
AID679541TP_TRANSPORTER: inhibition of MTX uptake (MTX: 1 uM, Piroxicam: 1000 uM) in OAT1-expressing S2 cells2002The Journal of pharmacology and experimental therapeutics, Aug, Volume: 302, Issue:2
Characterization of methotrexate transport and its drug interactions with human organic anion transporters.
AID1379031Effective permeability of compound at 50 ug/mL after 16 hrs by PAMPA-BBB assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Novel cinnamamide-dibenzylamine hybrids: Potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease.
AID182193Antiinflammatory activity against collagen II arthritis in rats, activity % inhibition in noninjected paw edema1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Antiinflammatory activity of substituted 6-hydroxypyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-triones. Atypical nonsteroidal antiinflammatory agents.
AID1529185Protein binding in human serum albumin after 4.5 hrs by LC-MS based rapid equilibrium dialysis method2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID1392733Permeability of the compound at 100 ug/ml after 10 hrs by PAMPA
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID160402Inhibition of human Prostaglandin G/H synthase 2 at 0.1 ug/mL expressed as mean percent inhibition of control PGE-2 production1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity.
AID472064Antiosteoarthritis activity in bovine articular chondrocytes assessed as inhibition of IL1-induced reduction of aggrecan mRNA expression at 10 uM after 5 days by Northern blot analysis relative to control2010European journal of medicinal chemistry, Jan, Volume: 45, Issue:1
New quaternary ammonium oxicam derivatives: synthesis and in vitro antiosteoarthritis evaluation.
AID1511118Permeability of the compound measured after compound dilution in PBS/EtOH buffer (70:30) by PAMPA-BBB assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
AID1192731Permeability of the compound in PBS/EtOH buffer at 100 ug/ml by PAMPA2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID235829Ratio of acute ulcerogenesis UD50/Randall-Selitto ED501988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and analgesic activity of pemedolac (cis-1-ethyl-1,3,4,9-tetrahydro-4-(phenylmethyl)pyrano[3,4-b]ind ole-1- acetic acid).
AID1374214Effective permeability of the compound in pH 7.4 buffer after 18 hrs by PAMPA-BBB assay2018Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1330750Effective permeability of the compound after 18 hrs by PAMPA2016European journal of medicinal chemistry, Nov-10, Volume: 123Rational modification of donepezil as multifunctional acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.
AID1338124Permeability of the compound at 100 uM up to 6 hrs by PAMPA2017European journal of medicinal chemistry, Jan-05, Volume: 125Design, synthesis and biological evaluation of new phthalimide and saccharin derivatives with alicyclic amines targeting cholinesterases, beta-secretase and amyloid beta aggregation.
AID12234881-Octanol-water distribution coefficient, log D of the compound at pH 7.42012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID1390042Effective permeability of the compound at 25 ug/ml after 18 hrs by PAMPA-BBB assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
AID1517867Permeability of compound by PAMPA-BBB assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
AID192726Compound is evaluated for mean ulcer index in rats at a dose of 10 mg/kg1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and antiinflammatory activities of 3-(3,5-di-tert-butyl-4-hydroxybenzylidene)pyrrolidin-2-ones.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1264455Permeability of the compound by high throughput PAMPA method2015European journal of medicinal chemistry, Nov-13, Volume: 105Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity.
AID1496040Effective permeability of the compound in PBS/EtOH at 50 ug/mL after 18 hrs by PAMPA-BBB assay2018Bioorganic & medicinal chemistry letters, 06-15, Volume: 28, Issue:11
Discovery of novel anti-tuberculosis agents with pyrrolo[1,2-a]quinoxaline-based scaffold.
AID1330184Increase in COX-1 (unknown origin) enzyme activity using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition in presence of TMPD by spectrophotometric analysis relative to control2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Synthesis, COX-1/2 inhibition activities and molecular docking study of isothiazolopyridine derivatives.
AID427198Membrane permeability dissolved in PBS/EtOH (80:20) mixture by PAMPA-BBB assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
AID1557178Permeability of the compound at 100 ug/ml measured after compound dilution in PBS/EtOH buffer (70:30) by PAMPA-BBB assay2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID162151Tested for inhibitory activity against Prostaglandin G/H synthase 1 from ovine1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Antiinflammatory 4,5-diarylpyrroles. 2. Activity as a function of cyclooxygenase-2 inhibition.
AID1279139Permeability of the compound at 25 ug/ml at pH 7.4 after 16 hrs by PAMPA2016Bioorganic & medicinal chemistry, Apr-01, Volume: 24, Issue:7
Design, synthesis and biological evaluation of novel donepezil-coumarin hybrids as multi-target agents for the treatment of Alzheimer's disease.
AID1334753Permeability of the compound at 100 ug/ml after 18 hrs by PAMPA assay2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID696005Permeability of the compound after 4 hrs by PAMPA assay2012European journal of medicinal chemistry, Dec, Volume: 58Microwave-assisted synthesis of hydroxyphenyl nitrones with protective action against oxidative stress.
AID1331425Aqueous solubility of the compound in Britton-Robinson buffer at pH 6.5 measured after 2 days by saturation shake flask based UV-vis spectroscopy
AID1279155Permeability of the compound at 25 ug/ml at pH 7.4 after 18 hrs by PAMPA2016Bioorganic & medicinal chemistry, Apr-01, Volume: 24, Issue:7
Design, synthesis and biological evaluation of novel donepezil-coumarin hybrids as multi-target agents for the treatment of Alzheimer's disease.
AID1261408Antitumor activity against mouse EAT implanted in Balb/C mouse assessed as change in paw volume at 40 mg/kg, po administered on day 3 post tumor inoculation measured on day 9 by plethysmometer analysis (Rvb = 95.5 +/- 5.2%)2015European journal of medicinal chemistry, Nov-02, Volume: 104Synthesis of thiophene-thiosemicarbazone derivatives and evaluation of their in vitro and in vivo antitumor activities.
AID384955Intrinsic aqueous solubility at pH 10 by shake-flask method2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
Molecular characteristics for solid-state limited solubility.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID681160TP_TRANSPORTER: inhibition of Adefovir uptake in OAT1-expressing CHO cells2000The Journal of pharmacology and experimental therapeutics, Oct, Volume: 295, Issue:1
Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1.
AID1261418Antitumor activity against mouse EAT implanted in Balb/C mouse assessed as change in paw volume at 40 mg/kg, po administered on day 3 post tumor inoculation measured on day 15 by plethysmometer analysis (Rvb = 166.5 +/- 6.0%)2015European journal of medicinal chemistry, Nov-02, Volume: 104Synthesis of thiophene-thiosemicarbazone derivatives and evaluation of their in vitro and in vivo antitumor activities.
AID91153Compound is evaluated for inhibitory effect on the generation of Leukotriene B4 (LTB4) from human neutrophils; NA means not active1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and antiinflammatory activities of 3-(3,5-di-tert-butyl-4-hydroxybenzylidene)pyrrolidin-2-ones.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1091958Hydrophobicity, log P of the compound in octanol-water by shaking-flask method2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1345284Human COX-1 (Cyclooxygenase)1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity.
AID1345206Human COX-2 (Cyclooxygenase)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Antiinflammatory 4,5-diarylpyrroles. 2. Activity as a function of cyclooxygenase-2 inhibition.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,853)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990731 (25.62)18.7374
1990's744 (26.08)18.2507
2000's603 (21.14)29.6817
2010's643 (22.54)24.3611
2020's132 (4.63)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials796 (25.81%)5.53%
Reviews118 (3.83%)6.00%
Case Studies213 (6.91%)4.05%
Observational2 (0.06%)0.25%
Other1,955 (63.39%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (28)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Comparison of Analgesic İmpacts of Piroxicam and Diclofenac Sodium in the Treatment of Primary Dysmenorrhea:A Double-Blind, Randomized Trial [NCT02253446]Phase 4400 participants (Actual)Interventional2013-05-31Completed
NSAIDs Versus Paracetamol Versus Paracetamol + NSAIDs in Traumatic Pain Management [NCT03222518]Phase 31,500 participants (Actual)Interventional2017-03-01Completed
Comparison of Two Routes of Administration of a Multimodal Analgesic Protocol in Postoperative Cesarean Section Oral vs Intravenous [NCT03626753]Phase 2/Phase 3200 participants (Actual)Interventional2015-01-01Completed
Comparative Evaluation of the Efficacy of Intra-ligamentary Injection of 20 Milligram (Mg) Piroxicam Versus 4% Articaine in Management of Endodontic Pain in Patients With Symptomatic Irreversible Pulpitis in Mandibular Molars [NCT03612323]Early Phase 120 participants (Anticipated)Interventional2018-11-30Not yet recruiting
Pre-emptive Intravenous Analgesia for Elective Inguinal Hernia Repair: Prospective Randomized Double-blinded Placebo Controlled Comparison of Lornoxicam and Paracetamol [NCT01069055]Phase 360 participants (Anticipated)Interventional2010-02-28Not yet recruiting
Single-center, Randomized, Placebo-controlled, Double-blind, Parallel Group Study to Evaluate Whether a Single-dose of Either 20 mg Piroxicam, 40 mg Piroxicam or 80 mg Piroxicam Shows an Effect on Ovulation After the Onset of LH Surge Compared to Placebo [NCT01320709]Phase 272 participants (Actual)Interventional2011-03-31Completed
Comparative Evaluation of the Effect of a Prophylactic Intraligamentary Injection of Dexamethasone and Piroxicam on Postoperative Pain in Teeth With Symptomatic Irreversible Pulpitis: A Randomized Controlled Trial [NCT03745105]42 participants (Anticipated)Interventional2018-12-25Not yet recruiting
Evaluation of the Effect of Different Acupuncture Dose on Premenstrual Syndrome and the Relationship Between Premenstrual Syndrome and TCM Syndrome Complex [NCT04296422]105 participants (Anticipated)Interventional2019-01-01Enrolling by invitation
Relevance of the Interaction Between Antihypertensive and Antirheumatic Drugs in a Family Practice [NCT00631514]Phase 488 participants (Actual)Interventional2005-01-31Completed
The Investigation of the Efficacity and Safety of Oral Non Steroidal Anti Inflammatory (NSAI) Drugs Such as Piroxicam as a Second Line Treatment of Patients Consulting the Emergency Department for Renal Colics [NCT05722782]Phase 2500 participants (Anticipated)Interventional2023-07-01Recruiting
Efficacy of Piroxicam as a Perioperative Analgesic for Patients Undergoing Fixation of Maxillofacial Fractures [NCT04062591]Early Phase 172 participants (Actual)Interventional2019-08-16Completed
Randomized Clinical Trial of Topical Piroxicam Versus a New Herbal Medicine Based Gel in the Treatment of Acute Extremity Pain After Emergency Department Discharge [NCT05054023]Phase 2/Phase 31,525 participants (Actual)Interventional2021-10-21Completed
Effect of Piroxicam Premedication on Postendodontic Pain in Mandibular Molars With Non-vital Pulp: A Randomized Controlled Trial [NCT03998826]60 participants (Anticipated)Interventional2019-09-01Not yet recruiting
A Double Blind, Double Dummy, Randomized, Comparative Study Of The Efficacy And Safety Of Valdecoxib 40 Mg BID, PRN In The First Menstrual Cycle Day And Then Once A Day, And Piroxicam 40 Mg Once A Day In The Treatment Of Patients With Primary Dysmenorrhea [NCT00649415]Phase 4154 participants (Actual)Interventional2003-01-31Completed
Comparative Study of Olive Oil With Piroxicam Gel in Osteoarthritis of the Knee [NCT00670475]Phase 260 participants (Actual)Interventional2008-04-30Completed
MILES STUDY - Mesotherapy In Lateral Epicondylitis, a Prospective Randomized Controlled Study [NCT04201249]Phase 2/Phase 382 participants (Anticipated)Interventional2019-12-01Recruiting
A Prospective, Open, Multi-Centre Photopatch Test Study of Patients Suspected of Photoallergy to Organic Sunscreens and Topical Nonsteroidal Anti-inflammatory Drugs Used Within Europe. [NCT00530387]1,000 participants (Actual)Interventional2008-07-31Completed
Effectiveness of Single Dose Pre Medication of Piroxicam and Prednisolone on Post Endodontic Pain After a One Visit Root Canal Treatment. Randomized Trial . [NCT04124822]Phase 2/Phase 360 participants (Actual)Interventional2018-05-30Completed
A Randomized, Parallel-Group, Double-Blind, Single-Dose Study Evaluating the Efficacy and Safety of Intravenous Lornoxicam (8 mg and 16 mg) Compared to Intravenous Placebo and Ketorolac 30 mg in Management of Acute Postoperative Pain Following Orthopedic [NCT00293631]Phase 2100 participants Interventional2005-11-30Completed
A Randomized, Double-Blind, Single-Dose Study, Placebo-Controlled Evaluation of the Safety and Efficacy of Intravenous Lornoxicam in the Acute Treatment of the Headache of Migraine. [NCT00293657]Phase 2150 participants Interventional2005-12-31Completed
Influence of Genotype of Cytochrome P450 (CYP2C9) on Clinical Efficacy and Pharmacokinetics of Piroxicam After Lower Third Molar Surgery [NCT02450487]Phase 4105 participants (Actual)Interventional2012-10-31Completed
Comparison of Preoperative Analgesics on the Efficacy of Inferior Alveolar Nerve Block on Patients With Symptomatic Irreversible Pulpitis: a Double Blinded, Randomized Controlled Trial. [NCT05488925]Phase 4120 participants (Actual)Interventional2021-06-21Completed
The Analgesic Efficacy of Oral Piroxicam Versus Buccal Fentanyl in Cancer Breakthrough Pain in Patients With Bone Metastases [NCT02382653]100 participants (Actual)Interventional2014-12-31Completed
A Phase 1, Single-Centre, Part-Crossover, OpenLabel, Partially-Randomised Study Designed to Evaluate the PK Profile of Piroxicam Following Administration of Nanoformed Oral IR Piroxicam Tablet and an IR Reference Product in Healthy Subjects [NCT05104931]Phase 112 participants (Actual)Interventional2020-12-02Completed
Comparison of the Efficacy of Prophylactic Intraligamentary Injection of Piroxicam Versus Mepecaine for Management of Post-endodontic Pain in Posterior Teeth [NCT03006107]26 participants (Anticipated)Interventional2016-12-31Not yet recruiting
Piroxicam and Levonorgestrel Co-treatment for Emergency Contraception: Randomised Controlled Trial [NCT03614494]Phase 2/Phase 3860 participants (Actual)Interventional2018-08-20Completed
Preemptive Use of Piroxicam-beta-Cyclodextrin on Tooth Sensitivity Caused by In-office Bleaching: Randomized, Triple-blind, Controlled Clinical Trial [NCT03153657]Phase 350 participants (Anticipated)Interventional2016-12-13Completed
The Investigation of the Efficacity and Safety of Oral Non Steroidal Anti Inflammatory (NSAI) Drugs Such as Piroxicam as a Second Line Treatment of Patients Consulting the Emergency Departement for Renal Colics. [NCT02304783]Phase 1/Phase 2500 participants (Anticipated)Interventional2014-01-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT02450487 (2) [back to overview]Number of Participants With Adverse Events
NCT02450487 (2) [back to overview]Score of Pain Measured by Visual Analogue Scale

Number of Participants With Adverse Events

Report of adverse effects during the postoperative period until suture removal seven days after extraction of third molar included and/or impacted in patients underwent surgery. (NCT02450487)
Timeframe: Seven days after surgery

InterventionParticipants (Count of Participants)
Interventional Group2

[back to top]

Score of Pain Measured by Visual Analogue Scale

Score of pain after third molar surgery is measured by visual analogue scale (0-100mm). (NCT02450487)
Timeframe: at 24 hours after surgery

Interventionscore on a scale (mm) (Mean)
Interventional Group25

[back to top]